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The increased use of imaging across research, clinical and commercial contexts has 
generated debate and calls for evidence on the benefits and harms of incidental findings 
(defined as those which are unrelated to the purpose of imaging) to inform policy and 
practice. Evidence on clearly non-serious incidental findings is of limited clinical usefulness; 
this thesis therefore focuses on potentially serious incidental findings (PSIFs), defined as 
those which may indicate the possibility of a condition which, if it was confirmed, would 
carry a real prospect of seriously threatening life span, or of having a substantial impact on 
major body functions or quality of life. 
In 2014, the UK Biobank Imaging Study began performing brain, cardiac and body magnetic 
resonance imaging (MRI), dual-energy X-ray absorptiometry and carotid Doppler 
ultrasound, and aims to image 100,000 of its population-based participants. The imaging data 
can be combined with extensive sociodemographic, lifestyle, physical measures, 
biochemical, genetic and linked healthcare data, to generate a research resource which will 
facilitate studies into a wide range of diseases. Due to the scale of the UK Biobank Imaging 
Study, PSIFs are a particularly pertinent issue. UK Biobank therefore evaluates the impact of 
its protocol for handling PSIFs, the data from which form the basis of this thesis. 
This thesis aims to provide empirical data on seven themes relating to PSIFs: their 
prevalence and nature; follow-up and final diagnoses; factors associated with PSIFs and with 
serious final diagnoses; participants’ understanding of consent to feedback of PSIFs; non-
medical impacts of feedback of PSIFs; opinions of receiving feedback of PSIFs; and the 
economic impact of feedback of PSIFs on hospital services. 
Chapter 1 outlines the scale of the challenge of incidental findings, and summarises current 
literature and gaps in our knowledge relating to each of the seven themes on PSIFs. Chapter 
2 reviews systematically and meta-analyses published studies of brain and body MRI of 
apparently asymptomatic adults. Chapter 3 introduces the UK Biobank, the UK Biobank 
Imaging Study, and the rationale behind and protocol used to handle PSIFs in 100,000 
largely asymptomatic participants: radiographer flagging of concerning images for a 
radiologist to review. Chapter 4 presents a study comparing two protocols to handle PSIFs in 
the first 1,000 imaged UK Biobank participants: radiographer flagging versus systematic 
radiologist review of all images. Chapter 5 investigates the factors associated with PSIFs and 
with serious final diagnoses. Chapter 6 examines the economic impact of feedback of PSIFs 




In the systematic review, pooled prevalences of PSIFs on brain, thorax, abdominal and brain 
and body MRI were: 1.4–1.7%; 1.3–3.0%; 1.9–4.5%; and 3.9–12.8% respectively, the upper 
estimates reflecting the inclusion of indeterminate findings. There was substantial 
heterogeneity, but few informative data on potential sources of this. Around half of PSIFs 
were suspected malignancies.  
Based on the first 7,334 participants in the UK Biobank Imaging Study (283 of whom had 
PSIFs), the PSIFs protocol had the largest influence on the prevalence of PSIFs and serious 
final diagnoses of any of the investigated factors: systematic radiologist review resulted in 
around 13 times more PSIFs and around four times more serious final diagnoses compared to 
radiographer flagging. A lower proportion of PSIFs detected by radiologists were finally 
diagnosed as serious compared to radiographer flagging (12% and 32% [Chapter 4 and 5]).  
Feedback of PSIFs resulted in substantial impacts in terms of: clinical assessments (all 
participants visited their general practitioner, and 90% underwent some form of other clinical 
assessment, mostly imaging or referral to a specialist [Chapter 4]); non-medical impacts on 
participants (including on emotional wellbeing, insurance and finances and work and 
activities in 17%, 9% and 6% respectively [Chapter 4]); and hospital service use and cost 
(81% of cases with PSIFs generated some hospital use and costs, which had increased 
compared to controls, and to cases’ hospital use and costs during the year before feedback of 
a PSIF [Chapter 6]). Importantly, as around 80% of PSIFs turned out not to be serious 
(Chapters 2, 4 and 5), many of these impacts may be unnecessary. 
Despite these negative impacts, the vast majority of participants were glad to have received 
feedback of a PSIF and to have taken part in the imaging study (98% and 99% respectively), 
although almost a quarter changed their minds over time about whether or not feedback 
should always be given. Around a quarter of participants incorrectly thought they could 
choose to receive feedback and UK Biobank has improved its consent materials accordingly 
(Chapter 4). 
Feedback of PSIFs impacts on participants and publicly-funded health services (and in turn 
patients in need); most PSIFs turn out not to be serious and many of these impacts may be 
unnecessary. Researchers can substantially influence these impacts via IFs policies, which 
must be designed to minimise unnecessary harms, and be clearly explained to participants to 
facilitate informed consent. These, and other implications of this thesis are further described 
in Chapter 7, which also discusses the results in the context of the broader literature, outlines 





Apparently asymptomatic people who volunteer to have a scan for a research study may be 
told that they have an abnormality which may impact on their health or quality of life. We 
call these abnormalities ‘potentially serious incidental findings,’ or PSIFs. This thesis uses 
published studies and new data from the world’s largest scan project, the UK Biobank 
Imaging Study, to provide more information on PSIFs, and their impacts on people and 
hospital services. 
From a review of published studies, we found that PSIFs occur on brain, chest, abdominal 
and brain and body magnetic resonance imaging in 1.4–1.7%, 1.3–3.0%, 1.9–4.5% and 3.9–
12.8% of apparently asymptomatic people respectively. Until they were assessed further, 
around half of these PSIFs were thought to be cancers.  
All UK Biobank participants with PSIFs saw their general practitioners, and 90% had some 
other tests or appointments. News of a PSIF impacted on some people’s emotional wellbeing 
(17%), insurance and finances (9%) and work and activities (6%). We found that 81% of 
people with PSIFs generated hospital costs, which were greatly increased compared to 
controls, and to their costs before they had feedback of a PSIF. As most PSIFs do not turn 
out to be serious disease (around 80%), some of these impacts on people and our hospitals 
may be unnecessary. Despite this, almost everybody was glad to have been told about their 
PSIF (98%) and to have had a research scan (99%), although almost a quarter changed their 
minds over time about whether or not people should always be told about a PSIF. Around a 
quarter misunderstood that UK Biobank would always tell them about a PSIF (thinking that 
they could choose to be told or not), so UK Biobank improved its consent materials. 
We found that by far the biggest influence on the detection of PSIFs, and of those which turn 
out to be serious, is the researchers’ protocol for handling PSIFs. Therefore, it is essential 
that researchers carefully design protocols which minimise the potential negative impacts of 
PSIFs, whilst still enabling important research which is needed to understand health and 
disease; our results may help them to do this. Our results suggest that researchers must strive 
to explain their PSIFs protocols clearly, and may help them to estimate and explain the 
potential impacts of PSIFs to people who are considering having a research scan, so that 










I declare that the thesis has been composed by myself and that the work has not been 
submitted for any other degree or professional qualification. I confirm that the work 
submitted is my own, except where work which has formed part of jointly-authored 
publications has been included. My contribution and those of the other authors to this work 
have been explicitly indicated and described below. I confirm that appropriate credit has 
been given within this thesis where reference has been made to the work of others. 
The work presented in Section 2.2 was previously submitted to the BMJ as ‘Potentially 
serious incidental findings on brain and body magnetic resonance imaging of apparently 
asymptomatic adults: systematic review and meta-analysis,’ by LM Gibson, L Paul, FM 
Chappell, M Macleod, WN Whiteley, R Al-Shahi Salman, JM Wardlaw, CLM Sudlow. 
Author contributions (student’s contributions in bold): study design (LMG, JMW, CLMS); 
data curation (LMG, LP); data analyses (LMG, FMC); data interpretation (LMG, MM, 
FMC, WNW, RA-SS, JMW, CLMS); creation of tables and figures (LMG, FMC, CLMS); 
writing – original draft preparation (LMG); writing – review and editing (all authors). 
The work presented in Section 3.2 was originally published as ‘Management of incidental 
findings on multimodal imaging in UK Biobank. LM Gibson, J Sellors, CLM Sudlow. In: 
Weckbach S. (eds) Incidental radiological findings. Medical Radiology. 2016. Springer, 
Cham.’ Permissions were obtained from the publisher and my co-authors to include this 
work in this thesis. Author contributions (student’s contributions in bold): creation of tables 
(LMG); writing – original draft preparation (LMG); writing – review and editing (all 
authors).  
The work presented in Section 4.2 was originally published as ‘Impact of detecting 
potentially serious incidental findings during multi-modal imaging [version 3; referees: 2 
approved, 1 approved with reservations]. LM Gibson, TJ Littlejohns, L Adamska, S Garratt, 
N Doherty, UK Biobank Imaging Working Group, JM Wardlaw, G Maskell, M Parker, R 
Brownsword, PM Matthews, R Collins, NE Allen, J Sellors, CLM Sudlow. Wellcome Open 
Research 2018; 2:114.’ This paper is available as open access and is appropriately cited 
within this thesis. In addition, I obtained permission from my co-authors to include this work 
in this thesis. Author contributions (student’s contributions in bold): study design (LMG, 
TJL, PMM, RC, NEA, JS, CLMS); data curation (LMG, TJL, LA, SG, CLMS); data 




CLMS); creation of tables and figures (LMG); writing – original draft preparation (LMG); 
writing – reviewing and editing (all authors); project administration (ND). 
The work presented in Section 5.2 has been conducted in collaboration with, and edited by, 
my co-authors in preparation for submission to a journal as ‘Factors associated with 
potentially serious incidental findings and with serious final diagnoses on multi-modal 
imaging in the UK Biobank Imaging Study: a prospective cohort study,’ by LM Gibson, J 
Nolan, TJ Littlejohns, E Mathieu, S Garratt, N Doherty, S Petersen, NCW Harvey, J Sellors, 
NE Allen, JM Wardlaw, CA Jackson, CLM Sudlow. Author contributions (student’s 
contributions in bold): study design (LMG, NEA, JMW, CAJ, CLMS); data curation (LMG, 
JN, TJL, EM, SG, CLMS); data analyses (LMG, JN); data interpretation (LMG, CAJ, 
CLMS); creation of tables and figures (LMG); writing – original draft preparation (LMG); 
writing – reviewing and editing (all authors); project administration (ND). 
The work presented in Section 6.2 has been conducted in collaboration with, and edited by, 
my co-authors in preparation for submission to a journal as ‘Use and cost of hospital services 
by UK Biobank participants with potentially serious incidental findings: a case-control study 
utilising linked English Hospital Episode Statistics data from 2013-2016,’ by LM Gibson, J 
Nolan, E Mathieu, TJ Littlejohns, S Garratt, S Sheard, N Doherty, C Keerie, NE Allen, JM 
Wardlaw, J Leal, AM Gray, CLM Sudlow. Author contributions (student’s contributions in 
bold): study design (LMG, CK, JMW, JL, AMG, CLMS); data curation (LMG, JN, EM, 
TJL, SG, SS, CLMS); data analyses (LMG, JN); data interpretation (LMG, TJL, JMW, JL 
AMG, CLMS); creation of tables and figures (LMG); writing – original draft preparation 
(LMG); writing – reviewing and editing (all authors); project administration (ND). 
    





I would like to thank my supervisors, Cathie Sudlow and Joanna Wardlaw, for the 
opportunity to design and conduct the work presented in this thesis. Particular thanks are due 
to Rustam Al-Shahi Salman, chair of my thesis committee, for guidance and support 
throughout my clinical research training fellowship. Thank you also to the members of the 
UK Biobank Executive Management Committee and the Imaging Working Group, in 
particular, Paul Matthews and Rory Collins, for their support to conduct the projects which 
form the majority of this thesis. 
I am grateful for all of the advice on and contributions to many aspects of the work within 
this thesis from my additional co-authors: Ligia Adamska, Naomi Allen, Roger 
Brownsword, Francesca Chappell, Nicola Doherty, Steve Garratt, Alastair Gray, Nick 
Harvey, Caroline Jackson, Catriona Keerie, Jose Leal, Thomas Littlejohns, Malcolm 
Macleod, Giles Maskell, Edouard Mathieu, John Nolan, Mike Parker, Laura Paul, Steffen 
Petersen, Jonathan Sellors, Simon Sheard and Will Whiteley.  
I would like to extend a special note of thanks to the UK Biobank participants and Imaging 
Centre and Co-ordinating Centre staff, without whom the projects would not have been 
possible. Finally, I am grateful to the Wellcome Trust for providing the funding to enable me 
to conduct this work.  
To acknowledge the contributions of my co-authors, ‘we’ will be used instead of ‘I’ 








Publications and other contributions arising 
from work associated with this thesis 
Peer reviewed paper 
Gibson LM, Littlejohns TJ, Adamska L, Garratt S, Doherty N, UK Biobank Imaging 
Working Group, Wardlaw JM, Maskell G, Parker M, Brownsword R, Matthews PM, Collins 
R, Allen NE, Sellors J, Sudlow CLMS. Impact of detecting potentially serious incidental 
findings during multi-modal imaging [version 3; referees: 2 approved, 1 approved with 
reservations]. Wellcome Open Research 2018, 2:114. 
Book chapters 
Gibson LM, Sudlow CLM, Wardlaw JM. Incidental findings: current ethical debates and 
future challenges in advanced neuroimaging. In: Neuroethics: anticipating the future. Illes J 
(Editor), Hossain S (Associate editor). Second edition. Oxford University Press, Oxford, 
UK: 2017; 54-69. 
Gibson LM, Sellors J, Sudlow CLM. Management of incidental findings on multi-modal 
imaging in UK Biobank. In: Incidental radiological findings. Weckbach S (Editor). First 
edition. Springer, Cham, Switzerland: 2016; 71-78.  
Abstract 
Gibson LM, Nolan J, Littlejohns TL, Mathieu E, Garratt S, Doherty N, Allen NE, Wardlaw 
JM, Jackson CA, Sudlow CLM. Risk factors associated with potentially serious incidental 
findings and with serious final diagnoses on multi-modal imaging in the UK Biobank 
Imaging Study. BMJ Evidence-based medicine (In Press September 2018). 
Presentations 
Incidental findings on imaging in the UK Biobank study. Clinical Neurosciences Seminar, 
Edinburgh, May 2017. 
Impact of detecting potentially serious incidental findings during multi-modal imaging: 





Impact of detecting potentially serious incidental findings during multi-modal imaging: 
experience from UK Biobank. Incidental Findings in Neuroimaging Research Meeting, 
Oxford, December 2017. 
Risk factors associated with potentially serious incidental findings and with serious final 
diagnoses on multi-modal imaging in the UK Biobank Imaging Study. Preventing 
Overdiagnosis Conference, Copenhagen, August 2018. 
Protocols 
Gibson L, Paul L, Wardlaw J, Sudlow C. Potentially serious incidental findings on brain and 
body magnetic resonance imaging conducted among apparently healthy adults: a systematic 
review. PROSPERO 2016:CRD42016029472. Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016029472 
Dataset 
Gibson L, Paul L, Sudlow CLM. Potentially serious incidental findings on brain and body 
magnetic resonance imaging conducted among apparently healthy adults: a systematic 
review and meta-analysis, [dataset]. 2017. Available from:  
https://datashare.is.ed.ac.uk/handle/10283/2773  
 
Analyses code files 
Gibson LM, Nolan J. Factors associated with potentially serious incidental findings and with 
serious final diagnoses on multimodal imaging in the UK Biobank Imaging Study: a 
prospective cohort study, [software]. 2018. Available from: 
https://datashare.is.ed.ac.uk/handle/10283/3112  
Magazine article 
Gibson L. Scans from ‘healthy’ volunteers reveal serendipitous findings: a blessing or a 







Abstract .................................................................................................................................... i 
Lay summary ......................................................................................................................... iii 
Declaration.............................................................................................................................. v 
Acknowledgements .............................................................................................................. vii 
Publications and other contributions arising from work associated with this thesis ...... ix 
Table of tables ...................................................................................................................... xv 
Table of figures ................................................................................................................... xvii 
Table of supplementary tables ........................................................................................... xix 
Table of supplementary figures ......................................................................................... xxi 
Chapter 1 Introduction ...................................................................................................... 1 
1.1 The challenge of incidental findings ....................................................................... 1 
1.1.1 Definitions .......................................................................................................... 1 
1.1.2 Scale of the challenge ......................................................................................... 3 
1.2 Current knowledge of IFs and PSIFs ...................................................................... 9 
1.2.1 Prevalence and nature of IFs on MRI of apparently asymptomatic volunteers . 9 
1.2.2 Follow-up and final diagnoses ......................................................................... 11 
1.2.3 Variation in the prevalence of PSIFs and of serious final diagnoses ............... 13 
1.2.4 Participants’ understanding of consent to feedback ......................................... 16 
1.2.5 Non-medical impacts of feedback on participants ........................................... 18 
1.2.6 Opinions of receiving feedback........................................................................ 20 
1.2.7 Economic impact of feedback .......................................................................... 21 
1.2.8 Efforts to manage IFs in imaging research ....................................................... 23 
1.3 Summary ............................................................................................................... 26 
1.4 Aims of this thesis ................................................................................................ 27 
Chapter 2 Potentially serious incidental findings on brain and body magnetic 
resonance imaging of apparently asymptomatic adults: systematic review and meta-
analysis 29 
2.1 Introduction .......................................................................................................... 29 
2.2 Potentially serious incidental findings on brain and body magnetic resonance 
imaging of apparently asymptomatic adults: systematic review and meta-analysis 
(submitted) ......................................................................................................................... 31 
2.2.1 Structured abstract ............................................................................................ 33 
2.2.2 What this paper adds ........................................................................................ 35 




2.2.4 Methods ............................................................................................................ 37 
2.2.5 Results .............................................................................................................. 40 
2.2.6 Discussion ......................................................................................................... 52 
2.2.7 Additional information ..................................................................................... 56 
2.3 Supplementary materials ....................................................................................... 59 
2.3.1 Supplementary methods ................................................................................... 59 
2.3.2 Supplementary figures ...................................................................................... 65 
2.3.3 Further supplementary tables ............................................................................ 78 
2.4 Conclusion ............................................................................................................ 99 
Chapter 3 Development and evaluation of the UK Biobank incidental findings 
protocol 101 
3.1 Introduction ......................................................................................................... 101 
3.2 Management of incidental findings on multi-modal imaging in UK Biobank ... 103 
3.3 Conclusion .......................................................................................................... 113 
Chapter 4 Impact of detecting potentially serious incidental findings during multi-
modal imaging .................................................................................................................... 115 
4.1 Introduction ......................................................................................................... 115 
4.2 Impact of detecting potentially serious incidental findings during multi-modal 
imaging ............................................................................................................................ 117 
4.3 Supplementary materials ..................................................................................... 147 
4.4 Conclusion .......................................................................................................... 175 
Chapter 5 Factors associated with potentially serious incidental findings and serious 
final diagnoses ..................................................................................................................... 177 
5.1 Introduction ......................................................................................................... 177 
5.2 Factors associated with potentially serious incidental findings and with serious 
final diagnoses on multi-modal imaging in the UK Biobank Imaging Study: a prospective 
cohort study ...................................................................................................................... 178 
5.2.1 Abstract........................................................................................................... 180 
5.2.2 Introduction .................................................................................................... 182 
5.2.3 Methods .......................................................................................................... 183 
5.2.4 Results ............................................................................................................ 187 
5.2.5 Discussion ....................................................................................................... 198 
5.2.6 Additional information ................................................................................... 201 




Chapter 6 Economic impact of potentially serious incidental findings on hospital 
services 207 
6.1 Introduction ........................................................................................................ 207 
6.2 Use and cost of hospital services by UK Biobank participants with potentially 
serious incidental findings: a case-control and before-after study utilising linked English 
Hospital Episode Statistics data from 2013-2016 ............................................................ 209 
6.2.1 Abstract .......................................................................................................... 210 
6.2.2 Introduction .................................................................................................... 212 
6.2.3 Methods .......................................................................................................... 213 
6.2.4 Results ............................................................................................................ 217 
6.2.5 Discussion ...................................................................................................... 236 
6.2.6 Additional information ................................................................................... 242 
6.3 Supplementary materials .................................................................................... 245 
6.4 Conclusion .......................................................................................................... 263 
Chapter 7 Discussion ...................................................................................................... 265 
7.1 Summaries of key findings relating to potentially serious incidental findings ... 265 
7.1.1 Prevalence and nature .................................................................................... 265 
7.1.2 Follow-up and final diagnoses ....................................................................... 266 
7.1.3 Factors associated with PSIFs and with serious final diagnoses .................... 266 
7.1.4 Participants’ understanding of consent to feedback ....................................... 268 
7.1.5 Non-medical impacts of feedback on participants ......................................... 268 
7.1.6 Opinions of receiving feedback...................................................................... 268 
7.1.7 Economic impact of feedback ........................................................................ 269 
7.2 Strengths and limitations .................................................................................... 270 
7.3 Impact on participants, research and policy ....................................................... 272 
7.4 Unanswered questions and future research ......................................................... 274 
7.5 Final summary .................................................................................................... 277 
Abbreviations ..................................................................................................................... 279 
Glossary .............................................................................................................................. 281 










Table of tables 
Table 2-1: Methods of follow up of 234 people with potentially serious incidental findings 
and severity of their final diagnoses ...................................................................................... 51 
Table 5-1: Characteristics of the UK Biobank cohort and the imaged sub-cohort included in 
this study .............................................................................................................................. 188 
Table 5-2: Odds ratios for potentially serious incidental findings (PSIFs) and serious final 
diagnoses comparing two protocols ..................................................................................... 190 
Table 5-3: Final diagnoses of 325 potentially serious incidental findings detected in 283 
participants ........................................................................................................................... 191 
Table 6-1: Numbers (%) of 179 cases (21 with serious and 158 with non-serious final 
diagnoses) and their 1:1 matched controls with ≥ 1 hospital contact during the year before 
and the year after feedback of a potentially serious incidental finding ................................ 219 
Table 6-2: Median numbers (interquartile and full range) of hospital contacts generated by 
179 cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 matched 
controls during the year before and after feedback of a potentially serious incidental finding
 ............................................................................................................................................. 224 
Table 6-3: Median (interquartile and full range) hospital costs (£) generated by 179 cases (21 
with serious and 158 with non-serious final diagnoses) and their 1:1 matched controls during 










Table of figures 
Figure 2-1: Forest plots of the per-study prevalence and pooled prevalence estimates of 
potentially serious incidental findings (PSIFs), and of PSIFs plus indeterminate incidental 
findings (IFs), detected on brain magnetic resonance imaging (MRI) .................................. 45 
Figure 2-2: Forest plots of the per-study prevalence and pooled prevalence estimates of 
potentially serious incidental findings (PSIFs), and of PSIFs plus indeterminate incidental 
findings (IFs), detected on thoracic, abdominal and brain and body magnetic resonance 
imaging (MRI) ....................................................................................................................... 47 
Figure 2-3: Numbers and types of potentially serious incidental findings (PSIFs) on magnetic 
resonance imaging (MRI) by body region ............................................................................. 48 
Figure 5-1. Participant flowchart ......................................................................................... 184 
Figure 5-2. Age- and sex-adjusted odds ratios for potentially serious incidental findings 
(PSIFs) by PSIFs protocol. .................................................................................................. 195 
Figure 5-3. Age- and sex-adjusted odds ratios for serious final diagnoses stratified by 
potentially serious incidental findings (PSIFs) protocol ...................................................... 197 
Figure 6-1: Participant flowchart ......................................................................................... 214 
Figure 6-2: Total numbers (% of total) of hospital contacts generated by 179 cases (21 with 
serious and 158 with non-serious final diagnoses) and their 1:1 matched controls during the 
year before and after feedback of a potentially serious incidental finding .......................... 222 
Figure 6-3: Total hospital costs in £ (% of total) generated by 179 cases (21 with serious and 
158 with non-serious final diagnoses) and their 1:1 matched controls during the year before 
and the year after feedback of a potentially serious incidental finding ................................ 227 
Figure 6-4: Cumulative hospital costs (£) generated by cases and controls over the year 










Table of supplementary tables 
Supplementary Table 2-1: Search strategy 1: Incidental findings on cardiac and abdominal 
MRI ........................................................................................................................................ 59 
Supplementary Table 2-2: Search strategy 2: Update for review of incidental findings on 
brain MRI ............................................................................................................................... 60 
Supplementary Table 2-3: Incidental findings on brain magnetic resonance imaging .......... 61 
Supplementary Table 2-4: Incidental findings on thoracic magnetic resonance imaging ..... 62 
Supplementary Table 2-5: Incidental findings on abdominal magnetic resonance imaging . 63 
Supplementary Table 2-6: Details of included studies ordered by region imaged and 
descending sample size .......................................................................................................... 79 
Supplementary Table 2-7: Sequences evaluated for incidental findings in included studies, 
ordered by region imaged and descending sample size ......................................................... 84 
Supplementary Table 2-8: 95% prediction intervals (and 95% confidence intervals to enable 
direct comparison) ................................................................................................................. 87 
Supplementary Table 2-9: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - brain ................................... 88 
Supplementary Table 2-10: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - thorax ................................. 89 
Supplementary Table 2-11: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - abdomen ............................. 90 
Supplementary Table 2-12: Difference in estimates of prevalence of PSIFs between 
subgroups ............................................................................................................................... 92 
Supplementary Table 2-13: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or IFs 
which required follow-up (as per each study’s definition), ordered by descending sample size 
- age ........................................................................................................................................ 93 
Supplementary Table 2-14: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or IFs 
which required follow-up (as per each study’s definition), ordered by descending sample size 
- sex ........................................................................................................................................ 95 
Supplementary Table 2-15: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or IFs 
which required follow-up (as per each study’s definition), ordered by descending sample size 
– other factors ........................................................................................................................ 97 




Supplementary Table 6-2: Details of 32 cases with at least one Elixhauser Index condition 
and their matched controls ................................................................................................... 248 
Supplementary Table 6-3: Median (interquartile and full range) inpatient costs (£) generated 
by 179 cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls during the year before and after feedback of a potentially serious incidental 
finding .................................................................................................................................. 252 
Supplementary Table 6-4: Median (interquartile and full range) outpatient costs (£) 
generated by 179 cases (21 with serious and 158 with non-serious final diagnoses) and their 
1:1 matched controls during the year before and after feedback of a potentially serious 
incidental finding .................................................................................................................. 257 
Supplementary Table 6-5: Median (interquartile and full range) hospital costs (£) generated 
by 179 cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls after feedback of a potentially serious incidental finding over 282.5 person-





Table of supplementary figures 
Supplementary Figure 2-1: Selection of included studies...................................................... 65 
Supplementary Figure 2-2: Forest plots of the per-study prevalence and pooled prevalence 
estimates of suspected malignant incidental findings (IFs), and of suspected malignant IFs 
plus possible indicators of malignancy, detected on brain, thoracic, abdominal and brain and 
body magnetic resonance imaging (MRI) .............................................................................. 67 
Supplementary Figure 2-3: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by imaging setting – brain studies ................................ 69 
Supplementary Figure 2-4: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by imaging setting – thorax studies .............................. 70 
Supplementary Figure 2-5: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by imaging setting – abdomen studies .......................... 71 
Supplementary Figure 2-6: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by imaging setting – brain and body studies ................. 72 
Supplementary Figure 2-7: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by blinding of readers to participants’ characteristics 
imaging setting – brain studies .............................................................................................. 73 
Supplementary Figure 2-8: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by blinding of readers to participants’ characteristics 
imaging setting – thorax studies ............................................................................................ 74 
Supplementary Figure 2-9: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by blinding of readers to participants’ characteristics 
imaging setting – abdomen studies ........................................................................................ 75 
Supplementary Figure 2-10: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by blinding of readers to participants’ characteristics 
imaging setting – brain and body studies ............................................................................... 76 
Supplementary Figure 2-11: Forest plot showing study-specific prevalence of potentially 
serious incidental findings, ordered by number of image readers – brain studies ................. 77 
Supplementary Figure 6-1: Total costs in £ (% of total) of inpatient care generated by 179 
cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 matched 
controls during the year before and the year after feedback of a potentially serious incidental 
finding .................................................................................................................................. 250 
Supplementary Figure 6-2: Total costs in £ (% of total) of outpatient care generated 179 




controls during the year before and the year after feedback of a potentially serious incidental 
finding .................................................................................................................................. 255 
Supplementary Figure 6-3: Total hospital costs in £ (% of total) generated by 179 cases (21 
with serious and 158 with non-serious final diagnoses) and their 1:1 matched controls during 
the 282.5 person-years of follow-up available after feedback of a potentially serious 






Chapter 1 Introduction 
1.1 The challenge of incidental findings 
1.1.1 Definitions 
In 2006, Illes et al. defined incidental findings (IFs) as “observations of potential clinical 
significance unexpectedly discovered in healthy subjects or in patients recruited to any 
imaging research study, and unrelated to the purpose or variables of the study” (Illes et al., 
2006). However, an increasing awareness and experience of managing individuals with IFs 
led major research funding bodies to state that IFs should be anticipated, rather than defined 
as ‘unexpected’ (Medical Research Council and Wellcome Trust, 2014). As such, an IF may 
be defined as a finding “concerning an individual research participant that has potential 
health or reproductive importance and is discovered in the course of conducting research but 
is beyond the aims of the study” (Wolf et al., 2008). However, researchers vary in their 
application of this definition. Rather than focusing on only those findings of ‘health or 
reproductive importance,’ some studies consider normal anatomical variants and post-
surgical appearances to be IFs (Sandeman et al., 2013), although some studies do then 
further sub-classify these as common asymptomatic findings (Hegenscheid et al., 2013). 
Ethicists have argued that individuals should only receive feedback of IFs which are 
clinically significant. For example, IFs which are life-threatening (such as malignancies), or 
IFs which could be treated (such as large abdominal aortic aneurysms), or where feedback 
may inform reproductive decision making (such as cystic fibrosis carrier status) (Wolf et al., 
2008). In practice, determining which IFs meet the definition of ‘clinically significant’ is 
difficult for two reasons: the limitations of research imaging, and the limits of current 
knowledge about particular IFs. 
1.1.1.1 Limitations of research imaging 
Research imaging may not facilitate firm diagnoses. Research imaging is tailored to generate 
imaging data in order to address a specific scientific question or questions. In contrast, 
clinical imaging is tailored to optimise the demonstration of a diagnosis, or diagnoses, which 
a doctor thinks may account for a patient’s particular set of clinical symptoms and signs. As 
such, research imaging can differ enormously from the imaging performed within clinical 
practice, and may be performed in a very different group of individuals. Any form of 




the study. For example, a study which uses body magnetic resonance imaging (MRI) to 
investigate the distribution of body fat in a group of asymptomatic individuals may also 
demonstrate structural diseases such as tumours or aneurysms. Different types of clinical 
imaging are required to firstly optimally demonstrate tumours versus aneurysms, and 
secondly to provide the specific visual information which is needed to inform the very 
different treatment plans for these two conditions, and in clinical practice patients with 
tumours will undergo different imaging to those with aneurysms. IFs on research imaging 
are therefore usually not demonstrated optimally, making judgements of their clinical 
severity difficult in some cases; and research imaging may not provide all of the detailed 
visual information needed to inform the treatment plan.  
Given the difficulties with optimal demonstration of IFs on research imaging, some authors 
have called for clinical imaging to be added to all research study protocols (Milstein, 2008). 
The potential benefit of this approach would be to make firm diagnoses within the research 
setting, saving publicly-funded healthcare systems from the service and cost burdens of 
investigating IFs. However, adding clinical imaging to a research protocol may simply not be 
feasible within a research context, due to additional costs, the limits of the available scanning 
time, or the tolerance of participants to lie still for further scans (Booth et al., 2010).  
1.1.1.2 Limitations of current knowledge of particular IFs 
The application of a definition of ‘clinically significant’ presupposes knowledge of the 
natural history of an IF; however, such data may be lacking. For example, a systematic 
review found that members of the general population with white matter hyperintensities had 
an approximately three times increased risk of incident stroke and of dementia compared to 
those without (Debette and Markus, 2010). From this, the authors concluded that participants 
with white matter hyperintensities should be investigated for other risk factors for stroke and 
dementia (Debette and Markus, 2010). However, the methods used to measure burden of 
white matter hyperintensities varied between studies, and it was not clear how the risk of 
stroke and dementia varied with either the volume or the presence versus absence of white 
matter hyperintensities. As such, informing participants about white matter hyperintensities 
may be of limited clinical value at present, but our judgements of the clinical severity of 
some IFs is likely to evolve as new evidence becomes available.  
Image readers may have variable access to clinical information about research participants, 
which may also cause difficulties in judging the clinical significance of an IF. For example, 




(along with brief data on their demographics and lifestyle risk factors such as smoking) 
(Gibson et al., 2018), but the radiologists do not have access to previous clinical imaging. In 
this context, an atypical-appearing kidney cyst will likely be fed back as this may represent 
malignancy. However, if previous imaging was available and could demonstrate no 
significant change over a reasonable time interval, this would enable a firmer judgement that 
such an IF is most likely non-serious, and may not warrant feedback. 
Taking in to account the limitations of research imaging, our current knowledge of the 
prognosis of IFs, and variable availability of clinical information on research participants, 
the UK Biobank study proposed the term ‘potentially serious IFs’ (PSIFs), defined as those 
‘indicating the possibility of a condition which, if confirmed, would carry a real prospect of 
seriously threatening life span, or of having a substantial impact on major body functions or 
quality of life’ (Gibson et al., 2018).  
Multiple chapters presented in this thesis are based on UK Biobank data, and as such the 
term ‘PSIFs’ is used to refer specifically to IFs which meet the UK Biobank definition; 
otherwise, the more general term ‘IFs’ is applied. The next section will briefly describe the 
recent development of large imaging studies, including the UK Biobank Imaging Study, in 
order to summarise the scale of the challenge of IFs.  
1.1.2 Scale of the challenge 
Our estimates of the scale of the challenge of IFs are informed by the development of large 
population-based imaging research projects, and the increase in imaging within non-research 
contexts, including public health screening programmes, clinical imaging and direct-to-
consumer (i.e. commercial) imaging. While this thesis focuses on PSIFs detected in 
apparently asymptomatic volunteers undergoing brain and body MRI, there is a large body 
of literature on IFs detected within non-imaging contexts, particularly genomics, of which 
the more recent and controversial developments will be summarised.  
1.1.2.1 Large population-based imaging research projects 
MRI is becoming increasingly popular as a research imaging tool, owing to the lack of 
ionising radiation. Worldwide, several large population-based studies are collecting single or 
multi-region MRI data on large subsets of – or their entire – cohorts. Data from the imaged 
cohorts will enable investigations of associations between imaging and other variables, so 
generating insights into health and disease (Bertheau et al., 2016; Collins, 2012; German 




Matthews and Sudlow, 2015; Petersen et al., 2017; Smith et al., 2015; Stephan et al., 2015; 
Suzuki et al., 2017; Volzke et al., 2011). 
The largest ongoing multi-region MRI studies are based in the UK and in Germany, and a 
further large study is being planned in Canada. The UK Biobank will generate the world’s 
largest multi-modal imaging dataset by performing brain, cardiac, and body MRI, carotid 
Doppler ultrasound and dual-energy X-ray absorptiometry (DXA) in 100,000 of its 500,000 
cohort (i.e. around one fifth of all the participants) (Matthews and Sudlow, 2015). As of 
September 2018, over 27,000 participants have been imaged (UK Biobank, 2018c). 
Participants were originally recruited between 2006 and 2010, when aged 40–69 years old, 
and underwent extensive phenotyping via questionnaire, blood sampling, physical 
measurements and cognitive testing (Sudlow et al., 2015). Their health is followed up via 
linkages to routinely collected healthcare data (Sudlow et al., 2015). In Germany, the Study 
of Health in Pomerania (SHIP) performed whole-body MRI in 2,500/4,416 (57%) of their 
population-based participants (Hegenscheid et al., 2013) which involved coronal plane 
whole-body MRI, with further sequences focused on imaging the spine, brain, neck, chest 
and abdomen and pelvis (Hegenscheid et al., 2009). The German National Cohort study has 
built on the experiences of the SHIP and collaborates with other ongoing national cohort 
studies including UK Biobank (German National Cohort (GNC) Consortium, 2014). They 
aim to conduct 3.0T MRI of the brain, heart, body and spine in 30,000 of their 200,000 
(15%) participants (Bertheau et al., 2016). The Canadian Alliance for Healthy Hearts and 
Minds (CAHHM) are currently recruiting participants from existing Canadian cohorts 
(including from the Canadian Partnership for Tomorrow Project which itself consists of 
cohorts from five studies, totalling > 300,000 participants), and perform brain, cardiac and 
abdominal MRI, plus dedicated cerebrovascular MRI sequences (Anand et al., 2016). 
In contrast to UK Biobank, the SHIP, the German National Cohort and CAHHM, other 
studies are performing (or have completed) MRI of single body regions, most commonly 
either of the brain or the heart. The Rotterdam Scan Study began performing brain MRI in a 
subset of participants in 1995 and 1999, and in 2005 extended its programme to image the 
entire cohort (Ikram et al., 2015; Ikram et al., 2011). As of July 2015, over 12,000 brain 
scans had been conducted in over 5,800 participants (Ikram et al., 2015). The Lothian Birth 
Cohort study acquired brain MRI in 700/1,091 (64%) members of its cohort three years after 
their initial recruitment (Wardlaw et al., 2011). Similarly, brain MRI was acquired in 
803/135,335 (0.6%) Canadian participants enrolled in the multinational Prospective Urban 




participants enrolled in the French Three City study (Stephan et al., 2015). Large cardiac 
MRI datasets have been, or are being, acquired in general populations (Schelbert et al., 2012; 
Tsao et al., 2011), and within populations with higher rates of cardiac disease (Marwick et 
al., 2013; Taylor, 2005; Victor et al., 2004). The Multi-Ethnic Study of Atherosclerosis, the 
Jackson Heart Study and the Dallas Heart Study aim to improve understanding of how 
cardiovascular disease could be prevented, particularly in black Americans, and to this end 
conducted cardiac MRI in 5,000/6,814 (73%) (Natori et al., 2006), around 2,000/5,301 
(38%) (Marwick et al., 2013; Taylor, 2005) and 2,793/6,101 (46%) participants respectively 
(Victor et al., 2004). Also in the USA, 1,794/3,539 (50.7%) participants enrolled in the 
Framingham Heart Study Offspring Cohort underwent cardiac MRI (Tsao et al., 2011). The 
ICELAND MI study performed cardiac MRI in 936/5,764 (16%) population-based 
participants involved in the Age, Gene/Environment Susceptibility Reykjavik study 
(Schelbert et al., 2012).  
Many other large epidemiological studies do not conduct imaging at present. The Medical 
Research Council funds 36 UK-based cohorts of over 1,000 participants each, the largest 
being the Million Women Study (N=1.3 million) (Medical Research Council, 2014). Three 
of the largest non-UK cohorts are in the magnitude of hundreds of thousands of adult 
participants: the China Kadoorie Biobank (N=512,891 adults aged 30–79) (Chen et al., 
2011), CONSTANCES (N=200,000 French adults aged 18–69) (Zins and Goldberg, 2015b) 
and the Mexico City Prospective Study (N=150,000) (CTSU, 2018).  The addition of 
imaging to these large cohorts in future would add further to the scale of the challenge of 
IFs. 
1.1.2.2 Other imaging settings 
The previous section described the scale of the challenge of IFs in terms of studies which 
perform MRI for research in large, population-based cohorts of apparently asymptomatic 
people. This section will describe the contributions of non-research imaging of apparently 
asymptomatic people and of clinical imaging of patients to the scale of the challenge of IFs. 
Apparently asymptomatic people (who we define as ‘community-dwelling people not 
selected for imaging on the basis of symptoms, risk factors, or disease’) may access MRI 
directly (Lee et al., 2008; Tarnoki et al., 2015; Tsushima et al., 2005) via imaging services 
marketed direct-to-consumers. They may also access imaging via occupational health 
assessments (Weber and Knopf, 2006), private health insurance (Cieszanowski et al., 2014) 




Direct-to-consumer marketing of prescription-only medications is not permitted in the UK 
(Magrini and Font, 2007), but there are no such limits on direct-to-consumer advertising of 
imaging services. In 2004, a study of 40 print advertisements for direct-to-consumer imaging 
services found that none mentioned the risks of having a scan (Illes et al., 2004a), such as the 
detection of IFs which, after clinical assessment, turn out not to be serious. In 2010, in a joint 
statement to the UK Health Secretary, the British Medical Association and the Academy of 
Medical Royal Colleges called for stronger regulation of the marketing of direct-to-consumer 
imaging tests, including mandatory provision of information on the risks of the test, and the 
implications of the results of the test and any follow-up that may be required (Meldrum and 
Douglas, 2010). To help inform people who were considering accessing direct-to-consumer 
imaging, the UK National Screening Committee and the National Health Service (NHS) 
published a leaflet, outlining the differences between these types of imaging, which are often 
referred to as ‘screening’, and public health screening services offered by the NHS (UK 
National Screening Committee and National Health Service, 2014). In brief, before 
implementation, proposed public health screening programmes are assessed against criteria 
to ensure they detect diseases which are important public health problems with good 
sensitivity and specificity at an early stage, for which an effective, acceptable treatment is 
available (Wilson et al., 1968). Screening programmes should only be implemented when 
they are deemed to provide net benefit over harm after consideration of the evidence, which 
should be reviewed at regular intervals (Harris et al., 2011). In contrast to the diseases 
targeted by public health screening programmes, direct-to-consumer imaging of 
asymptomatic people may not necessarily detect a disease at a stage where treatment will 
confer a survival benefit; this would depend on the exact imaging offered, and the disease of 
interest. However, public health screening programmes may also generate substantial 
volumes of IFs. Recent analyses of 17,309 participants’ low-dose computed tomography 
(CT) chest scans for lung cancer screening found that this programme generated extra-
pulmonary IFs requiring further evaluation in every fifth person (Nguyen et al., 2017), which 
will likely result in negative impacts, such as psychological distress, for some (Harris et al., 
2014). Furthermore, unlike diseases which are the focus of public health screening 
programmes, there is no clear evidence on which to base decisions about treatment for many 
IFs. Early treatment of some disorders, such as asymptomatic unruptured intracranial 
aneurysms, may in fact cause harm (Mohr et al., 2014). 
Rapidly increasing rates of clinical imaging threaten to overwhelm radiology services. 
Between 2010 and 2015, the numbers of different types of scans performed in Scotland all 




including radiographs, by 10% (The Royal College of Radiologists Standing Scottish 
Committee, 2016). In response, an emergency group convened to redesign Scottish radiology 
services at a national level (Scottish Radiology Transformation Programme and NHS 
National Services Scotland, 2017). Imaging is now commonly used to rule out concerning 
conditions, rather than being selectively applied to the smaller number of patients in whom 
there is a high probability of that specific diagnosis. In a study based in an American 
emergency department, staff requested 370 CT angiograms over 12 months for patients with 
suspected aortic dissection; 19 (5%) did have new dissections, but 30 (8%) had IFs which 
required follow-up (Prabhakar et al., 2015). Furthermore, clinical imaging for some 
particular conditions is now increasing, either due to increased coverage of tissue volumes 
(for example, whole-body CT for trauma patients who would have previously undergone 
targeted imaging (Sierink et al., 2014)) or new indications for so-called ‘routine’ imaging 
(for example, imaging prior to some operations (See et al., 2010)). These changes in the use 
of imaging in clinical practice contribute to the recent huge increases in demand for imaging 
services. 
IFs have been documented in studies of patients undergoing many different types of clinical 
imaging of different body regions, including positron emission tomography (Shie et al., 
2009), DXA (Bazzocchi et al., 2012), ultrasound (Choi et al., 2016), CT (James et al., 2017; 
Prabhakar et al., 2015; Sierink et al., 2014) and MRI (Sherrer et al., 2018). A systematic 
review of 44 studies of IFs detected in patients undergoing diagnostic imaging (N>100,000; 
one study did not report sample size) found that the mean frequency of IFs was around 24%. 
IFs were most common in patients undergoing CT (31%), and in patients with non-specific 
initial diagnoses (31%) (Lumbreras et al., 2010). However, the prevalence of IFs may vary 
widely between studies. A recent umbrella review of 20 systematic reviews of the prevalence 
of IFs on imaging of mixed patient and asymptomatic populations found evidence of 
substantial between-study heterogeneity in 15 of the included reviews (O'Sullivan et al., 
2018). For example, data from a systematic review of eleven studies of patients undergoing 
cardiac MRI found the prevalence of extra-cardiac IFs to be 34%, with an I2 of 99% 
(O'Sullivan et al., 2018). 
The increase in clinical imaging will result in more IFs, the numbers of which are likely to 
vastly outstrip those generated in research imaging settings. As described earlier, IFs may 
require even more imaging to reach firm diagnoses and guide treatment plans, and as such 
IFs from clinical imaging place a substantial burden on health services, which are already 




1.1.2.3 Non-imaging contexts 
While this thesis focuses on PSIFs detected on research MRI conducted in apparently 
asymptomatic volunteers, considerable attention has been given to IFs which arise from non-
imaging tests conducted across the life-course, from prenatal testing through to autopsy (Bui 
et al., 2014; Kingsley-Loso et al., 2015; Parker et al., 2013; Thomas et al., 2017). Recently, 
there have been considerable developments and controversies surrounding genomic IFs, 
which will be briefly summarised here.  
The human genome sequence was completed in 2003 and made available to researchers in 
order to further our knowledge of the role of genes in health and disease (National Human 
Genome Research Institute, 2012). Following a rapid period of technological advancement, 
the cost of sequencing fell from around $25 million in 2006, to less than $1,000 today 
(National Human Genome Research Institute, 2016). As such, genomics testing has become 
a much more accessible tool for research, as well as clinical testing, and is available direct-
to-consumers. As with imaging research, several large scale population-based studies are 
generating, or already hold, genomic data on large subsets or their entire cohort, such as UK 
Biobank (N=502,000) (UK Biobank, 2018a), the China Kadoorie Biobank (N>100,000) 
(China Kadoorie Biobank, 2015), the 100,000 Genomes Project (Samuel and Farsides, 2017) 
and CONSTANCES (N=200,000) (Zins and Goldberg, 2015a; b). 
As the use of genomics in research is expanding, so too is its role in clinical practice. 
Clinical genomics testing has a wide range of applications, from assessment of risk of 
complex diseases, identification of carriers of diseases such as cystic fibrosis, predictive 
screening in prenatal and new-borns, diagnostic testing for diseases such as Duchenne 
muscular dystrophy, predictive testing for diseases such as breast cancer and Huntington 
disease, and assessing likely responses to treatments such as immunosuppressive agents 
(Delaney et al., 2016). As genomics technologies reduced in price over recent years, 
companies began marketing genomics testing direct-to-consumers to enable them to assess 
health risks, carrier status, predict responses to medication and trace their ancestry (Roberts 
and Ostergren, 2013). 
In contrast to imaging IFs which are visually apparent to viewers, genomic IFs are not 
immediately apparent, but must be deliberately sought out (Green et al., 2013). In 2013 the 
American College of Medical Genetics and Genomics (ACMG) appointed a working group 
to make recommendations on handling genomics IFs responsibly (Green et al., 2013). While 




working group recommended that laboratories seek and report on 56 different mutations 
when performing any exome or genome sequencing, regardless of the initial indication for 
sequencing, patient preferences for feedback, or patient age (Green et al., 2013). The ACMG 
recommendations implied that the referring doctor would be required to disclose these to the 
patient, or the patient would have to decline being tested entirely (Kang et al., 2016). This 
situation presented ‘novel ethical and legal issues’ (Evans, 2013) such as where patient 
autonomy could be ignored and children may be given results about adult-onset illnesses 
(Kang et al., 2016). Furthermore, laboratories and clinicians may be liable whether or not 
they check for the recommended 56 mutations (Evans, 2013): on the one hand, failing to 
disclose any clinically actionable IFs may generate negligence claims against laboratories 
and physicians; on the other, disclosing IFs which result in emotional harm, such as the 
return of unwanted results, is considered an ‘[injury] caused by purposeful behaviour’ which 
may generate an intentional tort lawsuit (Evans, 2013). The ACMG subsequently revised its 
position to suggest that patients should be able to opt out of testing for genes that were 
unrelated to the indication for sequencing (ACMG Board of Directors, 2015).  
 
1.2 Current knowledge of IFs and PSIFs 
The increasing use of imaging in research, clinical diagnostics, public health screening and 
direct-to-consumer commercial imaging enterprises will likely only increase the challenge of 
imaging IFs in the years to come. This section will summarise our current knowledge of IFs 
and PSIFs on research imaging, organised in to seven themes: their prevalence and nature 
(Section 1.2.1); follow-up and final diagnoses (Section 1.2.2); variation in prevalence of 
PSIFs and serious final diagnoses (Section 1.2.3); participants’ understanding of consent to 
feedback of IFs (Section 1.2.4); non-medical impacts of feedback of PSIFs (Section 1.2.5); 
participants’ and healthcare professionals’ opinions on feedback of PSIFs (Section 1.2.6); 
and the economic impact of feedback of PSIFs (Section 1.2.7). 
1.2.1 Prevalence and nature of IFs on MRI of apparently 
asymptomatic volunteers 
Our current knowledge of the prevalence and types of IFs detected on brain MRI of 
apparently asymptomatic volunteers is largely informed by a systematic review (Morris et 
al., 2009). Meta-analyses of 16 studies of 19,559 apparently asymptomatic people found that 




and of 15 studies of 15,559 people the pooled prevalence of non-neoplastic IFs was 2.0% 
(95% CI 1.1–3.1%) (Morris et al., 2009).  
The division of IFs into neoplastic and non-neoplastic categories is not equivalent to the 
categories of potentially serious versus non-serious IFs. The most common neoplastic IFs 
were meningiomata (pooled prevalence 0.29% [95% CI 0.13–0.51%]) (Morris et al., 2009). 
In many cases meningiomata may not cause symptoms or serious disease, and those < 2 cm 
diameter are no longer fed back to participants within the population-based Rotterdam Scan 
Study (Bos et al., 2016).  
It is also important to distinguish whether or not prevalence estimates of IFs represent 
suspected conditions or final diagnoses. None of the studies included in this review 
systematically followed up unselected participants with an IF to gather data on final 
diagnoses. Therefore, while the pooled prevalence of intracranial aneurysms was 0.35% 
(95% CI 0.13–0.67%) (Morris et al., 2009) this may reflect the prevalence of suspected, 
rather than proven, aneurysms.  
The prevalence estimates from this systematic review exclude certain findings, such as 
normal anatomical variants (Morris et al., 2009). As such their estimates of prevalence of IFs 
are not overinflated by such findings. In turn, this highlights one area of caution with 
interpreting the overall prevalence estimates of individual studies, which may count normal 
variants such as mega cisterna magna (Haberg et al., 2016) or post-surgical appearances as 
IFs (Sandeman et al., 2013). The review also excluded silent brain infarcts from the non-
neoplastic pooled prevalence estimates after the authors considered how difficult it can be to 
accurately determine whether or not an infarct is truly asymptomatic, and the lack of 
evidence for benefits of primary prevention therapies in such patients (Morris et al., 2009). 
While silent brain infarcts were found in 7% of 2,000 participants from the Rotterdam Scan 
Study (Vernooij et al., 2007), the benefits of treating these remain unclear as there have not 
been any relevant randomised controlled trials (Smith et al., 2017). However, at least one 
such trial is planned (Sui, 2017), and as such, future studies may influence our understanding 
of the clinical significance of, and therefore measurement and prevalence of, IFs over time. 
Changes in imaging technology may also influence the prevalence of IFs over time. Morris 
et al. included studies published up to and including 2008, and found that IFs were more 
prevalent in studies which used high compared to low resolution imaging (4.3% [95% CI 




imaging technologies and their increased use as research tools over the past decade since this 
review was published, the prevalence of IFs may have increased.  
By contrast with our knowledge of brain IFs, there are no existing systematic reviews of the 
prevalence of IFs, PSIFs, or serious final diagnoses on body MRI conducted in healthy 
populations (O'Sullivan et al., 2018). Estimates of the prevalence of IFs on body MRI may 
be as great as 30% (The Royal College of Radiologists, 2011), but three of the four studies 
underpinning this estimate were conducted in patient, rather than apparently asymptomatic 
volunteer populations and used CT rather than MRI (Furtado et al., 2005; Machaalany et al., 
2009; Siddiki et al., 2008) (the remaining study described their sample as both ‘research 
participants’ and ‘patients’ (Orme et al., 2010)). As such, this estimate of IFs may not be 
easily generalisable to apparently asymptomatic populations undergoing body MRI. The 
prevalence of IFs seems to be greater on body, compared to brain MRI. One of the largest 
studies of brain and body imaging included 2,500 healthy volunteers, whose images were 
first reviewed by radiologists and any potentially relevant IFs were escalated for review by 
an advisory board (Hegenscheid et al., 2013). This process resulted in an overall prevalence 
of IFs of 2% (n=46) on brain, 3% (n=76) on chest, and 22% (n=552) on abdominal and 
pelvic MRI (Hegenscheid et al., 2013). 
In summary, IFs occur in approximately 1-2% of apparently asymptomatic volunteers who 
undergo brain MRI, but it is not entirely clear what proportion of these represent potentially 
serious IFs or serious final diagnoses. Furthermore, with advances in our knowledge of 
different conditions and of imaging technologies, these estimates may change over time. 
Conversely, relatively little is known of the prevalence of IFs on body MRI, but it is likely to 
be higher compared to brain MRI.    
1.2.2 Follow-up and final diagnoses 
As described in Section 1.1.1, the non-diagnostic nature of research imaging and our lack of 
knowledge of natural history and variable availability of clinical information about research 
participants will lead to IFs which are of uncertain clinical significance. Participants with 
such IFs will likely undergo further clinical assessments in order to resolve this uncertainty.  
In 1972, Rang described Ulysses syndrome, as patients ‘though healthy enough at the outset, 
make a long journey through the investigative arts and experience a number of adventures 
before reaching their point of departure once again’ (Rang, 1972). Its cause: ‘meritorious 




ordering tests to avoid criticism by seniors, and the gamut of tests available (Rang, 1972).  
Rang describes Ulysses syndrome as short-lived, and that ‘no mortality or permanent 
harmful effects have yet been noted.’ But by 2003, opinion on the harmful effects of over-
investigation had changed. Victims of Medical Imaging Technology (VOMIT) became a 
tongue-in-cheek acronym for the patients anxious as a result of tests, and the doctors whose 
time must be spent reassuring them (Hayward, 2003). By 2014, concerns about the causes of 
over-investigation and its effects on patients and health services led the Scottish Chief 
Medical Officer to question the fundamental principles of how we practise medicine today 
(Chief Medical Officer for Scotland, 2016).  
First we must understand the magnitude of the burden of clinical assessments performed for 
participants with IFs, and secondly, we must know how many of these turn out to be serious 
disease. Investigations which result in a non-serious final diagnosis may be deemed 
unnecessary in retrospect (Gibson et al., 2018). Clinical assessments of participants with IFs 
may involve appointments with general practitioners (GPs) or hospital doctors, blood tests, 
imaging, or more invasive tests such as biopsies, before a final diagnosis is reached. 
However, little is known of the burden of this follow-up, or in contrast, of the natural course 
of IFs which are not investigated and left untreated (Wardlaw et al., 2015), or the net benefit 
or harms to participants. While there are many case reports which describe the follow-up of 
individual patients, systematically collected, long-term data on unselected participants with 
IFs are relatively limited. The majority of Rotterdam Scan Study participants with IFs were 
managed using either wait-and-see policies, or discharged after one hospital appointment 
(144/188, 77%), but the numbers of participants undergoing particular types of clinical 
assessment, for example, repeat imaging, were not reported (Bos et al., 2016). Furthermore, 
this study only performed brain MRI, and the results may not be generalisable to the 
management of IFs detected on imaging of other body regions. As mentioned in Section 
1.2.1, data on final diagnoses, and of the prevalence of serious final diagnoses in particular, 
of IFs are lacking; none of the 16 studies included in a systematic review of IFs on brain 
MRI systematically followed up participants with IFs (Morris et al., 2009).  
Until large, long-term studies of unselected participants with IFs report data on the clinical 
assessments performed and the final diagnoses, we will not be able to provide potential 
research participants with details of the burden of follow-up they may endure in the pursuit 
of a final diagnosis, what proportion of participants’ journeys will lead them back to their 
point of departure, and what proportion will be given a diagnosis of serious disease. 




only: there is a possibility of demonstrating an IF, and if that occurs, some further tests and 
referrals may be required (Illes, 2006; Illes and Chin, 2008). 
1.2.3 Variation in the prevalence of PSIFs and of serious final 
diagnoses  
Best practice in handling IFs from research imaging encourages researchers to determine the 
likely prevalence of IFs which may be detected when studying a particular population 
(Medical Research Council and Wellcome Trust, 2014). Estimates of prevalence may vary 
depending on a number of different factors, which researchers may need to take into account 
when designing their IFs handling policies and creating participant consent materials. This 
section summarises our knowledge of the participant and study factors which may influence 
the prevalence of PSIFs and of serious final diagnoses.  
1.2.3.1 Participant factors 
Participant factors, such as age, sex, ethnicity, deprivation levels, lifestyle, body mass index 
(BMI) and medical history may result in variation of the prevalence of PSIFs or serious final 
diagnoses.  
Studies offer conflicting results on the variation of prevalence of IFs by age and sex. The 
prevalence of asymptomatic brain infarcts increased with the age of participants in the 
Rotterdam Scan Study, from 30/750 (4%) in those aged 45–59 years, to 47/257 (18%) in 
those aged 75–97 years. Conversely, there was no variation in the prevalence of incidental 
intracranial aneurysms with age in this same sample (Vernooij et al., 2007). The prevalence 
of IFs on brain MRI was higher in men compared to women all aged 73 enrolled in the 
Lothian Birth Cohort (134/368 [36%] versus 89/332 [27%] respectively, p=0.007) 
(Sandeman et al., 2013), whereas another study found no difference in the prevalence of IFs 
on brain MRI between men and women aged 22–84 years (N=1,113) (Hoggard et al., 2009). 
There are limited data on the associations between other factors and PSIFs and serious final 
diagnoses in apparently asymptomatic volunteers, and we can only speculate on the direction 
of any possible effects. Prevalence of PSIFs and of serious final diagnoses may vary by 
ethnicity or deprivation; if these result in differential access to healthcare, conditions are less 
likely to have been previously diagnosed, thus increasing the risk of PSIFs. The associations 
of harmful lifestyle factors such as high alcohol intake, smoking, poor diet, low physical 
activity and high BMI with structural diseases such as solid malignancies (Danaei et al., 




diagnoses. In a study of 148 volunteers who underwent whole-body MRI, those with IFs had 
a higher median BMI than those without (27 kg/m2 (interquartile range [IQR] 24–32 kg/m2) 
versus 24 kg/m2 (IQR 22–28 kg/m2), p=0.002) (Morin et al., 2009). However, the vast 
majority of IFs in this study would not have been considered as PSIFs. Similarly, pre-
existing morbidity may confer increased risks of structural diseases which may be detected 
incidentally. For example, a history of hypertension may conceivably increase the risk of 
incidentally detected large vessel aneurysms.  
1.2.3.2 Study factors 
The participant factors described above may affect the prevalence of PSIFs by influencing 
the underlying prevalence of diseases within a population. Study factors, relating to the 
imaging and the readers of those images, instead will affect the prevalence of PSIFs by 
influencing rates of disease demonstration and detection respectively.  
1.2.3.2.1 Imaging factors 
As described in Section 1.1.1.1, both research and clinical imaging are tailored to answer a 
particular question. This ‘tailoring’ occurs by varying parameters such as the field-of-view, 
the image resolution, use or omission of contrast media, and with regards to MRI, the 
strength of the magnet and the sequences performed. Studies from apparently asymptomatic 
volunteer and patient populations demonstrate how these factors may result in variation of 
the prevalence of IFs. 
The prevalence of IFs appears to increase with increasing field-of-view and with increasing 
image resolution, but does not seem to change with magnet strength. In a study of 254 
patients undergoing cardiac CT angiography, all had a low-dose whole-thorax CT before 
coned angiographic cardiac CT. The former, with a larger field-of-view, resulted in 66 
clinically significant extra-cardiac IFs in 52 (20%) patients; the latter, with smaller field-of-
view around the heart, resulted in four such findings in four (1.6%) patients (Kim et al., 
2009). IFs were detected more frequently on brain MRI of apparently asymptomatic 
volunteers imaged using high resolution sequences, compared to standard resolution 
sequences (4.3% versus 1.7%, p<0.001) (Morris et al., 2009). There was no difference in the 
prevalence of IFs on brain MRI of ‘normal volunteers’ imaged on a 1.5T compared to a 3.0T 
scanner (8% versus 10%, p=0.6) (Hoggard et al., 2009). 
The use of intravenous contrast agents may increase the overall prevalence of IFs, but may 




influence of contrast agents on the prevalence of PSIFs may not be important to large 
population-based imaging studies. Immediate adverse reactions to gadolinium-based contrast 
occur 0.2–3.3 times per 1,000 injections, and severe reactions (such as cardiac arrest) occur 
in approximately 1 in 40,000 injections (Prince et al., 2011). Even though these reactions are 
rare, it is difficult to justify these risks of harm to apparently asymptomatic volunteers who 
will undergo research imaging with no benefit to themselves. As such, the larger population-
based imaging studies (including UK Biobank which aims to image 100,000 people 
(Matthews and Sudlow, 2015)), do not perform contrast-enhanced imaging. 
1.2.3.2.2 Imaging reader factors 
Many different groups of readers may look at images collected for research (including 
scientists, radiographers, radiologists, and other medical specialists) and their level of 
experience may vary (The Royal College of Radiologists, 2011).  
It might be assumed that medically trained, experienced readers (such as consultant 
radiologists) are the most appropriate people to read images for IFs in order to detect and 
characterise them accurately. There is no evidence that the prevalence of IFs detected by 
subspecialist versus general radiologists differs. A systematic review of the prevalence of IFs 
on brain MRI conducted in apparently asymptomatic volunteers found no significant 
differences between the prevalence of IFs detected in 11 studies using neuroradiologists, 
compared to three studies using general radiologists (3.5% versus 2.3%, p=0.3) (Morris et 
al., 2009). 
However, shortages of radiology staff limit their availability for reporting research imaging 
(The Royal College of Radiologists, 2011). There was no significant difference in the 
proportion of 14 CT brain scans which were correctly classified as either normal or abnormal 
between a group of experienced readers (consultant neuroradiologists, consultant 
neurologists with an interest in stroke and consultant stroke physicians) compared to other 
readers (consultant neurologists, general practitioners and trainee physicians) (68% versus 
63%, p=0.3) (Wardlaw et al., 1999). Owing to the shortage of radiologists, further work is 
needed to compare the prevalence of PSIFs detected by different readers, and on stratified 
protocols whereby radiologists review only those scans which have been ‘flagged’ as 
needing their attention by a first-line staff member.  
Finally, the ability of readers to detect and characterise an IF may vary with the provision of 
information about participants, although there are currently no head-to-head comparisons to 




information to readers and the prevalence of either PSIFs or serious final diagnoses. A lack 
of information about participants could reduce prevalence of PSIFs if readers’ attention is 
not directed toward looking for particular abnormalities. Providing information on medical 
history may either result in ‘hypervigilance’ for related abnormalities, such as tumour 
recurrence in a research participant with a history of malignancy (thus increasing the 
prevalence of PSIFs), or conversely reduce the prevalence of PSIFs if readers can see that 
such findings have already been documented in medical records or are likely to be explained 
by the medical history. 
To summarise, there are limited data on the associations between participant factors and 
PSIFs, and that which is available on age and sex is inconsistent. The prevalence of IFs may 
increase with increasing field-of-view and image resolution, but may not vary with magnet 
strength. Finally, while radiologists may be assumed to be the most appropriate people to 
read images for IFs, staff shortages mean this is impractical to implement for all research 
imaging, and there are no head-to-head comparisons of different readers to inform this aspect 
of IFs policy design.  
1.2.4 Participants’ understanding of consent to feedback 
The principles of ethical medical research which involves human subjects, their data and 
other materials are stated in the Declaration of Helsinki (World Medical Organisation, 2013). 
With regards to facilitating informed consent for research: 
“Each potential subject must be adequately informed of the aims, 
methods, sources of funding, any possible conflicts of interest, 
institutional affiliations of the researcher, the anticipated benefits 
and potential risks of the study and the discomfort it may entail, 
post-study provisions and any other relevant aspects of the study” 
(World Medical Organisation, 2013).  
The research staff should check that the participant has understood the information, before 
seeking the participant’s voluntary consent (World Medical Organisation, 2013). The 
process of informed consent aims to respect the autonomy of potential research participants, 
and to protect them from potential harm (Jefford and Moore, 2008). Informed consent is also 
crucial to maintaining public trust in medical research (Farrar and Savill, 2014; Roache, 
2014), to enable studies of human volunteers to continue and thus generate insights which 




Regarding IFs, to facilitate informed consent for imaging research, study staff should inform 
participants of the potential for the detection of IFs, and explain how these will be handled 
(Farrar and Savill, 2014; Illes and Chin, 2008). The Netherlands Epidemiology of Obesity 
(NEO) population-based cohort study conducted MRI of the abdomen, plus either the brain 
or heart, in 2,580 individuals (de Mutsert et al., 2013). With regards to feedback of IFs, 
potential participants were informed that:  
“In principle, you do not receive the result of the MRI scan. The 
images of the MRI scan will be interpreted by a radiologist. When 
unexpected abnormalities are found that are likely to have serious 
health consequences when left undiagnosed, we will contact you 
and your GP within four weeks after the MRI scan. However, when 
no unexpected abnormalities are identified, this will not completely 
exclude medical abnormalities, as the quality of the images of the 
MRI scan performed for the NEO study may be not as good as an 
MRI scan for medical diagnostics” (de Boer et al., 2018).  
To assess participants’ understanding of this information, focus groups were conducted with 
23/56 (41%) NEO study participants who had received feedback of an IF (de Boer et al., 
2018). Despite the information on the limitations of the research imaging to completely 
exclude medical abnormalities, participants thought that a lack of IFs meant that they were 
healthy, and that the research MRI could detect diseases early (de Boer et al., 2018). These 
misperceptions had practical implications for participants, as they were seen as potential 
benefits of taking part in the study, and influenced their decisions to participate (de Boer et 
al., 2018).  
The NEO study participants also thought that all IFs would be fed back, rather than only 
those with likely ‘serious health consequences’ (de Boer et al., 2018). This may be due to 
participants’ underlying wishes for feedback of IFs. A study of 104 participants who had 
undergone neuroimaging for research found that 90% wished to be informed of any IF, 
regardless of its clinical significance (Kirschen et al., 2006). Similarly, qualitative interviews 
with 45 participants in the National Child Development Study cohort (N=17,000) who had 
not previously undergone MRI for research found that 41% would only participate if all IFs 
were fed back (Brown and Knight, 2010). 
 
These expectations of feedback of IFs may be related to beliefs around public health 
screening programmes (McCaffery et al., 2016), or participants’ motivations for undergoing 




symptoms arise as being advantageous to their health, allowing early treatment, and the 
opportunity to make decisions around family planning or enable relatives to undergo prompt 
screening (Opinion Leader, 2012; Ransohoff et al., 2002), benefits which are emphasised 
with regards to public health screening, but, as discussed above, may not necessarily occur in 
research imaging. The most common reason for taking part in imaging research appears to be 
the opportunity to get information about health. In SHIP, 394/405 (97%) participants said 
they took part to ‘know whether I am healthy’ (Schmidt et al., 2013). This sentiment is 
echoed by the early results of qualitative work with participants from the Rotterdam Scan 
Study (Bos and Vernooij, 2016) and participants from the NEO study, who took part in order 
to get results on either the presence or absence of diseases (de Boer et al., 2018). Feasibly, 
people in regions with overstretched publicly-funded healthcare systems may consider 
research imaging as a faster route to access a health service. Alternatively, people who are 
unable to afford healthcare in regions with private healthcare systems may look to research 
imaging as a ‘free scan’ (Wardlaw et al., 2015).  
These studies demonstrate participants’ misperceptions of the abilities of research imaging to 
make clinical diagnoses, and that their motivations to participate in studies may be based on 
these misperceptions. It is concerning that these misperceptions occur despite carefully 
worded consent materials which aim to give a realistic account of what participants can 
expect with regards to feedback. Evaluating participants’ understanding of consent is 
therefore key to developing a truly informed consent process.  
1.2.5 Non-medical impacts of feedback on participants 
Section 1.1.1 described how the limitations of research imaging may lead to a lack of firm 
diagnoses. In Section 1.2.2, we saw how feedback of such IFs will tend to generate medical 
impacts in the form of clinical assessments which expose participants to harm, and that these 
medical impacts will not be offset by clinical benefits in the event of a non-serious final 
diagnosis. This section summarises our current knowledge on the non-medical impacts of 
feedback of IFs on three domains: participants’ emotional wellbeing, insurance, and their 
work and activities. 
1.2.5.1 Emotional wellbeing 
Feedback of IFs may result in negative impacts on emotional wellbeing by generating 




During the SHIP study, 405/471 (86%) of participants with IFs responded to surveys about 
the impact of feedback on their emotional wellbeing. Almost half (190/405, 47%) reported 
that they experienced some distress while waiting to receive feedback of an IF, and almost 
one in ten (40/405, 10%) reported feeling strongly distressed during this period (Schmidt et 
al., 2013). After an IF had been disclosed, a quarter had concerns about their health (90/405, 
24%), and between 9–15% of respondents reported having sleeping difficulties, feelings of 
unrest, uncertainty or a depressed mood (Schmidt et al., 2013). Despite these reports, there 
were no differences in mental health component summary scores calculated from the Short 
Form Health Survey, or in depressive symptoms assessed using the Patient Health 
Questionnaire for groups of participants with IFs versus those without (Schmidt et al., 2016). 
This apparent contradiction may simply indicate the limited sensitivity of these instruments 
to detect the impact of IFs on emotional wellbeing (Schmidt et al., 2016). Similar to SHIP, 
focus groups conducted with participants who received feedback of an IF in the NEO study 
found that the period following disclosure was a ‘worrying’ and ‘uncertain’ time (de Boer et 
al., 2018).  
These anxiety levels may wane or fluctuate over longer periods. Preliminary results from 
qualitative work with participants who received feedback of IFs in the Rotterdam Scan Study 
indicated that this had not resulted in any long-term psychological harm (Bos and Vernooij, 
2016). Similarly, qualitative interviews with six US veterans who had pulmonary nodules 
fed back after clinical imaging found that their anxiety generally reduced over time (Sullivan 
et al., 2015). However, the veterans’ anxieties could also spike, particularly around the time 
of their follow-up scans, or after seeing media coverage of health topics such as cancer 
(Sullivan et al., 2015). 
1.2.5.2 Insurance  
Disclosure of an IF to an insurance company may result in withdrawal or refusal of coverage 
or increased premiums, whereas failing to disclose an IF may render insurance void (Apold 
and Downie, 2011). Research participants, scientists and doctors recognise the potential for 
feedback of IFs to impact on insurance (Booth et al., 2010; Murphy and Thompson, 2009), 
but the story of a neuroscientist in the US shows that this is not always the case (Anon, 
2005). After volunteering to help test a new research MRI scanner, he discovered he had an 
incidental brain tumour. He accepted a referral to a local neurosurgeon ‘without proper 
consideration,’ not realising the financial implications of his decision. After disclosing his 
diagnosis to his insurance company, they refused to cover him, leaving him in ‘the uneasy 




1.2.5.3 Work and activities 
Very little is known of the impact of feedback of IFs on participants’ work and activities 
beyond data from the SHIP study. Impairments to work or leisure activities were reported by 
13/405 (4%) and 17/405 (5%) of SHIP participants with IFs respectively (Schmidt et al., 
2013). Participants with life-threatening IFs reported impairments to their work and leisure 
activities more frequently than those with non-life-threatening IFs (28% versus 20%; 4% 
versus 3% respectively) (Schmidt et al., 2013).  
In summary, feedback of IFs generates distress and anxiety, which may fluctuate over time. 
Feedback of IFs impacts on participants’ work and leisure activities regardless of whether or 
not the IF is life threatening, but the impact on insurance is not known.  
1.2.6 Opinions of receiving feedback 
Given the potential for feedback of IFs to result in clinical assessments and negative impacts 
on emotional wellbeing, insurance, and work and activities, the opinions of participants who 
receive feedback, and their healthcare providers, are paramount to informing judgements on 
the net benefit and harms of feeding back PSIFs. While some studies ask for people’s views 
on hypothetical scenarios (Brown and Knight, 2010; Kirschen et al., 2006; Opinion Leader, 
2012), this section will describe studies of the opinions of participants who actually receive 
feedback, and of healthcare providers who have experience of managing patients with IFs. 
1.2.6.1 Participants’ opinions 
Despite reporting negative effects on emotional wellbeing (Section 1.2.5.1), qualitative 
interviews with 23 participants with IFs detected during the NEO study found that all were 
happy to have taken part in the study, and grateful to have been informed about their IFs (de 
Boer et al., 2018). A preliminary report of a qualitative study of participants from the 
Rotterdam Scan Study also suggested that participants were content with knowing about 
their IF, although the full report is not available as of September 2018 (Bos and Vernooij, 
2016).  
This apparent contradiction between participants’ gratitude for receiving feedback despite 
the negative effects on their wellbeing seems to reflect patients’ opinions of screening (de 
Boer et al., 2018). There is seen to be no ‘downside’ to screening: patients are grateful for 
positive results which confer the benefit of early detection of disease; patients are also 




While this may explain the apparent contradiction in the research participants’ responses, it 
also highlights potential misperceptions surrounding feedback of IFs detected on research 
imaging. As mentioned in Section 1.1.2.2, in contrast to screening, a ‘positive result’ (i.e. an 
IF) on research imaging may not indicate early detection of disease (but rather, a non-serious 
condition), and a ‘negative result’ (i.e. no IF) cannot confer reassurance of health due to the 
limitations of the imaging. 
1.2.6.2 Healthcare professionals’ opinions 
Many different healthcare professionals may be involved in caring for people with IFs, due 
to the range of potential different types of IFs. To our knowledge, there are no studies of 
healthcare professionals’ opinions on the benefits or harms of feedback of IFs to particular 
individuals, but three studies sought the general opinions of professionals who had 
previously managed patients with IFs.  
Semi-structured interviews with 30 family doctors found that they sometimes felt compelled 
to follow-up IFs from clinical imaging due to low tolerance of diagnostic uncertainty, local 
healthcare culture, and fear of missing serious diseases (Zafar et al., 2016). These doctors 
described the frustration that resulted from performing costly clinical assessments of IFs 
which they thought would not result in clinical benefit to their patient (Zafar et al., 2016).  
Similarly, within secondary care, a qualitative study of eight neurologists found that they 
also reported feeling compelled to follow up IFs when they too thought this was unnecessary 
(Booth and Boyd-Ellison, 2015). The neurologists described feeling pressure from patients to 
follow up IFs, particularly from patients seen within the private healthcare setting whom the 
neurologists perceived as feeling entitled to more tests (Booth and Boyd-Ellison, 2015). The 
neurologists also described an increased in their workload due to IFs detected on 
neuroimaging, and having to spend more time with patients who were anxious about their 
IFs (Booth and Boyd-Ellison, 2015).  
1.2.7 Economic impact of feedback  
Feedback of IFs will likely generate further clinical assessment (Sections 1.1, 1.2.2), and 
non-medical impacts for participants (Section 1.2.5). An unknown proportion of IFs will turn 
out not to represent serious disease, and any related clinical assessments and associated costs 
may have been unnecessary. The economic impacts of managing IFs are largely unknown; 
(Sandeman et al., 2013; Wardlaw et al., 2015) and this section will outline why measuring 




Due to the range of IFs which may be demonstrated on brain and body imaging, the range of 
services which may be needed to care for patients with IFs is huge. As a group, people with 
IFs will likely be managed by primary care physicians, and will also come in to contact with 
a broad range of specialist secondary care physicians, surgeons, and diagnostic services such 
as imaging. The care provided may comprise of various tests and treatments, which may 
vary between different patients, and between different healthcare providers, healthcare 
services, and healthcare systems. Taking into account that the costs of these services will 
vary by system, and over time, estimating the cost of care for patients with IFs is complex. 
Unsurprisingly, no published study takes in to account all of the potential sources of 
healthcare costs of managing IFs. Two UK studies (one of elderly volunteers undergoing 
research MRI [N=29], and one of patients undergoing CT colonography [N=225]) found 
mean costs of follow-up between £153 and £433 (Pinato et al., 2012; Xiong et al., 2006). 
However our knowledge of the cost of managing IFs is predominantly informed by studies 
of patients undergoing CT of a single body region in non-UK health systems (Bendix et al., 
2011; Flicker et al., 2008; Gluecker et al., 2003; Goehler et al., 2014; Lee et al., 2010; 
Machaalany et al., 2009; Maizlin et al., 2007; Mutneja et al., 2017; Pickhardt et al., 2008; 
Schramm et al., 2016; Veerappan et al., 2010; Wagner et al., 2002) which unfortunately may 
not be generalisable to apparently asymptomatic volunteers undergoing multi-region 
research MRI within the UK. Furthermore, these studies may be limited due to 
methodological issues. Some studies confined their measurement to costs of radiological 
follow-up only (Gluecker et al., 2003; Maizlin et al., 2007; Priola et al., 2013; Veerappan et 
al., 2010; Wagner et al., 2002), resulting in underestimates of the total cost of managing IFs. 
The duration of follow-up is unclear in some studies, making interpretations of their results, 
and comparisons between them difficult (Bromage et al., 2012; Maizlin et al., 2007; Mutneja 
et al., 2017; Pinato et al., 2012; Schramm et al., 2016; Wagner et al., 2002). Few studies 
provide measures of the precision of their estimates of cost, such as 95% CIs (Lee et al., 
2010; Pickhardt et al., 2008; Pinato et al., 2012).  
People who receive feedback of IFs may already be using healthcare services to manage 
existing conditions. Teasing apart the health service uses and costs generated during 
participants’ usual medical care from those generated during the clinical assessment of IFs 
from either patient records or self-reported diaries of care may be tedious, and may still 
underestimate resource use (Ridyard and Hughes, 2010). Data on the total cost of clinical 
assessment of people with PSIFs is of limited usefulness without the context of their usual 




The differences in overall health service use and costs between groups with PSIFs versus 
those without (or after versus before feedback of PSIFs) is not known, but this could be 
feasibly measured using routinely collected healthcare data. 
1.2.8 Efforts to manage IFs in imaging research  
With the developments in research and clinical imaging, and concerns about the potential 
impacts of IFs, the challenge of how best to manage IFs in order to avoid harm to research 
participants and wider society has been the focus of recent reports and studies’ policies. 
In 2009, representatives from the Royal College of Radiologists, research imaging centres, 
professional societies, funders, regulatory and ethics bodies and patient organisations 
convened at the Wellcome Trust in London. This meeting generated a report on the 
management of IFs on research imaging, published in 2011, which summarised the 
limitations of the knowledge base, the variability in centres’ IFs handling policies and access 
to radiology staff, and which highlighted that existing guidelines provided conflicting or 
ambiguous advice, and provided guidance for areas of future research (The Royal College of 
Radiologists, 2011). 
These uncertainties about handling IFs were further acknowledged in the ‘Framework on the 
feedback of health-related findings in research’ proposed in 2014 by two of the largest 
medical research funders in the UK (Medical Research Council and Wellcome Trust, 2014). 
They defined health-related findings as those with potential health or reproductive 
importance. In contrast to earlier calls for a uniform approach to handling IFs (Brown and 
Hasso, 2008), this framework offers researchers flexible guidance on what to consider when 
developing an appropriate IFs policy. It encourages researchers to recognise the uncertainties 
around IFs, to tailor feedback policies to the specific context of their study, and to manage 
participants’ expectations about the way that IFs will be handled (Medical Research Council 
and Wellcome Trust, 2014). Both the Wellcome Trust and the Medical Research Council 
mandate their researchers to submit an IFs policy along with any study application, and also 
have committed to covering the costs of feedback pathways for their funded studies (Farrar 
and Savill, 2014).  
The Wellcome Trust and Medical Research Council’s framework, or rather, its approach, has 
not yet been adopted internationally. The relevant guidance in Canada does not specifically 
advise researchers to design an IFs policy in advance of starting a study (Canadian Institutes 




existing guidance on how to handle particular IFs when they arise. The guidelines are 
ambiguous regarding the IFs which should be disclosed, advising on one hand that any IF 
which may have welfare significance for a participant should be disclosed, but on the other 
hand that researchers should exercise caution in disclosing findings which may have 
implications for insurance and employability (Canadian Institutes of Health Research et al., 
2014). This may cause difficulties in practice; how to disclose a finding of potential 
significance to a participant who works as a driver, or pilot, for example. 
Dutch researchers developed a list of minimum standards for handling IFs in imaging 
research after analysing qualitative interviews with 20 researchers (Bunnik et al., 2017). The 
Dutch minimum standards were further developed and refined following a two-day meeting 
of 14 representatives of large European population-based imaging studies. However, some of 
the proposed minimum standards may not be feasible. For example, they recommend that ‘in 
studies in which diagnostic-quality images are acquired, some form of routine review of 
research scans should be arranged’ (Bunnik et al., 2017). Given that the majority of studies 
will generate images with some level of anatomical detail on which a large lesion such as a 
tumour or aneurysm may well be visible, implementing this standard in the UK may 
overwhelm already overstretched clinical radiology services.  
In the same year that the Wellcome Trust and Medical Research Council’s Framework was 
made available, American guidance published by the Presidential Commission for the Study 
of Bioethical Issues also acknowledged the lack of empirical evidence to inform the 
management of IFs. The latter addressed this issue by calling on professional bodies to 
develop guidance for the management of IFs, and for empirical data on the detection, 
feedback and management of IFs, and for such research to be funded by federal agencies and 
other parties (Presidential Commission for the Study of Bioethical Issues, 2013). 
Following this report, several groups published guidance on the management of IFs on 
different imaging modalities, and of specific types of IFs (Heller et al., 2013; Hoang et al., 
2015; Khosa et al., 2013; MacMahon et al., 2017; Patel et al., 2013; Sebastian et al., 2013). 
Recently, one of the largest European population-based imaging studies, the German 
National Cohort, conducted an extensive literature review, sought radiological opinions 
about IFs, and developed lists of IFs that they consider to be for feedback or not (Bertheau et 
al., 2016). Further lists have been developed by professional bodies and other research 
studies (Bos and Vernooij, 2016; The Royal College of Radiologists, 2011). We need more 




different types of IFs, and what the final diagnoses turn out to be, in order to judge the 
usefulness of these lists.  
The UK Biobank Imaging Study subsequently adapted the lists generated by the German 
National Cohort to inform its feedback policy for IFs detected on multi-modal imaging of 
100,000 of its 500,000 existing participants (Gibson et al., 2018). UK Biobank developed a 
pragmatic IFs policy that aimed to minimise harm to this large number of apparently 
asymptomatic people (radiographer flagging of concerning scans for a radiologist to review 
(Gibson et al., 2018)). The UK Biobank Imaging Study only feeds back IFs that are 
‘potentially serious’ (defined as those ‘indicating the possibility of a condition which, if 
confirmed, would carry a real prospect of seriously threatening life span, or of having a 
substantial impact on major body functions or quality of life’ (Gibson et al., 2018)). This 
decision was informed by the nature of UK Biobank participants’ existing consent, and is 
consistent with other studies’ policies (Bertheau et al., 2016; Bos and Vernooij, 2016; UK 
Biobank Ethics and Governance Council, 2015). Before participant recruitment began, UK 
Biobank acknowledged that its staff may have professional or moral obligations to disclose 
abnormalities that may impact on participants’ health (e.g. during the initial recruitment visit, 
a research nurse may notice a hypertensive blood pressure reading or a skin melanoma) and 
participants joined UK Biobank after consenting to receive feedback of such findings (UK 
Biobank, 2013a). Within UK Biobank, it was deemed important to maintain a consistent 
approach to feedback of health-related information in order to promote participants’ 
understanding of the feedback policies and facilitate their informed consent to participate in 
different aspects of the UK Biobank study (UK Biobank, 2013a). Therefore for the imaging 
study, UK Biobank maintained the position of feeding back only findings which were likely 
to impact on health, and formalised its approach by defining (and adapting lists of) PSIFs in 
anticipation of the prevalence and clinical implications of IFs which would be demonstrated 
on the research imaging (UK Biobank, 2013a).   
 
Defining IFs which are for feedback or not may generate a tension between studies’ IFs and 
participants’ rights to know (and rights not to know) about their health. Such rights are 
endorsed by both the Convention on Human Rights and Biomedicine, and the United 
Nations Educational, Scientific and Cultural Organization’s Declaration on the Human 
Genome and Human Rights (Council of Europe, 1997; United Nations Educational Scientific 
and Cultural Organization, 1997). In addition, research participants’ rights not to know about 
their health may come into conflict with researchers’ professional and ethical obligations to 




found to have a brain tumour). UK Biobank take a pragmatic approach, by informing 
participants of what they can and cannot reasonably expect of the study (in light of the non-
diagnostic nature of the imaging and that images will not routinely be reviewed by medical 
staff), emphasising that only potentially serious abnormalities will be fed back, and that lack 
of feedback does not confer ‘health’ (UK Biobank, 2013a; 2014a). Participants consent to 
take part on this basis, and are not offered the option to ‘opt-out’ of feedback (UK Biobank, 
2013a). However, such an approach may not be suitable for all studies, and while it is likely 
that there is no ‘one-size-fits-all’ policy for handling IFs in research (UK Biobank, 2013a), 
empirical evidence is needed to inform appropriate policy design for studies conducted 
across a range of different contexts.  
1.3 Summary 
IFs occur in approximately 1–2% of apparently asymptomatic volunteers who undergo brain 
MRI, and some evidence suggests that the prevalence is likely to be higher on body MRI. 
Due to the limitations of research imaging, and of current knowledge about the natural 
history of particular IFs, the clinical significance of some IFs may not be clear, which may 
prompt further clinical assessments to resolve the diagnostic uncertainty. However, the 
numbers, types and costs of clinical assessments performed in pursuit of final diagnoses of 
IFs is not known, and are potentially challenging to study. Furthermore, an unknown 
proportion of these IFs will represent serious disease, so that any clinical assessments 
performed, non-medical impacts on participants’ emotional well-being, insurance, work and 
activities or uses and costs of health services may be deemed unnecessary in the event of 
non-serious final diagnoses. While a small number of studies suggest that participants may 
not hold negative opinions about feedback of IFs, despite experiencing negative impacts on 
emotional wellbeing, studies of healthcare professionals highlight their concerns about 
inappropriate uses of healthcare services to manage IFs.  
The increasing popularity of imaging as a research tool, particularly in large, population-
based cohorts, will only increase the scale of the challenge of imaging IFs in future. In 
response, major research funders have called for scientists to develop IFs policies before 
starting their studies, which should be underpinned by evidence and clearly communicated to 
participants. Researchers should estimate the likely prevalence of IFs which may be detected 
when imaging a particular population, but there is inconsistent evidence on the associations 
of IFs with age and sex, and the influence of other participant, imaging, and imaging reader 




prevalence of PSIFs and serious final diagnoses detected by other types of imaging readers 
are urgently needed to inform IFs policy design. Despite clear descriptions of IFs policies, 
some evidence suggests that participants may misperceive research imaging as being able to 
provide firm clinical diagnoses or firm reassurance of health, and that they misunderstand 
consent materials with regards to what will be fed back. 
More data are needed to inform on the prevalence and types of IFs on brain and body MRI 
conducted in apparently asymptomatic people. Long-term follow-up studies of unselected 
participants with IFs are needed to generate evidence on the clinical assessment, final 
diagnoses, non-medical impacts on participants, economic impact on health services, and 
participants’ and healthcare professionals’ opinions on handling IFs. These empirical data 
are crucial to informing judgements of the benefits and harms of feedback of IFs. A greater 
understanding of the factors which influence prevalence of IFs, including head-to-head 
comparisons of different imaging readers, will help researchers estimate the likely scale of 
the problem of IFs in their future studies. Evaluating participants’ understanding of consent 
with regards to IFs feedback policies will enable consent processes to be improved. 
Collectively, these data will help to inform the design of appropriate IFs policies which 
minimise harm to research participants and publicly-funded healthcare services.  
1.4 Aims of this thesis 
Generating new knowledge about IFs which are clearly non-serious would be of limited 
potential value to individuals considering undergoing imaging, and the researchers and 
healthcare providers managing them. Therefore, the remainder of this thesis focuses on 
PSIFs, which we define as IFs indicating the possibility of a condition which, if confirmed, 
would carry a real prospect of seriously threatening life span, or of having a substantial 
impact on major body functions or quality of life (Gibson et al., 2018). 
The remaining chapters of this thesis aim to address gaps in knowledge relating to at least 
one of the following themes relating to PSIFs: prevalence and nature; follow-up and final 
diagnoses; factors associated with PSIFs and with serious final diagnoses; participants’ 
understanding of consent to feedback of PSIFs; non-medical impacts of feedback of PSIFs 
on participants; opinions of receiving feedback of PSIFs; economic impact of feedback of 
PSIFs. 
Chapter 2 presents a systematic review and meta-analysis of published studies of brain and 




asymptomatic adults, describe factors associated with PSIFs, and summarise what is known 
on follow-up and final diagnoses. 
All of the remaining research analyses described in this thesis use data generated by the UK 
Biobank Imaging Study. Chapter 3 provides a summary of the UK Biobank, the UK Biobank 
Imaging Study, and the rationale behind and protocol for handling PSIFs on multi-modal 
imaging in 100,000 largely asymptomatic UK Biobank participants.  
Chapter 4 presents a study which compares two PSIFs handling protocols which were 
applied to the first 1,000 imaged UK Biobank participants: radiographer flagging of 
concerning images for a radiologist to review, versus systematic radiologist review of all 
images. Chapter 4 addresses multiple themes of this thesis, by presenting empirical data on 
the prevalence and nature of PSIFs on multiple body regions and imaging modalities, the 
follow-up generated and the resulting final diagnoses, and how these vary by each of the 
PSIFs protocols. Chapter 4 also presents data on: an initial exploration of participant factors 
associated with PSIFs; non-medical impacts of feedback of PSIFs on participants; 
participants’ understanding of consent to feedback of PSIFs; and participants’ and their GPs’ 
opinions on receiving feedback of a PSIF. 
Chapter 5 builds on aspects of the work presented in Chapter 4. By using data from a larger 
cohort of UK Biobank participants (N=7,334), Chapter 5 aims to improve the accuracy of 
our estimates of the prevalence of both PSIFs and serious final diagnoses, and investigate the 
associations of these with a wider range of participant factors. 
Chapter 6 furthers our knowledge of the impact of feedback of PSIFs. While Chapter 4 will 
describe the medical and non-medical impacts on participants, the case-control study 
presented in Chapter 6 aims to explore the economic impact of feedback of PSIFs on hospital 
services using linked routinely collected healthcare data.  
The results of these studies are summarised and discussed in the context of each other and 
the broader literature in Chapter 7, which will also describe the strengths, limitations and 
implications of this thesis and potential directions for future research. 
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Chapter 2 Potentially serious incidental 
findings on brain and body 
magnetic resonance imaging of 
apparently asymptomatic adults: 
systematic review and meta-
analysis 
2.1 Introduction 
Chapter 1 described the current literature and highlighted areas where robust, empirical data 
on incidental findings (IFs) are needed to inform the design of feasible IFs management 
policies and improve informed consent processes. The usefulness of the existing estimates of 
prevalence is limited by variation between studies’ definitions of IFs, some of which 
included clearly non-serious conditions (e.g. simple renal cysts (Morin et al., 2009)), or 
normal variant anatomy (e.g. mega cisterna magna (Haberg et al., 2016)). Data on the factors 
associated with potentially serious IFs (PSIFs) and serious final diagnoses would facilitate 
researchers’ estimations of the expected prevalence of both of these outcomes in future 
studies, and inform their design of consent materials, but there is conflicting evidence on the 
associations with participants’ age and sex, and limited informative data on the associations 
with other factors. While there are some data on the follow-up and final diagnoses of 
participants with IFs detected on brain magnetic resonance imaging (MRI) (Bos et al., 2016), 
more information about the burden of follow-up (such as the numbers undergoing particular 
types of follow-up) and final diagnoses of PSIFs detected on brain and other body regions 
would help facilitate the informed consent of potential research participants. 
The work presented in this chapter was originally developed to inform the ongoing UK 
Biobank Imaging Study, which aims to conduct brain, cardiac and body MRI, carotid 
Doppler ultrasound and dual-energy X-ray absorptiometry (DXA) in 100,000 largely 
asymptomatic people (Matthews and Sudlow, 2015). As such, this chapter focuses on 
apparently asymptomatic people (defined as community-dwelling people not selected for 
imaging on the basis of symptoms, risk factors, or disease) undergoing MRI, as this is the 
UK Biobank imaging modality which is most likely to generate PSIFs due to the large 
volume of imaged tissue and the range of pathologies which may be demonstrated therein.  
This chapter aims systematically to review studies of brain, thorax, abdomen and of brain 
and body MRI conducted among apparently asymptomatic adults to 1) determine the 
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prevalence and types of PSIFs, 2) describe factors associated with PSIFs, and 3) determine 
what is known about the follow-up and final diagnoses of people with PSIFs. 
This study was submitted to the BMJ; the manuscript is included in full in Section 2.2 and 
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2.2.1 Structured abstract 
Objectives 
To 1) determine prevalence and types of potentially serious incidental findings (PSIFs) on 
magnetic resonance imaging (MRI) in apparently asymptomatic adults, 2) describe factors 
associated with PSIFs, and 3) summarise information on follow-up and final diagnoses. 
Design 
Systematic review and meta-analyses. 
Data sources 
Medline and Embase (inception to 25th April 2017), citation searches of relevant articles and 
authors’ files. 
Review methods 
We included published studies reporting prevalence and types of incidental findings (IFs) 
detected among apparently asymptomatic adults undergoing MRI of brain, thorax, abdomen 
or brain and body. We extracted data on study population and methods, prevalence and types 
of IFs, and final diagnoses. We estimated pooled prevalence using random effects meta-
analysis, and heterogeneity using tau-squared statistics. 
Main outcome measures 
Prevalence of PSIFs on MRI of brain, thorax, abdomen, and brain and body.  
Results 
Among 5,905 retrieved studies, 32 (0.5%) met the inclusion criteria (n=27,643 participants), 
pooled prevalence of PSIFs on brain and body MRI was: 3.9% (95% confidence interval [CI] 
0.4–27.1%; brain 1.4% [95% CI 1.0–2.1%]; thorax 1.3% [95% CI 0.2–8.1%], abdomen 1.9% 
[95% CI 0.3–12.0%]); and 12.8% (95% CI 3.9–34.3%) when including IFs of uncertain 
potential seriousness, with generally substantial heterogeneity among included studies. 
Around half of PSIFs were suspected malignancies (brain 0.6% [95% CI 0.4–0.9%]; thorax 
0.6% [95% CI 0.1–3.1%]; abdomen 1.3% [95% CI 0.2–9.3%]; brain and body 2.3% [95% CI 





variation or factors associated with PSIFs. Limited data suggested that relatively few PSIFs 
had serious final diagnoses (48/234, 20.5%).  
Conclusions 
A substantial proportion of apparently asymptomatic adults will have PSIFs on MRI, but 
little is known of their health consequences. Systematic, long-term follow-up studies are 
needed to better inform on these and the implications for policies on feedback of PSIFs.  







2.2.2 What this paper adds 
What is already known on this topic 
Estimates of prevalence of IFs vary widely, and may be of limited value to practice as they 
often include non-serious IFs. 
Previous systematic reviews have focused on IFs detected on MRI of a single body region, 
patient populations undergoing MRI, or apparently asymptomatic people imaged using 
another modality.  
These estimates are not generalisable to brain and body MRI of apparently asymptomatic 
people, i.e. imaging which is increasingly conducted within large-scale imaging research and 
screening settings. 
What this study adds 
In meta-analyses of published studies, pooled prevalence of PSIFs on MRI of apparently 
asymptomatic people was 3.9% (1.4% brain, 1.3% thorax, 1.9% abdomen), and 12.8% (1.7% 
brain, 3.0% thorax, 4.5% abdomen) when including IFs of uncertain potential seriousness. 
Around half of PSIFs were suspected malignancies.  
Limited follow-up data suggest that most PSIFs may not be clinically serious on follow-up, 







Brain and body (i.e. brain, thorax and abdomen) magnetic resonance imaging (MRI) is 
increasingly used for clinical and commercial screening and for research, with several large-
scale population-based imaging initiatives ongoing around the world (Icelandic Heart 
Association, 1999; Ikram et al., 2015; Nationale Kohorte, 2018; Post, 2014; UK Biobank, 
2018c). The detection of incidental findings (IFs) unrelated to the purpose of the imaging 
(Wolf et al., 2008) is an inevitable consequence. Clinicians and researchers should therefore 
anticipate IFs and develop appropriate policies for managing them, taking into account their 
expected prevalence and clinical severity (Medical Research Council and Wellcome Trust, 
2014). Existing data on the prevalence of IFs from systematic reviews of MRI of a single 
body region (Morris et al., 2009), patient populations undergoing MRI (Dunet et al., 2016), 
or apparently asymptomatic people imaged using another modality (Jacobs et al., 2008), are 
not generalisable to brain and body MRI of apparently asymptomatic people (defined here as 
community-dwelling people not selected for imaging on the basis of symptoms, risk factors, 
or disease). 
The clinical severity of IFs ranges from non-serious (e.g. simple renal cyst) to potentially 
life-threatening (e.g. some malignancies), but their nature and severity are often unclear. 
Diagnostic radiological imaging is tailored optimally to demonstrate (or exclude) pathologies 
relevant to a patient’s presentation. By contrast, since IFs are, by definition, unrelated to the 
imaging’s purpose (Wolf et al., 2008), no imaging protocol is specifically designed to 
optimise firm diagnoses of these. Further specific clinical follow-up is therefore often needed 
to permit final clinical diagnoses of IFs.  
Given that knowing about clearly non-serious IFs would be of limited potential benefit, we 
focus here on ‘potentially serious’ IFs (PSIFs), defined as those indicating the possibility of a 
condition which, if confirmed, would carry a real prospect of seriously threatening life span, 
or of having a substantial impact on major body functions or quality of life (Petersen et al., 
2013). The development of well-informed approaches to the management of such PSIFs on 
brain and body MRI in apparently asymptomatic adults requires data on their prevalence and 
types, factors associated with these, and on the resulting final diagnoses. 
We therefore aimed systematically to review studies of brain, thorax, abdomen and of brain 
and body MRI to 1) determine the prevalence and types of PSIFs among apparently 





known about the follow-up and final diagnoses of people with PSIFs. This study was 
motivated by - and mainly conducted during preparations for - the ongoing UK Biobank 
multi-modal imaging study (including brain and body MRI) of 100,000 people (UK 
Biobank, 2018c). 
2.2.4 Methods 
We registered the protocol for this review with PROSPERO (Gibson et al., 2016a), and 
archived data online (Gibson et al., 2017a).  
2.2.4.1 Patient involvement 
Patients were not involved in the development or design of this study. 
2.2.4.2 Data sources 
We searched Medline and Embase from inception to 25th April 2017 for references to studies 
in any language which reported the prevalence of IFs in apparently asymptomatic adults 
undergoing cardiac, abdominal or brain and body (i.e. brain and thorax and abdomen) MRI 
(Supplementary Table 2-1). For brain MRI, we screened studies included in a published 
systematic review of IFs in apparently asymptomatic volunteers (Morris et al., 2009) and 
updated the search to 25th April 2017 (Supplementary Table 2-2). We searched authors’ files 
and forward and backward citations of retrieved studies for further relevant studies. 
2.2.4.3 Study selection 
One author (LG) screened all references for potentially eligible studies. A second author 
(LP) independently screened a random sample of 10% of references to assess the reliability 
of this process. Disagreements were resolved through discussion between these authors, with 
arbitration by a senior author (CLMS) if necessary. We retrieved full text articles of 
potentially eligible studies. One author (LG) assessed articles for inclusion, and discussed 
uncertainties with a senior author (CLMS). 
We defined apparently asymptomatic people as those who were not selected on the basis of 
any symptoms, risk factors, or disease, and who attended for population-based research 
imaging studies, commercial or occupational screening, or as research controls. We excluded 
studies of: patients (i.e. people selected for a study based on symptoms, risk factors or 
disease, or those admitted to or attending a health care facility for clinical diagnostic 





generalisability); pre-specified subgroups of IFs (which would underestimate the prevalence 
of other IFs); children (<18 years old). We excluded studies which were not published in 
full. If multiple publications arose from a study, we prioritised the primary review question 
of prevalence, and included data from the largest cohort.  
2.2.4.4 Data extraction 
One author (LG) extracted data from all included studies on study population, study 
methods, and prevalence and types of all IFs using a pre-piloted, standardised data-extraction 
spreadsheet. To assess the reliability of this process, a second author (LP) independently 
extracted data from a 10% random sample of studies. Disagreements were resolved through 
discussion between these authors. 
2.2.4.4.1 Study and population characteristics 
We extracted data on: sample size; numbers of men and women; mean age and age range of 
participants; country in which the imaging was conducted (or, if this was not reported, the 
country of the first author’s institution); body region(s) imaged; imaging setting (classified 
as either research [if participants were imaged during research studies], or non-research 
settings [imaging was performed in other contexts, including occupational imaging, or 
commercial imaging]). 
2.2.4.4.2 Study imaging and IF reporting methods 
We extracted data on: whether prevalence of IFs was assessed by reviewing MR images or 
reports; the specialist field and number of those reporting images; blinding of reporters to 
information about the participants; the MRI sequences performed; the dates that MRI was 
performed.  
2.2.4.4.3 Data on IFs 
We extracted data on: the total number of participants with IFs, the total number of IFs, or 
both if available; the number of participants with multiple IFs; the prevalence of IFs by age, 
sex, imaging sequence, reporter or any other factor assessed for association with IFs; all 
available data on follow-up investigations, treatment and final diagnoses for studies in which 







2.2.4.4.4 Classification of IFs and final diagnoses 
To determine which IFs were potentially serious according to our definition (Petersen et al., 
2013), we referred to a list of potentially serious and non-serious IFs developed by UK 
Biobank, based on consultations with radiologists, published literature and the German 
National Cohort’s methods (Bertheau et al., 2016) (Supplementary Tables 2-3, 2-4 and 2-5). 
For any IFs not on this list, we directly applied our definition of a PSIF; where there was 
insufficient published information to apply our definition, we used study definitions of 
severe IFs, accepting that these vary somewhat between studies (Gibson et al., 2017a). We 
sub-classified PSIFs as suspected malignancy (e.g. masses), non-malignant, or possible 
indicators of malignancy (IFs which were not masses, but could be related to malignancy, 
e.g. pleural effusions [Section 2.3.1.3]). We classified final diagnoses as serious if they were 
likely to significantly threaten lifespan or have a major impact on quality of life or major 
body functions, and not serious if this was not the case. We described IFs or final diagnoses 
that could not be classified as ‘indeterminate.’ 
2.2.4.5 Risk of bias assessment 
In the absence of a validated quality assessment tool for studies of the prevalence of IFs, we 
extracted data on study characteristics which may influence risk of bias (sample selection 
methods, blinding of reporters to information about the participants, the specialty and 
number of image readers, and whether data on IFs were generated from reads of images or 
extracted from reports), and planned to consider their potential influence on the results 
through a series of subgroup analyses.  
2.2.4.6 Data synthesis 
We meta-analysed studies with a random effects model (Borenstein et al., 2010), using 
maximum likelihood estimation methods (Hamza et al., 2008) and modelling within-study 
variance as binomial, to calculate pooled prevalence of PSIFs, and of suspected malignant 
IFs, separately for MRI of brain, thorax, abdomen, and brain and body. For the pooled 
estimates, we calculated both 95% confidence intervals (CI) and 95% prediction intervals; 
the latter indicate the range of true prevalence values expected in future studies (Riley et al., 
2011). We used t-scores (rather than the usual z score) to calculate 95% CIs, generating 
conservative estimates and allowing comparison with our prediction intervals (which also 
use t-scores). We included region-specific data from studies of brain and body MRI in the 
brain, thoracic and abdominal MRI meta-analyses. We derived data on thoracic IFs from 





prevalence of PSIFs and of suspected malignant IFs, we performed sensitivity meta-analyses 
by adding the indeterminate IFs to the PSIFs, and possible indicators of malignancy to the 
suspected malignant IFs. We calculated 95% CIs for individual studies’ prevalence estimates 
using Clopper Pearson exact methods. We assessed statistical heterogeneity using tau-
squared statistics, which provide a logit scale measure of between-study variance, 
represented in a more readily interpretable way by the 95% prediction intervals. We initially 
considered all study-level characteristics as potential candidates for subgroup analyses to 
explore reasons for heterogeneity of the prevalence of PSIFs. However, we chose not to 
conduct subgroup analyses that were likely to be un-informative (e.g. due to missing data for 
a large proportion of studies or substantial imbalance in subgroup sizes). We performed 
subgroup analyses by including study characteristics as covariates in the meta-analyses 
(Petitti, 2001). We decided not to perform formal statistical tests for possible publication bias 
since their application is limited in meta-analyses where outcome is expressed as a 
proportion (Bland, 2006; Hunter et al., 2014). We further decided not to conduct formal 
meta-analysis of data on the percentage of PSIFs that resulted in serious final diagnoses (i.e., 
the positive predictive value of PSIFs), to avoid undue emphasis on the limited data 
available. Instead, we described available findings and calculated a rough estimate of this 
percentage by summing numerators and denominators across the few studies with relevant 
data.  
We used Microsoft Excel 2013 for descriptive statistical analyses, StatsDirect 3.0.177 for 
calculating 95% CIs for individual studies, and SAS 9.4 PROC NLMIXED (www.sas.com) 
for meta-analyses. 
We obtained all data for this study from existing publications, and so did not need ethical 
approval.   
2.2.5 Results 
Two authors agreed on 99% of the duplicate screened reference selections, and 100% of the 
duplicate extracted data. 
2.2.5.1 Included studies 
We included 32 studies (Alphs et al., 2006; Baumgart and Egelhof, 2007; Bos et al., 2016; 
Boutet et al., 2017; Brugulat-Serrat et al., 2017; Cieszanowski et al., 2014; Goehde et al., 





2009; Illes et al., 2004b; Katzman et al., 1999; Kumar et al., 2008; Lee et al., 2008; Li et al., 
2015; Lo et al., 2008; Loy et al., 2015; Lubman et al., 2002; Menzler et al., 2010; Morin et 
al., 2009; Reneman et al., 2012; Sandeman et al., 2013; Saya et al., 2017; Sommer et al., 
2013; Tarnoki et al., 2015; Trufyn et al., 2014; Tsushima et al., 2005; Vogel-Claussen et al., 
2009; Wahlund et al., 1989; Weber and Knopf, 2006; Yue et al., 1997) of 27,643 participants 
(range 2 to 5,800 participants, mean/median age range 21 to 75 years, 14,037/27,643 
[50.8%] male) imaged between 1985 and 2016 (Supplementary Figure 2-1, Supplementary 
Table 2-6).  These 32 studies comprised eight of brain and body MRI (Baumgart and 
Egelhof, 2007; Cieszanowski et al., 2014; Goehde et al., 2005; Hegenscheid et al., 2013; Lo 
et al., 2008; Morin et al., 2009; Saya et al., 2017; Tarnoki et al., 2015), 22 of brain MRI 
(Alphs et al., 2006; Bos et al., 2016; Boutet et al., 2017; Brugulat-Serrat et al., 2017; Haberg 
et al., 2016; Hartwigsen et al., 2010; Hoggard et al., 2009; Illes et al., 2004b; Katzman et al., 
1999; Kumar et al., 2008; Lee et al., 2008; Li et al., 2015; Lubman et al., 2002; Menzler et 
al., 2010; Reneman et al., 2012; Sandeman et al., 2013; Sommer et al., 2013; Trufyn et al., 
2014; Tsushima et al., 2005; Wahlund et al., 1989; Weber and Knopf, 2006; Yue et al., 
1997) and two of cardiac MRI (Loy et al., 2015; Vogel-Claussen et al., 2009). No abdomen-
only studies were identified (Supplementary Table 2-6).  
Studies were performed in Europe (20 studies, 17,702 participants (Baumgart and Egelhof, 
2007; Bos et al., 2016; Boutet et al., 2017; Brugulat-Serrat et al., 2017; Cieszanowski et al., 
2014; Goehde et al., 2005; Haberg et al., 2016; Hartwigsen et al., 2010; Hegenscheid et al., 
2013; Hoggard et al., 2009; Loy et al., 2015; Menzler et al., 2010; Morin et al., 2009; 
Reneman et al., 2012; Sandeman et al., 2013; Saya et al., 2017; Sommer et al., 2013; Tarnoki 
et al., 2015; Wahlund et al., 1989; Weber and Knopf, 2006)), North America (six studies, 
5,789 participants (Alphs et al., 2006; Illes et al., 2004b; Katzman et al., 1999; Trufyn et al., 
2014; Vogel-Claussen et al., 2009; Yue et al., 1997)), Asia (four studies, 3,576 participants 
(Lee et al., 2008; Li et al., 2015; Lo et al., 2008; Tsushima et al., 2005)), and Australia (two 
studies, 576 participants (Kumar et al., 2008; Lubman et al., 2002)) (Supplementary Table 2-
6). All but three assessed images for IFs; one assessed imaging reports (Lubman et al., 
2002), and two did not report on this (Lee et al., 2008; Wahlund et al., 1989). All studies 
involved radiologists, except one in which a cardiologist reported IFs on cardiac MRI 
(Supplementary Table 2-6) (Loy et al., 2015); in two studies, radiologists were involved in 
confirming IFs detected by others (trained readers [defined as researchers with training to 
doctor of medicine-level or training in neuropsychiatry] in one study (Bos et al., 2016) and 





2.2.5.2 Imaging sequences 
The vast majority of participants were imaged using scanners of 1.5T or less (19 studies, 
23,809/27,643 [86.1%] participants (Baumgart and Egelhof, 2007; Bos et al., 2016; Boutet et 
al., 2017; Cieszanowski et al., 2014; Goehde et al., 2005; Haberg et al., 2016; Hegenscheid 
et al., 2013; Kumar et al., 2008; Lee et al., 2008; Lubman et al., 2002; Menzler et al., 2010; 
Morin et al., 2009; Sandeman et al., 2013; Saya et al., 2017; Sommer et al., 2013; Tsushima 
et al., 2005; Vogel-Claussen et al., 2009; Weber and Knopf, 2006; Yue et al., 1997)). 
However, seven studies (1,556/27,643 [5.6%] participants) used 3.0T scanners (Brugulat-
Serrat et al., 2017; Hartwigsen et al., 2010; Hoggard et al., 2009; Lo et al., 2008; Loy et al., 
2015; Tarnoki et al., 2015; Trufyn et al., 2014), two studies (370/27,643 [1.3%] participants) 
used 1.5T in some participants and 3.0T in others (Li et al., 2015; Reneman et al., 2012), and 
four studies (1,908/27,643 [6.9%] participants) did not report magnet strength (Alphs et al., 
2006; Illes et al., 2004b; Katzman et al., 1999; Wahlund et al., 1989) (Supplementary Table 
2-7). All but three brain MRI studies (Cieszanowski et al., 2014; Sommer et al., 2013; 
Wahlund et al., 1989) used T1-weighted imaging; one further study used T1-weighted 
imaging in an unknown subset of participants (Hoggard et al., 2009). Of the ten thoracic 
MRI studies, eight used non-contrast whole thorax imaging (n=4,817) (Baumgart and 
Egelhof, 2007; Cieszanowski et al., 2014; Goehde et al., 2005; Hegenscheid et al., 2013; Lo 
et al., 2008; Morin et al., 2009; Saya et al., 2017; Tarnoki et al., 2015) and five used cardiac-
specific sequences (n=4,099) (Baumgart and Egelhof, 2007; Goehde et al., 2005; 
Hegenscheid et al., 2013; Loy et al., 2015; Vogel-Claussen et al., 2009). All abdominal MRI 
studies used T1-weighted imaging (Supplementary Table 2-7). 
2.2.5.3 Risk of bias assessment  
Only one study appeared to have imaged an unselected, random population sample 
(n=2,500) (Hegenscheid et al., 2013). The majority of the remainder imaged selected 
samples or did not clearly report sampling methods. At least one radiologist reported all 
images in almost all studies; 14 studies had more than one reader for each set of images 
(8,199/27,643 [29.7%] participants (Baumgart and Egelhof, 2007; Cieszanowski et al., 2014; 
Goehde et al., 2005; Haberg et al., 2016; Hartwigsen et al., 2010; Hegenscheid et al., 2013; 
Illes et al., 2004b; Lo et al., 2008; Menzler et al., 2010; Sandeman et al., 2013; Saya et al., 
2017; Tarnoki et al., 2015; Tsushima et al., 2005; Vogel-Claussen et al., 2009)) 
(Supplementary Table 2-6). Data on blinding of readers to participants’ characteristics were 
incomplete, with only 16 studies (19,617/27,643 [71.0%] participants) clearly reporting 





Boutet et al., 2017; Cieszanowski et al., 2014; Goehde et al., 2005; Haberg et al., 2016; 
Hegenscheid et al., 2013; Li et al., 2015; Lubman et al., 2002; Menzler et al., 2010; 
Reneman et al., 2012; Sandeman et al., 2013; Saya et al., 2017; Sommer et al., 2013; Weber 
and Knopf, 2006; Yue et al., 1997) (Supplementary Table 2-6).  There were no direct within-
study comparisons of radiologist versus non-radiologist readers, of single versus multiple 
readers, or of blinding versus non-blinding of readers to participants’ characteristics to 
reliably inform on any potential biases such methods may have on the prevalence of PSIFs.  
2.2.5.4 Prevalence and types of PSIFs 
Although 14 studies reported data on multiple IFs per participant, none provided the number 
of participants with >1 PSIF, or data to enable calculations of this (Alphs et al., 2006; Boutet 
et al., 2017; Goehde et al., 2005; Haberg et al., 2016; Hartwigsen et al., 2010; Hegenscheid 
et al., 2013; Lee et al., 2008; Morin et al., 2009; Sandeman et al., 2013; Saya et al., 2017; 
Sommer et al., 2013; Trufyn et al., 2014; Vogel-Claussen et al., 2009; Weber and Knopf, 
2006). We therefore based prevalence estimates on the assumption that no participant had >1 
PSIF, recognizing that a very small number of participants may have more than one. The 
pooled prevalences of PSIFs on brain, thoracic, abdominal and brain and body MRI were 
1.4% (95% CI 1.0–2.1%), 1.3% (95% CI 0.2–8.1%), 1.9% (95% CI 0.3–12.0%) and 3.9% 
(95% CI 0.4–27.1%) respectively. When indeterminate IFs were included, pooled prevalence 
estimates increased to 1.7% (95% CI 1.1–2.6%), 3.0% (95% CI 0.8–11.3%), 4.5% (95% CI 
1.5–12.9%) and 12.8% (95% CI 3.9–34.3%) respectively. Study-specific prevalence 
estimates ranged widely, with correspondingly wide prediction intervals, and tau-squared 
values ranging from 0.8 to 5.7 (indicative of substantial variance between studies) (Figures 













Figure 2-1: Forest plots of the per-study prevalence and pooled prevalence estimates 
of potentially serious incidental findings (PSIFs), and of PSIFs plus indeterminate 
incidental findings (IFs), detected on brain magnetic resonance imaging (MRI) 
CI = confidence interval 
Tau-squared is an estimate of between-study variance on the logit scale. Zero 
represents no variance, and increasing values of tau-squared indicate increasing 
heterogeneity. 
Blue = Per-study point prevalence and pooled prevalence estimate of PSIFs on brain 
MRI  
Orange = Sensitivity analyses which include IFs classified as indeterminate in the per-
study point prevalence and pooled prevalence estimate of PSIFs on brain MRI. Details 
of the types and numbers of PSIFs are provided in Figure 2-3 and Supplementary 
Table 2-9, while details of indeterminate findings are available online (Gibson et al., 
2017a). 
a. We excluded 138 vascular IFs detected in six studies that used MR 
angiography, from pooled analyses (Alphs et al., 2006; Goehde et al., 2005; 












Figure 2-2: Forest plots of the per-study prevalence and pooled prevalence estimates 
of potentially serious incidental findings (PSIFs), and of PSIFs plus indeterminate 
incidental findings (IFs), detected on thoracic, abdominal and brain and body 
magnetic resonance imaging (MRI) 
CI = confidence interval 
Tau-squared is an estimate of between-study variance on the logit scale. Zero 
represents no variance, and increasing values of tau-squared indicate increasing 
heterogeneity. 
Blue = Per-study point prevalence and pooled prevalence estimate of PSIFs on 
thoracic, abdominal and brain and body MRI  
Orange = Sensitivity analyses which include IFs classified as indeterminate in the 
per-study point prevalence and pooled prevalence estimate PSIFs on thoracic, 
abdominal and brain and body MRI. Details of the types and numbers of PSIFs are 
provided in Figure 2-3 and Supplementary Tables 2-10 and 2-11, while details of 
indeterminate findings are available online (Gibson et al., 2017a). 
a. We excluded 200 IFs detected in studies that used specialist imaging 
sequences (97 breast lesions in a study including MR mammography 
(Hegenscheid et al., 2013), 87 colonic polyps in two studies which included 
MR colonography (Baumgart and Egelhof, 2007; Goehde et al., 2005), 15 
vascular findings such as stenosis or plaque in four studies which included 
MR angiography (Baumgart and Egelhof, 2007; Goehde et al., 2005; 
Hegenscheid et al., 2013; Tarnoki et al., 2015), and one myocardial infarction 
in a study which included post-contrast cardiac imaging (Goehde et al., 






Across body regions, suspected malignancies were the most common types of PSIFs 
(accounting for roughly half of all such findings), with vascular findings also common on 
brain MRI (Figure 2-3 and Supplementary Tables 2-9, 2-10 and 2-11). Pooled prevalences of 
suspected malignant PSIFs were: brain 0.6% (95% CI 0.4–0.9%; thorax 0.6% (95% CI 0.1–
3.1%); abdomen 1.3% (95% CI 0.2–9.3%); and brain and body 2.3% (95% CI 0.3–15.4%). 
When possible indicators of malignancy were included, these were 0.6% (95% CI 0.4–
0.9%), 1.0% (95% CI 0.2–5.4%), 1.6% (95% CI 0.2–10.9%) and 3.0% (95% CI 0.4–20.4%) 
respectively (Supplementary Figure 2-2). 
 
 
Figure 2-3: Numbers and types of potentially serious incidental findings (PSIFs) on 
magnetic resonance imaging (MRI) by body region 
Further details of the types of PSIFs are provided in Supplementary Tables 2-9, 2-10 
and 2-11. We sub-classified PSIFs as suspected malignancy (e.g. masses), possible 
indicators of malignancy (incidental findings (IFs) which were not masses, but could 
be related to malignancy, e.g. pleural effusions) or non-malignant (Section 2.3.1.3). 
For the purposes of this figure, PSIFs which were not suspected malignancies, 






2.2.5.5 Subgroup analyses 
Examination of the available data (Supplementary Tables 2-6 and 2-7) showed that several 
potential subgroup analyses would be uninformative due to very imbalanced subgroups or 
non-reporting of the relevant data for a large subset of studies. One or both of these reasons 
precluded subgroup analyses with respect to magnet strength (almost all 1.5T), contrast use 
(incomplete data), data source (almost all studies used images rather than reports of these), 
image reader specialty (almost all studies had reporting by radiologists), and sample 
selection method (only one study randomly selected participants) (Hegenscheid et al., 2013). 
We did not conduct subgroup analyses by: age or sex, because we did not have individual 
participant data to allow meaningful comparisons; study country, since there was no clear a 
priori reason for variation in PSIFs prevalence by country; or body region because studies of 
brain and body MRI contributed data on different body regions from the same participants, 
violating the assumption that data within different subgroups are independent. We conducted 
brain and body and region-specific MRI subgroup analyses for imaging setting (research 
versus non-research) and for several factors which may inform on risks of bias (blinding of 
readers to participant characteristics and number of image readers) where sufficient data 
allowed. There was no evidence of any clinically meaningful or statistically significant 
difference in prevalence of PSIFs following the inclusion of subgroups as covariates 
(Supplementary Figures 2-3 to 2-11, Supplementary Table 2-12).  
2.2.5.6 Study-specific reports of factors associated with PSIFs 
Eight studies reported factors associated with PSIFs (Bos et al., 2016; Brugulat-Serrat et al., 
2017; Haberg et al., 2016; Hoggard et al., 2009; Morin et al., 2009; Saya et al., 2017; 
Sommer et al., 2013; Yue et al., 1997), while a further five reported factors associated with 
IFs requiring follow-up, which we considered an approximate proxy for PSIFs (Hartwigsen 
et al., 2010; Illes et al., 2004b; Loy et al., 2015; Sandeman et al., 2013; Tsushima et al., 
2005) (Supplementary Tables 2-13, 2-14 and 2-15). Two studies found significant 
associations between IFs requiring follow-up and increasing age (Hartwigsen et al., 2010; 
Illes et al., 2004b), while a further two studies found a consistently higher prevalence of IFs 
requiring follow-up (Tsushima et al., 2005) and cavernomata (Brugulat-Serrat et al., 2017) in 
older age groups, albeit not statistically significant (Supplementary Table 2-13). There was 
no clear variation in prevalence of PSIFs by sex (Supplementary Table 2-14). Too few data 
were available on other factors (including medical history, symptoms, lifestyle factors and 





data were available on the associations between imaging sequence or reporter specialty with 
prevalence of PSIFs. 
2.2.5.7 Follow-up and final diagnoses 
Only five studies systematically followed-up and reported data on the final clinical diagnoses 
of selected subsets of participants with IFs (total number of such participants followed up = 
234), representing 1.4 to 18.2% of all imaged participants in these studies (Table 2-1) (Bos et 
al., 2016; Lo et al., 2008; Morin et al., 2009; Sandeman et al., 2013; Saya et al., 2017). 
Summing arithmetically across these studies, overall only 48 of these 234 participants (i.e. 
about one fifth) had clinically serious final diagnoses (although half had indeterminate final 
diagnoses, mostly from one study of brain MRI (Bos et al., 2016), in which participants were 
managed under ‘wait and see’ policies). No study reported follow-up in a manner which 
enabled enumeration of the clinical assessments (e.g. further imaging examinations, specialty 















































































































































































































































































































































































































































































































































































































































































































































































































































Table 2-1: Methods of follow up of 234 people with potentially serious incidental findings 





- = not specified, . = not applicable 
a. This could be considered as a study-specific proxy for potentially serious incidental 
findings (PSIFs) but is not identical to the consistent definition that we applied in 
meta-analyses of prevalence of PSIFs. Hence study-specific n here differs from study 
specific numbers of PSIFs in meta-analyses. 
b. Decision for referral depended on the IF and consultation with clinicians. 
c. Decision for referral depended on discussion between radiologists and a 
geriatrician and other clinicians as necessary. 
d. Highly significant findings were defined as those requiring prompt medical follow-
up, such as indeterminate masses in solid organs, enlarged lymph nodes and ovarian 
masses/cysts, as judged by consensus of two radiologists. Participants’ family 
doctors were informed of the finding. 
e. Definition of IFs requiring further work-up, or processes for judging this are not 
reported. 
f. As determined by study radiologists, follow-up was discussed by a multi-
disciplinary team including principal investigators, radiologists and other study staff 
(not otherwise specified). 
 
2.2.6 Discussion 
2.2.6.1 Principal findings 
We performed meta-analyses of published studies of the prevalence of PSIFs among 
apparently asymptomatic adults undergoing MRI of brain, thorax, abdomen or brain and 
body. The pooled prevalence of PSIFs was 3.9% (1.4% brain, 1.3% thorax, 1.9% abdomen). 
When additionally including IFs of uncertain potential seriousness, the pooled prevalence 
increased to 12.8% (1.7% brain, 3.0% thorax, 4.5% abdomen). There was wide variation 
among studies in their prevalence estimates, likely reflecting variation between studies in 
participants’ characteristics, imaging setting, sample selection methods, and methods of 
detecting IFs, as well as the challenges of applying a consistent definition of PSIFs to the 
available descriptions of IFs in published papers. Suspected malignant IFs accounted for 
around half of all PSIFs on brain, thoracic, abdominal and brain and body MRI (0.6%, 0.6%, 
1.3% and 2.3% respectively). The very limited systematic follow-up data available (mainly 
from brain MRI studies) demonstrated that only about 1/5 people with a PSIF had a serious 






2.2.6.2 Strengths and limitations of this study 
By including all identified published data on the prevalence of PSIFs on brain, thoracic, 
abdominal and brain and body MRI, and by applying as consistent as possible a definition of 
PSIFs across studies, we have provided data on the prevalence of those IFs which may have 
an important impact on health. This is the first review to include data on PSIFs from 
different body regions, enabling comparisons of prevalence between regions. As such, our 
results are informative to people undergoing, or staff conducting, brain and body or region-
specific MRI in apparently asymptomatic adult volunteers. As most studies comprised 
selected apparently asymptomatic populations, our results are directly applicable to imaging 
performed for research and non-research settings such as screening. 
While we have not shown evidence of a statistically significant difference in the prevalence 
of PSIFs between body regions, the pooled point prevalences were generally higher on 
abdomen MRI, and on brain and body MRI compared to either brain or thorax MRI, 
particularly so when indeterminate findings were included in sensitivity analyses. This 
pattern is biologically plausible and was also seen in data from some primary studies 
(Gibson et al., 2018; Hegenscheid et al., 2013; Lo et al., 2008; Morin et al., 2009; Tarnoki et 
al., 2015). It is possible that the heterogeneity between included studies, the relative rarity of 
PSIFs, methods of meta-analyses and conservative calculation of 95% CIs may have 
obscured true differences in the prevalence of PSIFs between regions. Results on IFs from 
ongoing large population-based imaging studies (including the UK Biobank imaging sub-
study, which by September 2018 had imaged >27,000 of an intended 100,000 participants) 
should be able to confirm or refute this pattern in future (Bertheau et al., 2016; German 
National Cohort (GNC) Consortium, 2014; Gibson et al., 2016b; UK Biobank, 2018c). 
There was no evidence of any meaningful differences in the prevalence of PSIFs between 
studies conducted in research or imaging settings for any body region, or between studies 
using readers blinded to participant characteristics versus not blinded or not stated, or for 
brain MRI studies using one versus >1 reader. Further subgroup analyses which may inform 
on factors influencing variation in prevalence in different body regions were limited, as data 







Data were included in the review after screening and extraction by one, rather than multiple 
authors. While this may limit the accuracy of the data extraction, it is unlikely to have 
substantially impacted on our results given the very good agreement with a second reviewer 
on a 10% subset of the studies. Due to the lack of data on the participants with >1 PSIF, 
prevalence estimates were based on the assumption that only one PSIF occurs per 
participant; however, it is unlikely that a substantial proportion of participants had >1 PSIF. 
The prevalence of IFs deemed ‘potentially serious’ may vary with opinion and over time as 
evidence of their natural history accrues.  
We could not explore the influence of technical imaging factors (e.g. image resolution, 
magnet strength) on the prevalence of PSIFs, due to limited data availability and reporting 
consistency, but these are unlikely to substantially influence the detection of the most 
common PSIFs (suspected malignancies and aneurysms). The vast majority of included 
studies involved systematic radiologist reviews of images to detect IFs. No study directly 
compared radiologist to non-radiologist readers, although other policies to detect IFs may 
produce very different results, such as radiographer flagging of concerning examinations for 
a radiologist to review (Gibson et al., 2016b).  
2.2.6.3 Comparison with other studies 
A recently published umbrella review of IFs arising from a range of imaging modalities 
(including MRI) found no existing systematic reviews of the prevalence of IFs in apparently 
asymptomatic volunteers on cardiac, abdominal or brain and body MRI for comparison with 
our findings (O'Sullivan et al., 2018).  
Our update of an existing systematic review by Morris et al. (Morris et al., 2009) of IFs on 
brain MRI resulted in similar prevalence of suspected malignant IFs. The aforementioned 
recent umbrella review reported a prevalence of IFs on brain MRI of 22% (95% CI 14–
31%), around ten times higher than our pooled prevalence estimate for brain MRI (Morris et 
al., 2009; O'Sullivan et al., 2018; Takashima et al., 2017). The majority of this difference is 
likely to be due to the umbrella review’s inclusion of all reported IFs, regardless of their 
potential clinical significance, whereas we focused on PSIFs. Some of the difference may 
also be due to different study inclusion criteria (reflecting the different focus of the umbrella 
review, which had broader inclusion criteria, including studies of patients as well as 
apparently asymptomatic people), as well as a difference in meta-analytic methodologies. 
Prevalence data, as proportions, will have a binomial distribution. The umbrella review used 





directly modelling binomial data, whereas we used an exact method, which does model the 
within-study variance as binomial to generate unbiased estimates (Hamza et al., 2008).   
The recent umbrella review also reported far more final diagnosis data from studies derived 
from Morris et al. than we have here (Morris et al., 2009; O'Sullivan et al., 2018). In order to 
calculate the proportion of IFs resulting in known final diagnoses, the participants who form 
the denominator should all undergo systematic follow-up in order to generate an accurate 
numerator. We therefore scrutinised reports of all our included studies and found that only 
five reported such systematic methods; we did not consider diagnosis data from other studies 
to be robust, since they may represent suspected, rather than final diagnoses. 
2.2.6.4 Implications of this study 
Apparently asymptomatic people may undergo brain and body MRI by participating in 
research, or access non-research MRI via referral from a doctor (Tarnoki et al., 2015), or 
directly (Lee et al., 2008; Tarnoki et al., 2015; Tsushima et al., 2005) (e.g. as part of 
occupational screening (Weber and Knopf, 2006), private health insurance (Cieszanowski et 
al., 2014), or company health care programmes (Goehde et al., 2005; Tarnoki et al., 2015)). 
Our prevalence data could be used to inform consent for MRI in both research and non-
research settings. Such data could also help researchers calculate anticipated numbers of 
participants with PSIFs in future studies, to inform the design of appropriate IFs handling 
policies. 
Our review highlights the limited data available on the follow-up and final diagnoses of 
PSIFs. Such data would inform judgements about the benefits versus harms of feeding back 
PSIFs, an issue which warrants further investigation with systematic, long-term follow-up of 
participants with PSIFs. Unlike public health screening programmes, which fulfill specific 
criteria to ensure net benefit (Wilson et al., 1968), identification of a PSIF does not always 
lead to detection of disease at a stage where intervention will confer benefit. Many PSIFs 
will turn out to be clinically non-serious, but require potentially anxiety-provoking follow-up 
and potentially uncomfortable or harmful investigations to discover this. Even for those 
PSIFs that do turn out to be clinically serious, for most there is no clear evidence base to 
inform decisions about treatment, and early treatment of some disorders may confer harm 
(Mohr et al., 2014). Our prevalence data could inform power calculations for future clinical 
trials of conservative or active treatments of PSIFs, in order to develop good medical 
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2.3 Supplementary materials 
 
2.3.1 Supplementary methods  
 
2.3.1.1 Search strategies 
Search strategy 1 and 2 were designed/adapted respectively by Dr Lorna Gibson (MBChB) 
and Professor Cathie Sudlow (DPhil). 
Databases:  Embase  
Ovid MEDLINE 
Supplementary Table 2-1: Search strategy 1: Incidental findings on cardiac and 
abdominal MRI 
Line number Search term 
1 exp Magnetic Resonance Imaging/ 
2 exp Nuclear Magnetic Resonance Imaging/  
3 (magnetic resonance or MRI or MR or NMR).tw.  
4 1 or 2 or 3 
5 (abdom$ or cardiac or heart or cardio$ or whole-body or (whole adj2 
body)).tw. 
6 *Abdomen/ 
7 *Heart/  
8 5 or 6 or 7 
9 4 and 8 
10 Incidental findings/ 
11 (incidental$ or subclinical or serendipit$ or unexpected or 
asymptomatic).tw. 
12 10 or 11 
13 Humans/ 
14 9 and 12 and 13 
15 (Conference abstract or Conference report or Conference paper or 
Conference review or Case reports or comment or editorial or letter or 
news).pt. 






Supplementary Table 2-2: Search strategy 2: Update for review of incidental findings 
on brain MRI 
Line number Search term 
1 (MR or MRI or magnetic resonance imaging or neuroimaging).tw. 
 
2 (screen$ or incidental$ or healthy or asymptomatic or volunteer or 
control).tw. 
3 (cranial or brain$ or neuro$).tw. 
4 *Magnetic Resonance Imaging/ 
5 *Brain/ or exp Brain Diseases/ 
6 Humans/ 
7 1 and 2 and 3 and 4 and 5 and 6 
8 (Conference abstract or Conference report or Conference paper or 
Conference review or Case reports or comment or editorial or letter or 
news).pt. 
9 7 not 8 
10 limit 9 to yr="2008 -Current"  
11 remove duplicates from 10 







2.3.1.2 Lists used to classify incidental findings (IFs) as potentially serious or 
non-serious 
UK Biobank developed lists of findings which would be considered potentially serious, and 
findings not considered serious for use by radiographers and reporting radiologists. These 
lists were based on lists generated by the German National Cohort (Bertheau et al., 2016), 
and are subject to ongoing review. These lists were used to classify incidental findings (IFs) 
reported in included studies as potentially serious, or non-serious. 
Supplementary Table 2-3: Incidental findings on brain magnetic resonance imaging 
Potentially serious  Not serious 
Acute brain infarction Asymmetrical ventricles 
Acute hydrocephalus Chiari malformationd  
Acute intracranial haemorrhagea  Chronic hydrocephalus 
Arachnoid cystb Developmental anomalies 
(including venous anomalies) 
Colloid cyst of third ventricle Lipoma of corpus callosum 
Intracranial mass lesionc Non-acute brain infarction 
Mastoiditis Non-specific white matter 
hyperintensities 
Suspected intracranial aneurysm or vascular 
malformation 
Regional or global atrophy 
 Suspected demyelination 
a. Not old bleeds, or microbleeds only detected on gradient recalled echo sequences. 
b. Only if large and considered likely to increase the risk of developing a subdural 
haematoma.  
c. Except meningiomata in locations considered highly unlikely to cause problems. 






Supplementary Table 2-4: Incidental findings on thoracic magnetic resonance imaging 
Potentially serious  Not serious 
Aortic dissection Atelectasis 
Cardiac mass (including thrombus) Calcified pleural plaque 
Central pulmonary embolus  Calcified pulmonary nodule 
Haemodynamically relevant pericardial effusion 
> 2 cm 
Emphysema 
Heart valve defectsa Right sided descending aorta 
Hilar, mediastinal, axillary or cervical 
lymphadenopathyb 
 
Lobar pneumonia or lung consolidation  
Lung mass > 2 cm  
Mediastinal mass > 2 cm  
Pleural effusion  
Pleural mass > 2 cm  
Pneumothorax  
Severe left or right ventricular dilation or 
dysfunction 
 
Severe left ventricular hypertrophy > 2 cm thick 
wall 
 
Thoracic aortic aneurysm > 5 cm  
a. Severe regurgitation jet of any valve or severe turbulence (suggesting valve 
stenosis). 







Supplementary Table 2-5: Incidental findings on abdominal magnetic resonance 
imaging 
Potentially serious  Not serious 
Abdominal aortic aneurysm > 5 cm Abdominal wall hernia 
Acute exudative pancreatitis Bladder diverticulum 
Adrenal lesion > 2 cm Chronic cholecystitis 
Ascites Chronic pancreatitis 
Cholestasis (intra- or extra-hepatic)a Fatty liver 
Deep vein thrombosis Fibroids 
Hepatomegaly Gallstones 
Ileus Hiatus hernia 
Intra-abdominal mass > 3 cm Left sided inferior vena cava 
Irregular/nodular liver margin Liver cyst 
Lymphadenopathyb Renal calculus 
Multiple small non-cystic, liver lesions (non 
haemangioma-like) 
Simple renal cyst 
Pneumoperitoneum Single kidney 
Portal vein occlusion  
Pyelonephritis  
Renal artery stenosis > 80% or bilateral  
Solid/cystic pancreatic tumour  
Solid gallbladder lesion  
Solid liver lesion   
Solid/semi-solid renal tumour > 2 cm  
Spleen infarction  
Splenomegaly > 15 cm  
Urinary obstruction  
Urinary tract mass > 2 cm  
a. Common bile duct > 15 mm (or > 20 mm post-cholecystectomy). 









2.3.1.3 Sub-classification of potentially serious incidental findings (PSIFs) 
 
Suspected malignancy 
We sub-classified PSIFs as suspected malignancy if they described tumours, masses, 
complex cysts or lesions.  
Possible indicator of malignancy 
Other PSIFs which may be indicative of malignancy are those which are not masses, and 
may be related to either malignancy, or another aetiology. These included pleural and 
pericardial effusions, enlarged lymph nodes, hydronephrosis, splenomegaly, biliary 
dilatation, ascites, hydrocephalus and severe bone oedema. 
Non-malignant 
If a PSIF could not be classified as either suspected malignancy, or as a possible indicator of 










Supplementary Figure 2-1: Selection of included studies 
1. Eleven studies were excluded after reviewing the full-text article: two were 
superseded by larger cohorts reported in other articles; two included patients 
and apparently asymptomatic volunteers and did not report data separately for 
apparently asymptomatic volunteers; two did not report the age of 
participants; two included adults and children and did not report data 
separately for adults; one was a study of children; one investigated a single 
type of incidental finding; one did not report the age of participants 
undergoing brain imaging, and it was not clear if participants were apparently 













  Supplementary Figure 2-2: Forest plots of the per-study prevalence and pooled 
prevalence estimates of suspected malignant incidental findings (IFs), and of 
suspected malignant IFs plus possible indicators of malignancy, detected on brain, 
thoracic, abdominal and brain and body magnetic resonance imaging (MRI) 





Tau-squared is an estimate of between-study variance on the logit scale. Zero 
represents no variance, and increasing values of tau-squared indicate increasing 
heterogeneity. 
Blue = Per-study point prevalence and pooled prevalence estimate of suspected 
malignant IFs on brain, thoracic, abdominal and brain and body magnetic resonance 
imaging (MRI)  
Orange = Sensitivity analyses which include IFs classed as possible indicators of 
malignancy in the per-study point prevalence and pooled prevalence estimate of 
suspected malignant IFs on brain, thoracic, abdominal and brain and body MRI 
a. Suspected malignant IFs include tumours, masses, complex cysts and 
lesions. 
b. Possible indicators of malignancy include pleural and pericardial effusions, 
enlarged lymph nodes, hydronephrosis, splenomegaly, biliary dilatation, 
ascites, hydrocephalus and severe bone oedema. 
c. As per Figure 2-2, we excluded IFs detected in studies that used specialist 
imaging sequences (97 breast lesions in a study including MR mammography 
(Hegenscheid et al., 2013), and 87 colonic polyps in two studies which 
included MR colonography (Baumgart and Egelhof, 2007; Goehde et al., 2005)) 







Supplementary Figure 2-3: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by imaging setting – brain studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We defined research imaging as that performed as part of a research study. We 
classified other imaging of apparently asymptomatic participants as non-research (i.e. 
studies of occupational screening, commercial screening [i.e. paid for by the 
participant] or medical screening [whether referred by a doctor, or self-referred, or 






Supplementary Figure 2-4: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by imaging setting – thorax studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We defined research imaging as that performed as part of a research study. We 
classified other imaging of apparently asymptomatic participants as non-research (i.e. 
studies of occupational screening, commercial screening [i.e. paid for by the 
participant] or medical screening [whether referred by a doctor, or self-referred, or 







Supplementary Figure 2-5: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by imaging setting – abdomen studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We defined research imaging as that performed as part of a research study. We 
classified other imaging of apparently asymptomatic participants as non-research (i.e. 
studies of occupational screening, commercial screening [i.e. paid for by the 
participant] or medical screening [whether referred by a doctor, or self-referred, or 






Supplementary Figure 2-6: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by imaging setting – brain and body 
studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We defined research imaging as that performed as part of a research study. We 
classified other imaging of apparently asymptomatic participants as non-screening 
(i.e. studies of occupational screening, commercial screening [i.e. paid for by the 
participant] or medical screening [whether referred by a doctor, or self-referred, or 







Supplementary Figure 2-7: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by blinding of readers to participants’ 
characteristics imaging setting – brain studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We classified studies which reported they did not blind readers, or studies who did 








Supplementary Figure 2-8: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by blinding of readers to participants’ 
characteristics imaging setting – thorax studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We classified studies which reported they did not blind readers, or studies who did 








Supplementary Figure 2-9: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by blinding of readers to participants’ 
characteristics imaging setting – abdomen studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We classified studies which reported they did not blind readers, or studies who did 








Supplementary Figure 2-10: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by blinding of readers to participants’ 
characteristics imaging setting – brain and body studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
We classified studies which reported they did not blind readers, or studies who did 








Supplementary Figure 2-11: Forest plot showing study-specific prevalence of 
potentially serious incidental findings, ordered by number of image readers – brain 
studies 
PSIFs = potentially serious incidental findings, CI = confidence interval 
Number of image readers refers to the numbers of readers who assessed all images 
for IFs. Three studies of brain PSIFs (2,432/27,349 [8.9%] participants) (Lee et al., 2008; 
Li et al., 2015; Wahlund et al., 1989) did not provide data on number of image readers 
and were excluded from this subgroup analysis. There were sparse data within 
subgroups of studies involving one image reader for thorax, abdomen, and brain and 
body studies (PSIFs were present in only 1/188, 2/248 and 3/148 participants 



















































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 2-6: Details of included studies ordered by region 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































MRI = magnetic resonance imaging, I = imaging, UK = United Kingdom, USA = United 
States of America, R = reports, - = Information not specified or not sufficiently well 
described 
a. Sample size indicates the number of apparently asymptomatic volunteers 
imaged, as some studies also included patient groups (see footnote g). 
b. Indicates whether or not the participants were randomly sampled from the 
base population. 
c. Indicates whether information on incidental findings (IFs) was determined 
from review of images (I), or reports (R), or not specified (-). 
d. Blinded to information about participants. 
e. Median age; no data on mean age were available. 
f. Morin 2009: All scans were reviewed by a single radiologist, and only scans 
with a potentially highly significant abnormality were reviewed by two 
radiologists. 
g. Study included groups of patients and apparently asymptomatic volunteers, 
only data from the apparently asymptomatic volunteers were included in this 
review. 
h. Bos 2016: All scans were reviewed by a group of trained readers (researchers 
or neuropsychologists) for IFs. Two neuroradiologists reviewed only scans 
with suspected IFs. We have assumed that the reported data on IFs pertain to 
those confirmed by the neuroradiologists. 
i. Study was included in the review, as it was deemed to involve only a small 
proportion of children, as judged in consensus by two authors (LG and CLMS) 
based on available data on the age of the study population. 
j. Kumar 2008: All scans were reviewed by a single radiologist, and only scans 
with suspected abnormalities were reviewed by a second reader, a 
neuropsychiatrist. 
k. Li 2015: All scans were reviewed by an MRI operator for IFs, and confirmed by 
a neuroradiologist, blinded to participants’ clinical status. It is not clear if the 
neuroradiologist reviewed all participants’ scans for IFs, or just those with 
abnormalities detected by the MRI operator. We have assumed that the 















































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 2-7: Sequences evaluated for incidental findings in 























































































































































































































































































































































































































































































































































































































































































































































































































































FLAIR = fluid attenuated inversion recovery, MRA = magnetic resonance angiography, 
STIR = short-tau inversion recovery, CE = contrast enhanced, NS = not specified 
a. Some studies report the prevalence of incidental findings (IFs) detected in 
participants who all attended for the same type of imaging, for example, a 
single research study with a single imaging protocol. These studies are 
indicated by ‘Y.’ In contrast, some studies report the prevalence of IFs 
detected in participants scans that have been ‘pooled’ from more than one 
research project, and therefore involve more than one imaging protocol. These 
studies are indicated by ‘N,’ with details provided in additional footnotes. 
b. Either gradient recalled echo, or susceptibility-weighted imaging. 
c. ‘Other’ sequences include additional brain or chest or abdominal sequences, 
such as proton density, diffusion weighted imaging, colonography, 
mammography, in and out of phase abdominal imaging etc. Please see 
individual papers for details. 
d. Sequence performed in a subset of participants. 
e. Yue 1997: 0.35 Tesla MRI used at three imaging centres, 1.5 Tesla MRI used at 
one imaging centre. No data available on numbers of participants imaged 
using the different scanners. 
f. Katzman 1999: Participants’ scans were pooled from multiple neuroimaging 
studies, but all had at least T1- and T2-weighted brain imaging. 
g. Sommer 2013: Participants’ scans were pooled from multiple neuroimaging 
studies, but only T2 images were assessed for IFs. 
h. Hoggard 2009: Participants’ scans were pooled from multiple neuroimaging 
studies, but 456 had at least axial T2-weighted imaging of the whole brain, and 
the remaining 69 from a single neuroimaging study only had T1-weighted 
imaging. 
i. Reneman 2012: Seven participants were imaged using a 3.0T MRI scanner, 
with only a 3D T1-weighted sequence. 
j. Li 2015: Number of control participants scanned with each magnet was not 
reported. Participants imaged using the 1.5T scanner underwent 3D-fast 
spoiled gradient echo T1-weighted imaging. Participants imaged using the 
3.0T scanner underwent 3D- magnetization-prepared rapid gradient-echo T1-
weighted imaging. Additional, unspecified, sequences were performed when 
necessary for diagnostic purposes. 
k. Illes 2004: Participants’ scans were pooled from multiple neuroimaging 
studies, and each participant underwent at least one of the sequences 
indicated. 
l. Wahlund 1989: No information on sequence types is available. 
m. Lubman 2002: Participants’ scans were pooled from multiple neuroimaging 
studies, and participants had at least a T1-weighted sequence. 
n. Vogel-Claussen 2009: Method of imaging coronary arteries differed across the 
sample: 23 participants underwent steady state free precession coronary MRA 
images using breath-hold technique, and the remaining 231 underwent 3-
dimensional steady-state free precession navigator assisted free breathing 





Supplementary Table 2-8: 95% prediction intervals (and 95% confidence intervals to 
enable direct comparison) 







95 % confidence 
interval 
(%) 
PSIFs only    
  Brain 1.4 0.2 to 8.3 1.0 to 2.1 
  Thorax 1.3 0 to 76.8 0.2 to 8.1 
  Abdomen 1.9 0 to 81.1 0.3 to 12.0 
  Brain and body 3.9 0 to 95.4 0.4 to 27.1 
PSIFs and indeterminate IFs    
  Brain 1.7 0.2 to 12.3 1.1 to 2.6 
  Thorax 3.0 0 to 67.4 0.8 to 11.3 
  Abdomen 4.5 0.2 to 55.2 1.5 to 12.9 
  Brain and body 12.8 0.4 to 85.7 3.9 to 34.3 
Suspected malignant IFs    
  Brain 0.6 0.1 to 4.0 0.4 to 0.9 
  Thorax 0.6 0 to 29.6 0.1 to 3.1 
  Abdomen 1.3 0 to 76.8 0.2 to 9.3 
  Brain and body 2.3 0 to 86.5 0.3 to 15.4 
Suspected malignant IFs and 
possible indicators of 
malignancy 
   
  Brain 0.6 0.1 to 4.2 0.4 to 0.9 
  Thorax 1.0 0 to 57.4 0.2 to 5.4 
  Abdomen 1.6 0 to 81.0 0.2 to 10.9 
  Brain and body 3.0 0 to 91.8 0.4 to 20.4 






Supplementary Table 2-9: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - brain 
Types of PSIFs among 27,349 volunteers N PSIFs 
Percentagea of 
PSIFs (total N=688) 
Suspected malignancy 317 46 
  Intracranial mass 179 26 
  Pituitary mass 67 9.7 
  Pituitary cyst 55 8.0 
  Extracranial mass 12 1.7 
  Atypical cerebellar lesion 2 0.29 
  Intracranial cystb 1 0.15 
  Skull: Potentially serious lesion 1 0.15 
Suspected aneurysm 214 31 
Suspected vascular malformation 106 15 
Suspected other: 46 6.7 
  Arachnoid cyst 18 2.6 
  Not specified: potentially serious 13 1.9 
  Acute infarct 4 0.58 
  Missing pituitary neurohypophysis signal 4 0.58 
  Subdural haematoma 3 0.44 
  Colloid cyst 2 0.29 
  Mesial temporal sclerosis 1 0.15 
  Syringomyelia 1 0.15 
Possible malignancy: hydrocephalus 5 0.73 
MRI = magnetic resonance imaging, PSIFs = potentially serious incidental findings 
a. All percentages are rounded to two significant figures. 
b. This intracranial cyst was followed up with MRI, and we presumed that there 






Supplementary Table 2-10: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - thorax 
MRI = magnetic resonance imaging, PSIFs = potentially serious incidental findings 
a. All percentages are rounded to two significant figures 
Types of PSIFs among 5,111 volunteers N PSIFs 
Percentagea  of 
PSIFs (total N=238)  
Suspected malignancy 132 55 
  Lung  72 30 
    Nodule 56 24 
    Lobar pneumonia or lung consolidation 8 3.4 
    Lesion requiring follow-up 5 2.1 
    Mass 3 1.3 
  Other region 60 25 
    Neck tumor 52 22 
    Thyroid lesions or enlargement 4 1.7 
    Cardiac mass 1 0.42 
    Chest lesion 1 0.42 
    Liver lesion requiring follow-up  1 0.42 
    Mediastinal lesion requiring follow-up 1 0.42 
Suspected other 55 23 
  LV hypertrophy 17 7.1 
  Valve defects 16 6.7 
  Goitre with tracheal compression 9 3.8 
  Heart failure  5 2.1 
  Reduced contractility 5 2.1 
  Hypertrophic cardiomyopathy 1 0.42 
  Suspected pulmonary hypertension 1 0.42 
  Thoracic aortic stenosis 1 0.42 
Possible malignancy 41 17 
  Lymphadenopathy 22 9.2 
  Pleural effusion 16 6.7 
  Pericardial effusion 2 0.84 
  Urinary obstruction 1 0.42 





Supplementary Table 2-11: Types of potentially serious incidental findings (PSIFs) in 
descending order of frequency, as percentages of total PSIFs - abdomen 
 
MRI = magnetic resonance imaging, PSIFs = potentially serious incidental findings 
Types of PSIFs among 4,817 volunteers N PSIFs 
Percentagea  of 
PSIFs (total N=412)  
Suspected malignancy 325 79 
  Renal 131 32 
  Ovarian 79 19 
  Liver 50 12 
  Uterine or cervical malignancy 15 3.6 
  Pancreas 12 2.9 
  Adrenal gland 8 1.9 
  Testicular, epididymal or seminal vesicle 7 1.7 
  Bladder 6 1.5 
  Colon or rectum 6 1.5 
  Spleen 5 1.2 
  Lumbar intraspinal neurinoma  1 0.24 
  Lumbar spine lesion requiring follow-up  1 0.24 
  Prostate 1 0.24 
  Psoas 1 0.24 
  Retroperitoneal mass 1 0.24 
  Stomach 1 0.24 
Possible malignancy 55 13 
  Biliary dilatation 25 6.1 
  Lymphadenopathy 16 3.9 
  Splenomegaly 8 1.9 
  Chronic urinary obstruction 5 1.2 
  Ascites  1 0.24 
Suspected other 18 4.4 
  Irregular/nodular liver margin 9 2.2 
  Haemochromatosis 5 1.2 
  Abdominal aortic stenosis 3 0.73 
  Reflux nephropathy 1 0.24 





a. All percentages are rounded to two significant figures. 
b. Denominator is 1,921 women. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 2-13: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or IFs 
which required follow-up (as per each study’s definition), ordered by descending sample 





PSIF = potentially serious incidental finding, N = no, Y = yes, NC = not calculated as 
zero frequency in both groups. 
a. P-values relate to chi-square tests unless otherwise stated.  
b. Tsushima 2005: IFs requiring follow-up, as judged by the study’s radiologist. 
c. Not all IFs requiring follow-up were classed as PSIFs but the distribution of 
PSIFs between age groups was not possible to calculate from the reported 
data; in this context, we use ‘IFs requiring follow-up’ as an approximate proxy 
for PSIFs 
d. Two-tailed Fisher exact test. 
e. Hartwigsen 2010: IFs requiring follow-up, the method of judging this was not 
reported. 
f. From independent samples t-test, reported in the study paper. No numerical 
data on age of each group (e.g. mean) were reported. 






Supplementary Table 2-14: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or 
IFs which required follow-up (as per each study’s definition), ordered by descending 
sample size - sex 
Study and 




















90 (2.8) 44 (1.7) 0.006c 
  Pituitary cyst or 
mass 
35 (1.1) 32 (1.2) 0.7c 
Yue 1997 3672 
(2141) 
Cavernoma 4 (0.2) 1 (0.1) 0.4 
  Pituitary cyst or 
mass 







5 (1.4) 10 (1.3) 1.0 




1 (0.2) 0 (0.0) 1.0 
  Cavernoma 2 (0.4) 1 (0.2) 0.4 
  Cerebral 
aneurysm 
14 (2.6) 5 (1.1) 0.1 
  Glioma 1 (0.2) 0 (0.0) 1.0 
  Pituitary cyst or 
mass 
2 (0.4) 1 (0.2) 1.0 
  Vestibular 
schwannoma 














15 (4.3) 3 (1.3) 0.1 
Kumar 2008 478  
(226) 
Pituitary cyst or 
mass 
3 (1.3) 1 (0.4) 0.4 




4 (5.8) 6 (7.3) 0.8 
Brain and body     
Morin 2009 148    
(54) 
PSIFs 1 (1.9) 2 (2.1) 0.4 





PSIFs, or IFs requiring follow-up, as appropriate. 
a. P-values relate to two-tailed Fisher exact tests unless otherwise stated.  
b. P-value relates to chi-square test. 
c. Tsushima 2005: IFs requiring further evaluation, as judged by the study’s 
radiologist. 
d. Not all IFs requiring follow-up were classed as PSIFs but the distribution of 
PSIFs between women and men was not possible to calculate from the 
reported data; in this context, we use ‘IFs requiring follow-up’ as an 
approximate proxy for PSIFs. 
e. Sandeman 2013: IFs requiring further referral, as judged by the study’s 
geriatrician and radiologists. 







Supplementary Table 2-15: Summary of available data on potential determinants of 
prevalence of potentially serious incidental findings (PSIFs, as per our definition) or 
IFs which required follow-up (as per each study’s definition), ordered by descending 
































































































































































































































































































































































































































































































































































































































PSIF = potentially serious incidental findings, - cannot be calculated, HIV = human 
immunodeficiency virus, NR = not reported 
a. Some studies included in the review involved patient groups, data from these 
were not included in the review, but are presented here to summarise 
prevalences of IFs between patient groups and apparently asymptomatic 
people.  
b. Corresponds to sample sizes reported elsewhere in this review, i.e. apparently 
asymptomatic people only. 
c. PSIFs, or IFs requiring follow-up, as appropriate. 
d. P-values relate to two-tailed Fisher exact tests.  
e. Tsushima 2005: IFs requiring further evaluation, as judged by the study’s 
radiologist. 
f. Not all IFs requiring follow-up were classed as PSIFs but the distribution of 
PSIFs between groups with and without each factor was not possible to 
calculate from the reported data; in this context, we use ‘IFs requiring follow-
up’ as an approximate proxy for PSIFs. 
g. Cardiac disease included congestive heart failure, myocardial infarction, 
angina pectoris, left ventricular hypertrophy atrial fibrillation; or 
electrocardiographic evidence of past myocardial infarction, left ventricular 
hypertrophy, or atrial fibrillation.  
h. From a medical history taken by a neurologist. 
i. ≥ 60g of alcohol per day. 
j. > 20 cigarettes per day. 
k. Systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg, 
or on treatment for hypertension, or history of hypertension. 
l. Fasting total cholesterol > 250 mg/dl, or history of hyperlipidaemia. 
m. Sommer 2013: Not further defined.  





This chapter aimed systematically to review studies of brain, thorax, abdomen and of brain 
and body MRI conducted among apparently asymptomatic adults to determine the 
prevalence and types of PSIFs, factors associated with PSIFs, and describe what is known 
about the follow-up and final diagnoses of people with PSIFs. 
Previous studies’ estimates of the prevalence of IFs were limited by variation in the 
definition of IFs. By applying as consistent as possible a definition of PSIFs across studies, 
we have provided data on the prevalence of those IFs which may have an important impact 
on health. Meta-analyses of 32 published studies (n=27,643 participants) found that the 
pooled prevalences of PSIFs on brain, thorax, abdomen and brain and body MRI were 1.4%, 
1.3%, 1.9% and 3.9% respectively. When IFs of uncertain potential seriousness were 
included in meta-analyses, these prevalence estimates rose to 1.7%, 3.0%, 4.5% and 12.8% 
respectively. Around half of PSIFs were described as suspected malignancies (brain 0.6%; 
thorax 0.6%; abdomen 1.3%; brain and body 2.3%). There was substantial within-study and 
between-study variation in prevalence estimates, but few data to reliably inform on sources 
of this.  
Limited published follow-up data from five studies (n=234 participants with PSIFs) found 
that only a minority of participants (n=48, 21%) had a serious final clinical diagnosis. The 
available data did not allow the quantification of clinical assessments of participants with 
PSIFs. Informative data on the factors associated with PSIFs were also limited, but suggested 
some association with age, and no clear association with sex. The majority of studies 
employed IFs handling policies which involved systematic radiologist review of images, 
highlighting the lack of studies providing information on any variation in prevalence of 
PSIFs which may occur with other policies. 
To better inform on the clinical assessments and final diagnoses of, and factors associated 
with PSIFs, systematic, long-term follow-up studies of unselected participants with PSIFs 
are needed. The next two chapters describe such a study, UK Biobank, and the evaluation of 
its policy to handle IFs generated during its multi-modal imaging study which is compared 
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Chapter 3 Development and evaluation of the 
UK Biobank incidental findings 
protocol  
3.1 Introduction 
UK Biobank is a major research resource comprising comprehensive phenotypic and genetic 
data on a cohort of over 500,000 British adults with data on incident diseases generated via 
linkages to routinely collected healthcare data (Sudlow et al., 2015). The UK Biobank 
dataset therefore facilitates studies of a large number of potential risk factors for a wide array 
of conditions with major public health impacts (Sudlow et al., 2015). To further enhance the 
existing dataset, the UK Biobank Imaging Study aims to collect multi-modal imaging data 
from a sub-cohort of 100,000 UK Biobank participants (Matthews and Sudlow, 2015). As 
such, potentially serious incidental findings (PSIFs) are a particularly pertinent issue for the 
UK Biobank Imaging Study, and it requires a protocol for handling them (Gibson et al., 
2018). In this chapter, we describe the rationale behind, and process of, the UK Biobank IFs 
protocol: radiographer flagging of concerning images for a radiologist to review, with 
feedback of radiologist-confirmed PSIFs to participants and their general practitioners (GPs).  
The UK Biobank IFs protocol will inevitably fail to identify all PSIFs which represent 
serious final diagnoses, due to the non-diagnostic nature of the research imaging and lack of 
systematic radiologist review of all images. Chapter 1 highlighted that members of the public 
may expect that all research images are reviewed by radiologists (The Royal College of 
Radiologists, 2011), and for research imaging to be able to generate firm clinical diagnoses 
(Kirschen et al., 2006). Therefore, it is imperative that UK Biobank participants have 
realistic expectations of how their PSIFs will be handled. This chapter will briefly describe 
the methods to evaluate participants’ understanding of their consent to the UK Biobank IFs 
protocol; the results are presented in Sections 4.2 and 4.3. 
Chapter 2 demonstrated a lack of studies which inform on the prevalence of PSIFs generated 
by protocols other than systematic radiologist review. There is no ‘one-size-fits-all’ 
incidental findings (IFs) protocol which will suit every imaging context (Gibson et al., 
2018); rather, the choice of protocol should be justifiable, and based on empirical evidence. 
Judgements of the benefits and harms of feedback of PSIFs will be informed by data on the 
clinical assessments generated, and their final diagnoses. Chapter 2 demonstrated that such 
published data are limited, and that long-term, systematic follow-up studies of unselected 
participants with PSIFs are needed. To address this lack of data on the variation of the 
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prevalence of PSIFs under different protocols, and the methodological shortcomings of 
previous studies, this chapter also briefly describes the methods used to compare the UK 
Biobank IFs protocol with systematic radiologist review; the results are presented in Sections 
4.2 and 4.3.  
This chapter was originally published as a book chapter by Springer (Gibson et al., 2016b), 





3.2 Management of incidental findings on multi-
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Abstract
UK Biobank is a major national health 
resource which aims to improve prevention, 
diagnosis and treatment of a wide range of 
serious and life- threatening illnesses. UK 
Biobank recruited 500,000 people aged 
between 40 and 69 years in 2006–2010, who 
underwent a range of measurements and 
 provided detailed information about them-
selves, donated biological samples for future 
analyses and agreed to have their health fol-
lowed long term. Among a range of ongoing 
enhancements, the UK Biobank Imaging 
Study aims to perform brain, cardiac and body 
magnetic resonance imaging, dual-energy 
X-ray absorptiometry and carotid Doppler 
ultrasound in 100,000 participants, generating 
the world’s largest multimodal imaging 
dataset.
As incidental findings (IF) are an expected 
consequence of its imaging study, UK Biobank 
developed a pragmatic, scalable protocol for 
handling IF, in which participants and their 
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general practitioners receive feedback in 
 limited circumstances: when, during image 
acquisition, a radiographer notices a poten-
tially serious IF (‘indicating the possibility of 
a condition which, if confirmed, would carry a 
real prospect of seriously threatening life span 
or of having a substantial impact on major 
body functions or quality of life’) and a radi-
ologist subsequently confirms a potentially 
serious IF.
UK Biobank has compared its IF protocol 
against a commonly used protocol (systematic 
review of all images by radiologists) and col-
lected comprehensive data on the impact of 
feedback of potentially serious IF on partici-
pants and health services. The results will be 
published separately and will provide robust, 
empirical evidence to inform debates sur-
rounding handling IF and designs of future 
studies’ IF policies.
1  Introduction
1.1  UK Biobank
UK Biobank is a large, prospective epidemiologi-
cal research resource which recruited approxi-
mately 500,000 people aged 40–69 between 2006 
and 2010 (Sudlow et al. 2015). UK Biobank aims 
to enable studies of the prevention, diagnosis and 
treatment of common and serious diseases and is 
open to use by researchers from anywhere in the 
world for health-related research which is in the 
public interest (Collins 2012). The UK Biobank 
resource contains detailed baseline questionnaire 
and physical measurement data, genotyping and 
biochemical assay data, and biological samples 
from all participants (Sudlow et al. 2015). UK 
Biobank participants have agreed to have their 
health followed, and data on health outcomes are 
derived via linkages to routinely collected 
national healthcare datasets. Enhanced data col-
lection is ongoing in subsets of participants, and 
in April 2014, UK Biobank embarked on its most 
ambitious enhanced data collection project to 
date: the UK Biobank Imaging Study.
We aim to describe the UK Biobank Imaging 
Study, the development of the UK Biobank inci-
dental findings (IF) protocol and UK Biobank’s 
programmes of evaluation of this protocol: (i) of 
participants’ understanding of consent in relation 
to receiving feedback about a potentially serious 
IF (defined as one indicating the possibility of a 
condition which, if confirmed, would carry a real 
prospect of seriously threatening life span or of 
having a substantial impact on major body func-
tions or quality of life) and (ii) the impact of the 
UK Biobank IF protocol on participants and 
health services, the results of which will be pub-
lished separately.
1.2  The UK Biobank Imaging 
Study
Over the next seven years, UK Biobank will per-
form brain, cardiac and body magnetic resonance 
imaging (MRI), carotid Doppler ultrasound and 
dual-energy X-ray absorptiometry (DXA) in 
100,000 of its participants and generate the 
world’s largest multimodal imaging dataset. The 
data will enable researchers to investigate associa-
tions between imaging-derived phenotypes (IDP) 
and the wealth of exposure and outcome data 
from baseline and other enhanced data collections 
and health record linkages within the resource.
Research imaging is currently underway at the 
purpose-built imaging centre in Stockport, with 
further centres planned. On arrival at the imaging 
centre, participants undergo registration, pre-
screening and consent, followed by imaging. In 
order to provide contemporaneous non-imaging 
data, at the end of the visit, participants repeat the 
entire baseline assessment and an additional 
12-lead electrocardiogram. Each participant’s 
imaging visit lasts approximately four hours.
The UK Biobank Imaging Working Group 
collaborated with over 100 scientists to design 
the UK Biobank Imaging Study protocol, which 
aims to balance the acquisition of high-quality 
imaging data against feasible methods which are 
acceptable to participants (Matthews and Sudlow 
2015; UK Biobank 2015e). These data enable 
UK Biobank to generate a wide range of IDP 
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(Table 1) and facilitate the development and test-
ing of new image analyses methods, the results of 
which are being integrated into, and thus further 
enhancing, the UK Biobank resource (Matthews 
and Sudlow 2015).
Participants undergo an approximately 30-min 
3.0 T brain MRI (Skyra, Siemens, Erlangen, 
Germany), which includes structural (T1, T2 
fluid-attenuated inversion recovery, susceptibility- 
weighted imaging and T2*), functional and diffu-
sion imaging (UK Biobank 2016). From these 
images, UK Biobank generates IDP including 
measures of volumes of total grey matter, cortical 
grey matter, total white matter, cerebrospinal 
fluid and structures such as the thalamus, detailed 
data on activation and statistical effect sizes in 
different regions during fMRI tasks and diffusion 
parameters such as fractional anisotropy in dif-
ferent white matter tracts (UK Biobank 2016; 
Miller et al. 2016).
A 20-minute non-contrast cardiac MRI is 
acquired using a 1.5 T Magnetom Aera scanner 
(Siemens Healthcare, Erlangen, Germany). 
Sequences include long and short axis cine, aor-
tic distensibility cine, tagging and aortic valve 
flow images, from which IDP such as cardiac 
output, ejection fraction and end-diastolic, end- 
systolic and stroke volumes are calculated and 
from which a wide range of additional measures 
are being derived using novel, automated meth-
ods (UK Biobank 2015b; Petersen et al. 2013).
Participants are then repositioned within the 
1.5 T scanner and undergo a 10-min body MRI. In 
total, these images cover tissues from the neck to 
the knees and include a T1 abdomen, T1 pancreas 
and a liver and pancreas multi-echo sequence. 
From these images, semiautomated measures of 
liver fat, fibrosis and haemosiderosis percentages 
can be made, in addition to body composition 
measurements of subcutaneous and visceral fat 
and thigh muscle mass (UK Biobank 2015a; West 
et al. 2016). Ongoing methodological develop-
ments will lead to the derivation of an increas-
ingly wide range of measures.
Table 1 Summary of imaging modalities and imaging-derived phenotypes included in the UK Biobank Imaging Study
Imaging modality 







available Examples of available IDP
Brain MRI
(UK Biobank 2016)
3.0 T Skyra1 30 T1, T2 FLAIR, 
SWI, T2*, fMRI, 
DWI
749 Tissue volumes, 





1.5 T Magnetom 
Aera1
20 Cine (long axis, 
short axis, aorta), 
tagged, aortic valve 
flow





1.5 T Magnetom 
Aera1
10 T1 abdomen, T1 
pancreas, liver and 
pancreas multi-
echo, Dixon







iDXA2 20 Whole body, 
thoracolumbar 
spine, hips, knees
120 Bone area, mineral 














16 Minimum, maximum and 
mean CIMT
IDP imaging-derived phenotypes, MRI magnetic resonance imaging, FLAIR fluid-attenuated inversion recovery, SWI 
susceptibility-weighted imaging, fMRI functional MRI, DWI diffusion-weighted imaging, DXA dual-energy X-ray 
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Carotid Doppler ultrasound images are 
acquired during a 10-min examination using a 
5–13 MHz linear array transducer and a 
CardioHealth Station (Panasonic, Leicester, UK). 
Two-dimensional transverse and longitudinal 
plane images of each carotid artery are saved as 
cine loops, followed by two measures of intima- 
media thickness per carotid artery. From these 
images, mean, minimum and maximum calcula-
tions of carotid intima-media thickness are gen-
erated, and additional measures of plaque 
characteristics will follow (UK Biobank 2015d).
DXA images of the whole body, thoracolum-
bar spine, hips and knees are acquired using an 
iDXA scanner (GE-Lunar, Wisconsin, USA). 
The scanner automatically generates multiple 
IDP of the bone area, mineral content and density 
and body composition measures of lean and fat 
mass (UK Biobank 2015c).
Descriptions of all available IDP from each 
modality, and non-imaging variables, are avail-
able from the UK Biobank showcase (http://
www.ukbiobank.ac.uk/data-showcase).
2  UK Biobank IF Protocol
2.1  Development of the UK 
Biobank IF Protocol
Incidental findings (IF) are findings deemed 
beyond the aims of a study (Wolf et al. 2008). IF 
are particularly pertinent to the UK Biobank 
Imaging Study given the nature of IF which may 
be identifiable on multimodal imaging of 100,000 
largely asymptomatic participants. The handling 
of IF in research imaging is the subject of wide-
spread debates (Gibson et al. 2016 In Press), and 
while there is no ‘one-size-fits-all’ approach to 
detecting and feeding back IF, researchers should 
anticipate IF and design appropriate IF handling 
policies (Medical Research Council and 
Wellcome Trust 2014).
The UK Biobank IF protocol was developed 
following an extensive process which involved 
reviewing existing policies for feedback of find-
ings to UK Biobank participants, published evi-
dence and guidance on IF, received external legal 
advice on the scope of the duty of care and con-
sultations with the independent UK Biobank 
Ethics and Governance Council, UK Biobank’s 
major funders (Wellcome Trust and Medical 
Research Council) and with the Royal College of 
Radiologists and the Society and College of 
Radiographers. In addition, UK Biobank sought 
to learn from the experiences and approaches 
taken to handling IF used by several other large- 
scale research imaging projects, including the 
German National Cohort, the Rotterdam Scan 
Study, the Multi-Ethnic Study of Atherosclerosis 
(MESA), and the Reykjavik Heart Study. UK 
Biobank also consulted with relevant experts to 
explore the legal and ethical factors which were 
applicable to the development of the IF protocol.
The UK Biobank IF protocol was developed 
from first principles as a pragmatic protocol that 
could be implemented on a large scale with the 
objective of striking the optimum balance of 
most net benefit and least net harm to 100,000 
largely asymptomatic participants (UK Biobank 
2015e). Under this protocol, participants only 
receive feedback in specific, limited circum-
stances: when a radiographer identifies a 
 potentially serious IF during the acquisition or 
quality assessment of images during the imaging 
visit and a radiologist subsequently confirms the 
presence of a potentially serious IF. UK Biobank 
defines a potentially serious imaging IF as ‘as a 
finding which indicates the possibility of a condi-
tion which, if confirmed, would carry a real pros-
pect of seriously threatening life span, or of 
having a substantial impact on major body func-
tions or quality of life.’
2.2  Consent Processes
Before attending the imaging centre, UK Biobank 
provides participants with an information leaflet 
which includes a description of the IF protocol 
and what they should and should not reasonably 
expect (UK Biobank 2014b).
The information leaflet explains that the scans 
are not intended to diagnose an illness or identify 
a particular abnormality and that they will not be 
looked at routinely by doctors. Participants are 
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informed that if, during the scan, the radiogra-
pher notices something which they think may be 
serious, only then will the scan be reviewed by a 
doctor; if the doctor thinks there may be a poten-
tially serious finding, the participant and their GP 
will be informed. The leaflet gives examples of 
IF which would be fed back to participants (a 
tumour) and those which would not (gallstones or 
a simple cyst).
UK Biobank’s consent form explicitly asks for 
participants’ consent on the basis that (a) they 
understand that these scans are for research pur-
poses only and that they will not be routinely 
examined by medical staff and should not be 
regarded as part of a ‘health check,’ (b) that they 
give permission for UK Biobank to contact them 
and their GP in the event that a potentially serious 
IF is found on a scan and (c) that a lack of contact 
from UK Biobank does not imply that no poten-
tially serious IF exists, but simply that no such 
abnormality was noticed by the staff taking the 
scans (UK Biobank 2014a).
2.3  Identification of IF
UK Biobank modified a list of IF developed by 
the German National Cohort to detail those IF 
which may be detected on brain, cardiac or body 
MR or DXA which UK Biobank would consider 
potentially serious and warrant feedback to par-
ticipants and their GPs and those which it would 
consider not serious and would not be fed back. It 
was deemed that carotid Doppler ultrasound con-
ducted by radiographers would not produce any 
IF which would be considered potentially 
serious.
The list is not exhaustive, and in the event that 
an IF is detected which is not included in the list, 
radiographers and radiologists are guided by the 
UK Biobank definition of a potentially serious IF 
(those which indicate the possibility of a condi-
tion which, if confirmed, would carry a real pros-
pect of seriously threatening life span or of 
having a substantial impact on major body func-
tions or quality of life) to judge whether an IF is 
deemed potentially serious or not (UK Biobank 
2014b).
2.4  Feedback of IF
If the reviewing expert decides that the IF is not 
serious, then no further action is taken. If, on the 
other hand, the reviewing expert confirms that the 
IF is potentially serious, then they provide a short 
summary for the participant and a more compre-
hensive summary for the participant’s GP (UK 
Biobank 2015e).
The GP is informed that the images have not 
been optimised for the purpose of identifying 
abnormalities and have not been reviewed in a 
clinical setting. Further investigations and/or 
referrals are left to the discretion of the GP. As 
required, the participant’s doctors are able to 
review the scans collected by UK Biobank (UK 
Biobank 2015e).
3  Evaluation of the Impact of 
the UK Biobank IF Protocol
3.1  Evaluating Participants’ 
Understanding of Consent
Given that systematic radiologist review of all 
acquired images is not undertaken, the UK Biobank 
IF Protocol will inevitably fail to identify some 
potentially serious IF which represent serious dis-
eases. Public expectations relating to feedback of 
IF may well be unrealistic, the public associate 
imaging with clinical diagnoses (Kirschen et al. 
2006), and expect that images will be reviewed by 
experts (The Royal College of Radiologists 2011). 
It is therefore crucial to manage participants’ 
expectations of what will be fed back, and what 
will not, and specifically to ensure that they under-
stand that the imaging does not constitute a ‘health 
check’ and that lack of feedback of a potentially 
serious IF does not represent an ‘all clear.’ The 
intention of the UK Biobank information materials 
and consent process is to provide participants with 
a fair, reasonable and realistic expectation of the 
outcome of their visit for imaging in the UK 
Biobank Imaging Study. UK Biobank developed a 
questionnaire to assess participants’ understanding 
of this consent, which is sent to imaged participants 
two days after their imaging visit.
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Participants are asked whether or not they 
thought they consented to the following: return of 
scans and results at the end of the imaging visit; 
to choose whether they and their GP would be 
informed; that they and their GP would automati-
cally be contacted; that they would receive feed-
back of a potentially serious IF during the 
imaging visit; whether they would receive feed-
back of an IF after the imaging visit. These data 
are periodically reviewed so that the design of the 
UK Biobank Imaging Study consent materials 
can be improved and results will be published 
separately.
3.2  Comparing the UK Biobank IF 
Protocol with Full Review 
of Images by Radiologists
There is no ‘best’ policy for handling IF detected 
during research imaging of healthy populations, 
and existing studies vary in their approach (The 
Royal College of Radiologists 2011). However, 
there are likely to be ‘better’ and ‘worse’ policies 
for handling IF, which will depend on the context 
of the individual research study. Imaging studies 
should develop IF policies which are appropriate 
to their context (Medical Research Council and 
Wellcome Trust 2014), and evaluation studies 
which directly compare different approaches to 
IF will guide decisions as to which policy is more 
appropriate.
UK Biobank therefore designed such an eval-
uation study, the methods and results of which 
will be published in a forthcoming research arti-
cle. In brief, UK Biobank assessed the prevalence 
of potentially serious IF and the proportions of 
these which were finally diagnosed as serious 
(i.e. true positives) and not serious (i.e. false posi-
tives) as a result of the UK Biobank IF Protocol 
compared with a common approach to handling 
IF in other imaging studies: systematic review of 
images by radiologists. UK Biobank also investi-
gated the rate of serious final diagnoses which 
were detected by radiologists but missed by the 
UK Biobank IF Protocol (i.e. false negatives). 
The impact of feedback of potentially serious IF 
on participants and health services was informed 
by questionnaires to participants and their GPs. 
This evaluation was encouraged by the main 
funders of UK Biobank (the Medical Research 
Council and the Wellcome Trust) and the UK 
Biobank’s independent Ethics and Governance 
Council.
Results on the rates of prevalence of poten-
tially serious IF, false positives, false negatives 
and the impact of feedback of potentially serious 
IF were crucial in guiding judgement of the 
potential net benefit and net harm of each 
protocol.
3.3  Qualitative Work
In order to provide context for and greater explo-
ration of the results of the quantitative evaluation 
study of the UK Biobank IF Protocol described 
above, UK Biobank commissioned the research 
company TNS-BMRB to conduct a parallel qual-
itative study of participants’ experiences of the 
imaging visit, understanding of the consent they 
had given, the process and opinions of receiving 
feedback of a potentially serious IF and the 
impact of receiving feedback of a potentially 
serious IF (TNS-BMRB 2015). These qualitative 
data were collected with the aim of informing the 
protocol on feedback of IF for the main phase of 
the UK Biobank Imaging Study. The detailed 
methods and results of this study will be made 
available in a separate report.
3.4  Ongoing Evaluation
UK Biobank continues to send questionnaires to 
participants two days following their imaging 
visit in order to evaluate their understanding of 
consent and to send questionnaires six weeks and 
six months following imaging to collect data on 
final diagnoses, clinical follow-up and impact on 
participants. In addition, UK Biobank continues 
to send questionnaires after six months to GPs in 
order to collect data on final diagnoses, clinical 
follow-up and GPs’ opinions on the net benefit 
and harm of providing feedback of a potentially 
serious IF on their patients.
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This systematic follow-up of participants 
will provide much-needed robust, empirical 
data on the impact on participants and health 
services and data on final diagnoses and false-
positive rates. Such data, along with linkages to 
national healthcare datasets, will enable UK 
Biobank to continually monitor the impact of its 
IF protocol and to address additional questions 
raised by the UK Biobank evaluation study 
described which warrant further research: 
whether or not early diagnosis of serious disease 
results in net benefit for asymptomatic partici-
pants and what are the health economic conse-
quences of the UK Biobank Imaging IF Protocol. 
These data will contribute evidence to the 
debates surrounding the management of IF in 
research imaging and inform the practical 
design of appropriate and feasible IF policies 
for future imaging studies.
4  Summary
The UK Biobank Imaging Study aims to image 
100,000 healthy participants and will generate 
the world’s largest multimodal imaging dataset. 
UK Biobank has developed a pragmatic, scal-
able protocol for handling IF during the Imaging 
Study which results in feedback of IF to partici-
pants and their GPs in only limited circum-
stances: where a radiographer notices a 
potentially serious IF, images are reviewed by a 
radiologist, and feedback given if the radiologist 
confirms the presence of a potentially serious 
IF. This approach differs from many studies, 
including other large national imaging projects, 
in which systematic review of images by radiol-
ogists for IF is undertaken. The impact of the UK 
Biobank IF protocol is under continuous evalua-
tion, and data collection is ongoing of partici-
pants’ clinical follow-up and final diagnoses and 
the impact on participants’ emotional well-
being, insurance and finances and work and 
activities. In addition, UK Biobank has per-
formed a head-to-head comparison of its IF pro-
tocol against systematic review by radiologists, 
and following initial data analyses and revision 
of consent materials, it continues to assess 
 participants’ understanding of consent. Such 
analyses will be of value not only to UK Biobank, 
but will provide much-needed robust, empirical 
data on the impact of feedback of IF which will 
address current gaps in knowledge and inform 
the design of IF policies in future imaging 
studies.
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The UK Biobank IFs protocol involves radiographer flagging of concerning images for 
review by radiologists. As this approach differs from other studies, which have mostly used 
systematic radiologist review of all images for IFs, UK Biobank aims to evaluate its protocol 
by 1) surveying participants to assess their understanding of consent with regards to 
feedback of PSIFs; 2) comparing the UK Biobank IFs protocol with systematic radiologist 
review of all images; 3) surveying participants with PSIFs, and their GPs, up to six months 
following feedback of a PSIF to collect data on clinical assessments, final diagnoses, and 
impacts (Gibson et al., 2016b).  
This evaluation programme involves long-term, systematic follow-up of all (i.e. unselected) 
participants with PSIFs, a methodology which has been lacking from the majority of 
previous studies. Taken together with the extensive phenotypic and linked healthcare data 
which are available for UK Biobank participants, the UK Biobank dataset provides a unique 
opportunity to address several gaps in our knowledge of PSIFs (Gibson et al., 2016b). The 
following three chapters describe studies which utilise UK Biobank data to inform on the: 
differences in prevalence of PSIFs and serious final diagnoses generated by the UK Biobank 
IFs protocol compared to a protocol involving systematic radiologist review of all images, 
participants’ understanding of consent with regards to feedback of PSIFs, and participants’ 
and GPs’ opinions on feedback of PSIFs (Chapter 4); factors associated with PSIFs and with 
serious final diagnoses (Chapters 4 and 5); economic impacts on hospital services following 












Chapter 4 Impact of detecting potentially 
serious incidental findings during 
multi-modal imaging 
4.1 Introduction 
Judgements about the benefits and harms of feeding back potentially serious incidental 
findings (PSIFs) should be informed by evidence on the prevalence and impact of PSIFs on 
participants and health services (Gibson et al., 2017b). While Chapter 2 demonstrated that 
the prevalence of PSIFs varies by imaged body region, there were no studies which informed 
on the variation in prevalence of either PSIFs or serious final diagnoses by radiologist versus 
non-radiologist readers, as the majority of studies included in Chapter 2 involved systematic 
review of all images for IFs by at least one radiologist. However, the current shortage of 
radiologists in the UK, and the non-clinical setting of many UK imaging research centres 
(The Royal College of Radiologists, 2011), means that data on the impact of alternative 
approaches to handling IFs are required to inform the design of pragmatic IFs policies. 
Although systematic radiologist review of all images may be assumed to be the most 
appropriate IFs handling policy (Kirschen et al., 2006; Milstein, 2008), there are limited data 
on the clinical assessments generated and the final diagnoses of PSIFs detected by 
radiologists on research imaging to confirm or refute this claim; long-term, systematic 
follow-up of unselected participants with PSIFs is needed (Chapter 2).  
Chapter 1 described a small focus group from the Netherlands Epidemiology of Obesity 
(NEO) study that sought people’s opinions on feedback of PSIFs (de Boer et al., 2018), and 
highlighted that other studies had sought opinions based on hypothetical scenarios (Brown 
and Knight, 2010; Kirschen et al., 2006; Opinion Leader, 2012). More data from participants 
who had actually received feedback of an IF would help to address several gaps in our 
knowledge of their experiences, such as: their opinions of receiving feedback; the impact of 
feedback on their emotional wellbeing, insurance and finances or on work and activities; 
their understanding of what they had consented to with regards to feedback. Previous studies 
of healthcare professionals’ opinions focus on handling IFs detected on clinical imaging of 
patients (Booth and Boyd-Ellison, 2015; Zafar et al., 2016); staff who are managing 
apparently asymptomatic people with IFs generated via research imaging may have different 
opinions. 
The previous chapter described the UK Biobank, its multi-modal imaging study of 100,000 





flagging of concerning images for a radiologist to review), and the methods for evaluating 
this protocol (Gibson et al., 2016b). 
This chapter provides further detail on the methods of, and presents the results of, the 
evaluation of the UK Biobank IFs protocol. By performing long-term, systematic follow-up 
of all participants with PSIFs, and their general practitioners (GPs), this study addresses 
several of the gaps in our knowledge which are described above by providing robust, 
empirical data on: the prevalence and final diagnoses of PSIFs generated by two different 
protocols (radiographer flagging versus systematic radiologist review); clinical assessments; 
impacts on participants’ emotional wellbeing, insurance and finances, and work and 
activities; participants’ understanding of consent regarding the UK Biobank IFs handling 
policy; participants’ and GPs’ opinions about receiving feedback of a PSIF; factors 
associated with PSIFs. 
The study has been published as ‘Impact of detecting potentially serious incidental findings 
during multi-modal imaging [version 3; referees: 2 approved, 1 approved with reservations]. 
LM Gibson, TJ Littlejohns, L Adamska, S Garratt, N Doherty, UK Biobank Imaging 
Working Group, JM Wardlaw, G Maskell, M Parker, R Brownsword, PM Matthews, R 
Collins, NE Allen, J Sellors, CLM Sudlow. Wellcome Open Research 2018; 2:114.’ The 
article is included in full in Section 4.2 and the supplementary materials are included in full 
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Introduction
UK Biobank (www.ukbiobank.ac.uk) is a major resource for 
research into the determinants of a wide range of serious and 
life-threatening diseases, to improve their prevention, diagnosis 
and treatment1. It is a prospective study which recruited 500,000 
men and women aged 40–69 across the UK between 2006 and 
20101. It includes extensive questionnaire and physical meas-
urement data from the baseline visit, biological samples (with 
genotyping and biomarker assay data), longitudinal follow-up 
data from national health-related datasets and additional informa-
tion from remote monitoring and web-based questionnaires.
The UK Biobank imaging study aims to perform brain, cardiac 
and body magnetic resonance imaging (MRI), dual-energy 
x-ray absorptiometry (DXA) and carotid Doppler ultrasound in 
100,000 UK Biobank participants in dedicated imaging centres 
over seven years (http://imaging.ukbiobank.ac.uk/). By November 
2017, over 20,000 participants had attended an imaging assess-
ment visit (http://imaging.ukbiobank.ac.uk/), making it already 
the world’s largest ever multi-modal imaging study2.
Incidental findings (IFs), defined as ‘findings discovered in the 
course of research that are beyond the aims of the study,’3 are a 
predictable consequence of much research, and studies need 
appropriate protocols for handling them (https://wellcome.ac.uk/
funding/managing-grant/wellcome-trust-policy-position-health-
related-findings-research/)4. IFs are particularly pertinent to the 
UK Biobank imaging study given its large scale and the potential 
seriousness of IFs that may be detected. While clinical care and 
screening programmes aim to provide clinical benefit to patients, 
research studies have the primary aim of producing generalisable 
knowledge. Nevertheless, while research studies do not aim to 
benefit participants directly, they are obliged to minimise poten-
tial harms to participants and the wider public. Hence, although 
the UK Biobank imaging study aims to collect research data, 
rather than to detect or diagnose serious disease, it does require 
a protocol to handle IFs should they arise.
The UK Biobank imaging IFs protocol was developed as a 
pragmatic, scalable process, aiming to produce the best pos-
sible resource for biomedical research while minimising any 
potential harms for 100,000 largely asymptomatic UK Biobank 
participants. UK Biobank reviewed current practice, the extensive 
literature3,5,6 and relevant published guidance (https://www.rcr.
ac.uk/publication/management-incidental-findings-detected- 
during-research-imaging), sought independent legal advice, 
and consulted with its independent Ethics and Governance 
Council, the UK’s Royal College of Radiologists and Society 
and College of Radiographers, funders, relevant experts and 
leading imaging research projects (including the Multi- 
Ethnic Study of Atherosclerosis [http://www.hopkinsmedicine.
org/heart_vascular_institute/clinical_trials/preventive/mesa.
html], the Reykjavik Heart Study [http://www.hjartarannsokn.
is/index.aspx?GroupId=406], the Rotterdam Scan Study7 and the 
German National Cohort [http://nako.de/])2. Key contextual 
factors considered were the non-clinical setting of the imaging 
visit, in which the scanning sequences are optimised for research 
use rather than clinical diagnosis, and the nature of the partici-
pants’ existing consent (in particular the approach to the feedback 
of IFs). However, cost effectiveness was not considered relevant2.
The UK Biobank imaging IFs protocol involves feedback to 
participants and their general practitioners (GPs) when a radiog-
rapher observes a potentially serious IF during image acquisition 
that is subsequently confirmed by a specialist radiologist. UK 
Biobank defines a potentially serious IF for these purposes as 
one indicating the possibility of a condition which, if confirmed, 
would carry a real prospect of seriously threatening life span, or of 
having a substantial impact on major body functions or quality of 
life.
The need for evidence to inform IFs policy
Limited data exist on the impact of feedback of IFs on partici-
pants and health services8–11, and on how these vary by different 
policies for handling IFs. Most published data on opinions of 
receiving such feedback are based on hypothetical scenarios, 
rather than studies of research participants who have actually 
received feedback12–14. It is often assumed that early observation 
on imaging of presumed disease (prior to clinical presentation) is 
inevitably beneficial, but data on final clinical diagnosis and the 
impact of feedback of IFs are scarce15. Such data would inform 
debates about these assumptions, and the design of appropriate, 
acceptable protocols to handle IFs detected in research, public 
health screening or commercial imaging settings.
In this evaluation of the first 1000 participants in the UK Biobank 
imaging study, we assessed the number and types of potentially 
serious IFs detected and their final clinical diagnoses, compar-
ing the UK Biobank imaging IFs protocol with systematic radi-
ologist review of all of the images. We also assessed the impact of 
providing feedback about potentially serious IFs on participants, 
their friends, families and health services, with respect to: clini-
cal assessments undertaken; emotional wellbeing, finances, work 
and daily activities; and participants’ and their general practitioners’ 
(GP) opinions about receiving feedback.
Methods
Participants
Existing participants of the UK Biobank cohort study who lived 
within about 100 miles of UK Biobank’s first imaging centre 
in Stockport were invited to participate in the UK Biobank 
imaging study. The invitation contained a link to the UK Biobank 
imaging study website (http://imaging.ukbiobank.ac.uk/), and 
willing participants were asked to telephone the Participant 
Recruitment Centre where they could ask questions about the 
study and answer pre-screening safety questions. Participants 
were excluded if they had metal inside their body or an implanted 
            Amendments from Version 2
We have added new references (de Boer et al., 2018, and Bos 
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medical device which could create imaging artefacts or pose a 
risk during MRI, if they were likely to find it difficult to lie still, 
or if they were unlikely to tolerate the imaging due to known 
claustrophobia.
Consent
All participants received written information about the imag-
ing study, including details about the UK Biobank imaging IFs 
protocol, and provided consent before taking part, including 
consent for UK Biobank to inform them and their GP if a 
potentially serious IF was identified (Supplementary File 1). We 
surveyed all participants with a questionnaire two days after their 
imaging assessment to assess their understanding of the informa-
tion and consent process (http://www.ukbiobank.ac.uk/resources/).
Imaging
Participants underwent a 30 minute brain MRI (3.0 Tesla Skyra 
scanner, Siemens, Erlangen, Germany), a 30 minute non-contrast 
cardiac and body MRI (1.5 Tesla Aera scanner, Siemens, 
Erlangen, Germany) from neck to knees (Supplementary File 2), 
and a 15 minute DXA scan (iDXA, General Electric, New York, 
United States of America) of whole body, lumbar spine and hip, 
with lateral vertebral fracture assessment. Participants also under-
went carotid doppler ultrasound, but this was not considered to 
have the potential to yield potentially serious IFs (Supplementary 
File 3). Imaging protocols were optimised for research purposes 
and did not constitute standard diagnostic examinations.
List of potentially serious IFs
UK Biobank consulted radiologists, reviewed the literature, and 
considered the German National Cohort’s list of imaging IFs16 to 
develop a list of IFs considered to be potentially serious, as well 
as examples of those not considered serious (Supplementary 
File 3). Both radiographers and reporting radiologists used this 
list in conjunction with UK Biobank’s definition of a potentially 
serious IF when judging whether any observed IF was potentially 
serious or not.
Two protocols for handling IFs
Images from the first 1000 participants were assessed using two 
protocols which ran simultaneously. Under the UK Biobank 
IFs protocol (‘radiographer flagging’), if a radiographer noticed 
a potentially serious IF during image acquisition and quality 
assessment, the relevant set of images was flagged for subsequent 
review by a radiologist. Under ‘systematic radiologist review’, all 
images were systematically reviewed by a radiologist. Radiogra-
phers were trained in the relevant imaging protocols but did not 
receive specific training in image interpretation as UK Biobank 
is a research resource and conducts research imaging. The radi-
ographers were not instructed to actively look for, or to avoid 
looking for IFs; rather, they were instructed that should they hap-
pen to notice a concerning finding, they should flag it for review. 
As such, UK Biobank does not aim to provide any form of health 
service, including image interpretation. Radiologists and radi-
ographers were aware of the comparison study, but were blind 
to each other’s opinions. To aid interpretation of images assessed 
either during systematic radiologist review, or those flagged 
by radiographers, we provided reporting radiologists with data 
collected during the imaging visit on the participant’s age, 
sex, body mass index, self-reported smoking status, alcohol 
consumption, medical history and medications.
Within a few weeks of their imaging visit, we wrote to all 
participants who had a potentially serious IF reported by a radi-
ologist, whether it had been both flagged by a radiographer and 
confirmed by a radiologist (radiographer flagging) or detected 
by a radiologist during systematic review of all images (system-
atic radiologist review). We explained that a potentially serious 
abnormality (or, sometimes, abnormalities) had been observed, 
and advised the participant to visit his/her GP for advice about any 
further action required (Supplementary File 4). We also wrote 
to these participants’ GPs, providing a copy of the radiologist’s 
report and, if requested, copies of the relevant scans 
(Supplementary File 5).
Questionnaires to participants with potentially serious IFs 
and their GPs
We surveyed participants with potentially serious IFs approxi-
mately six weeks after writing to them and their GP and 
approximately six months after their imaging visit to assess 
the impact of this information. Both participant questionnaires 
collected data on clinical assessment (blood tests, imaging, 
specialty referral, changes in medication, invasive procedures and 
operations), final diagnoses, and opinions on receiving feedback 
and participating in the imaging study, with additional questions 
at six months on emotional wellbeing, insurance, finances, work 
and activities. We also surveyed GPs at six months about clinical 
assessments, final diagnoses (including copies of any relevant 
clinical correspondence) and their perceptions of the impact on 
their patients of receiving feedback (http://www.ukbiobank.ac.uk/
resources/). We reconciled multiple responses on similar items 
from the three questionnaires by prioritising ‘yes’ responses and 
included data from coding of free text responses (http://www.
ukbiobank.ac.uk/resources/).
Determining final clinical diagnoses
Because there is a paucity of empirical evidence on the natural 
history and final diagnoses of IFs15, and no validated risk scores 
for quantitatively determining the risk to lifespan of particular 
IFs which are detected on research imaging, our classification 
of final diagnoses as ‘serious’ was based on clinical judgement. 
A consultant physician and an experienced speciality clinical 
radiology trainee independently classified final diagnoses for 
each participant who received feedback about a potentially 
serious IF, by reviewing all available questionnaire data together 
with additional relevant clinical information from further corre-
spondence or telephone calls with the participant and/or their GP. 
Working from the definition of a potentially serious IF, we clas-
sified final clinical diagnoses as: serious if they were likely to 
significantly threaten lifespan or have a major impact on quality of 
life or major body functions; not serious if this was not the case, 
or if the available data suggested that the diagnosis was already 
known; and uncertain if there were insufficient data to clas-
sify as serious or not. We classified participants with more than 
one potentially serious IF according to their most serious final 
diagnosis. Given this inherent subjectivity in the classification 
of serious final diagnoses, we measured the repeatability of the 
clinical judgements of final diagnoses severity by calculating 
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the percentage of participants in whom both classifying doctors 
agreed on their initial classification. We resolved disagreements 
through discussion and mutual consensus.
Qualitative study
To provide additional context, UK Biobank commissioned a 
social research company (TNS-BMRB; www.tns-bmrb.co.uk) to 
conduct a parallel qualitative study. This aimed: (1) to explore 
participants’ understanding of and opinions about the proc-
ess of consent relating to feedback of potentially serious IFs 
through deliberative group discussions with two groups of around 
10 participants each (a more and a less affluent group) prior to 
their imaging assessment; and (2) to assess views on the process 
and impact of receiving feedback through one-to-one interviews 
with 15–20 participants (including more and less affluent male 
and female participants) with IFs on different imaging modali-
ties, and with both serious and non-serious final clinical diagnoses. 
Further details of the methods of recruitment, interview content 
and qualitative analysis methods are available at http://www.
ukbiobank.ac.uk/resources/.
Statistical analyses
We summarised data from questionnaires as counts and propor-
tions. We compared groups using chi-squared or Fisher’s exact 
tests for proportions and Student’s independent t-test for 
continuous variables. We considered p values of <0.05 to be 
statistically significant and analysed data using Microsoft Excel 
2013 and SPSS Statistics version 21.
Ethics approval
UK Biobank obtained approval specifically for the imaging 
study, participant information and consent materials and this 
evaluation, including surveying participants and their GPs 
(North West Research Ethics Committee, Reference Number: 
11/NW/0382).
Results
The first 1000 eligible participants were imaged between 
April and October 2014. Their mean age was 62 (range 44–77) 
years, and 524 (52.4%) were female. Each MRI imaging modal-
ity was conducted in >94% participants, and DXA in >99% 
(Figure 1).
Understanding of consent
Around 60% of the first 1000 participants (607/1000) completed 
the questionnaire assessing understanding of consent. The vast 
majority correctly understood that they would not receive their 
scans or results at the end of the imaging visit (540/607, 86.7%) 
and that they would not be told about any potentially serious IF 
during the visit (89.0%), but around a quarter incorrectly thought 
that they could choose whether or not to be informed about any 
potentially serious IF (158/607, 26.0%) (Supplementary File 6).
Potentially serious IFs
Radiographers flagged 66 potentially serious IFs in 66 (6.6%) 
participants. Of these, 18 (1.8%) were confirmed as potentially 
serious by radiologists. Radiologists detected potentially serious 
IFs in 179 (17.9%) participants (Figure 1), who included the 
18 participants with potentially serious IFs flagged by 
radiographers. Participants with potentially serious IFs were 
slightly older than those without (mean age 63 versus 61 years, 
p=0.03), but their sex distribution did not differ significantly 
(55.3% vs 51.8% female, p=0.4).
Final diagnoses
Data on final diagnoses were available from one or more ques-
tionnaires, clinical correspondence and/or telephone contact in 
176/179 (98.3%) participants. The two doctors agreed on the 
per-participant classification of final diagnoses in 172/179 
(96.1%) cases. The seven cases of initial disagreement were readily 
resolved by discussion.
A higher proportion of participants with potentially serious IFs 
had serious final diagnoses (i.e. true positives) with radiogra-
pher flagging (5/18, 27.8%) than with systematic radiologist 
review (21/179, 11.7%, Figure 1, Table 1). A higher proportion 
and substantially greater absolute number had non-serious final 
diagnoses (i.e. false positives) with systematic radiologist review 
(158/179, 88.3%) than radiographer flagging (13/18, 72.2%). 
However, radiographer flagging missed 16 of the 21 participants 
with a serious final diagnosis detected by systematic radiologist 
review (i.e. false negatives) (Figure 1, Table 1, Supplementary 
File 7).
The numbers and proportions of participants with potentially 
serious IFs and with serious versus non-serious final diag-
noses varied substantially by imaging modality. Most of the 158 
false positives generated by systematic radiologist review were 
identified on cardiac or body MRI (54 on cardiac and 65 on body 
[mainly abdominal] MRI; Table 1). Participants with poten-
tially serious IFs from brain and cardiac MRI were more likely 
to have a serious final diagnosis (around half under radiographer 
flagging, and 20% under systematic radiologist review) than those 
with potentially serious IFs from the other imaging modalities 
(Table 1).
Systematic radiologist review generated 217 potentially serious 
IFs in 179 participants. More than one potentially serious IF 
occurred in 33 participants (28 had two and five had three), 
although no participant had more than one serious final diag-
nosis. The 21 serious final diagnoses included aortic aneurysms, 
tumours, structural and functional cardiac disease, and osteoporotic 
fractures, while non-serious final diagnoses comprised benign 
lesions, diagnoses already known to the participant and/or their 
GP, and suspected lesions which were not confirmed. Radiogra-
pher flagging detected five of these 21 serious final diagnoses (one 
arachnoid cyst with hydrocephalus, one meningioma compressing 
brainstem, and three thoracic aortic aneurysms), and missed 16/21 
(two pituitary tumours, two thoracic aortic aneurysms, three lung 
tumours, two cardiomyopathies, and one each of: atrial fibrillation, 
coronary heart disease, heart block with left ventricular impair-
ment, abdominal aortic aneurysm, gastrointestinal stromal tumour, 
pancreatic neuroendocrine tumour, and an osteoporotic crush frac-
ture) (See Supplementary File 7).
Follow-up questionnaires
Each of the three follow-up questionnaires was returned for 
≥70% of 179 participants with a potentially serious IF; at least 
one questionnaire was returned for 93.3% and all three for 45.8% 
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Figure  1.  Participant  flowchart.  MRI = magnetic resonance imaging, DXA = dual energy x-ray absorptiometry. 168 participants had 
incomplete imaging: 18 underwent DXA but not MRI due to safety issues, 50 did not complete all MRI (28 due to claustrophobia, 13 due to 
scanner failure, nine for other reasons). 2Final diagnosis assigned to participants with more than one potentially serious incidental finding was 
the most serious (serious>uncertain>not serious). 3Three of these participants had uncertain final diagnoses, see Supplementary File 7.
(Table 2). Denominators varied for different types of clinical 
assessment and impact due to different proportions of completed 
responses to the relevant questions (Table 3).
Clinical assessment
All participants with follow-up questionnaire data had con-
tacted their GP. Almost all had some form of clinical assessment 
(153/170 [90.0%]), most frequently blood tests (29.4%), fur-
ther imaging (78.8%) or specialist referral (64.1%), with smaller 
proportions having other tests (8.8%), change of medication 
(10.5%) or an invasive procedure or operation (14.2%) (Table 3). 
The proportions having each type of clinical assessment 
were generally higher for those with a serious compared with 
non-serious final diagnosis, particularly medication changes 
(44.4% serious versus 6.3% non-serious) and invasive procedures 
(61.1% versus 8.3%). However, the absolute numbers having 
clinical assessment were far higher among the many more par-
ticipants with non-serious final diagnoses. Of the 153 participants 
reporting some form of clinical assessment, 133 had a non-serious 
final diagnosis, suggesting that further clinical assessment might 
not have been necessary (Table 3).
Of particular note, similar absolute numbers of participants 
had invasive, potentially harmful, procedures irrespective of 
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      Brain MRI 2 2 4 0.4 50.0
      Cardiac MRI 3 2 5 0.5 60.0
      Body MRI 0 8 8 0.8 0.0
      DXA 0 1 1 0.1 0.0
      > 1 modality 0 0 0 0.0 0.0
Total (any modality) 5 13 18 1.8 27.8
Systematic radiologist 
review
      Brain MRI 4 14 18 1.8 22.2
      Cardiac MRI 13 54 67 6.7 19.4
      Body MRI 3 65 68 6.8 4.4
      DXA 1 10 11 1.1 9.1
      > 1 modality2 0 15 15 1.5 0.0
Total (any modality) 21 158 179 17.9 11.7
PSIF = potentially serious incidental finding, MRI = magnetic resonance imaging, DXA = dual energy X-ray absorptiometry
1 Includes three participants whose final diagnoses remained uncertain as of April 2016: one participant with a lung 
nodule was still under assessment; another participant with a lung nodule had been diagnosed with lymphoma, but it 
remained unclear whether the nodule was related to the lymphoma or not; and we were unable to contact one participant 
to determine the final diagnosis of DXA appearances suggesting a crush fracture.





Six-week participant questionnaire 132 (74)
Six-month participant questionnaire 125 (70)
Six-month GP questionnaire 125 (70)
At least one questionnaire returned1 167 (93)
All three questionnaires returned 82 (46)
1At least one of a six-week participant, six-month participant, or 
six-month GP questionnaire
whether their final diagnosis was considered to be serious (n=11) 
or non-serious (n=12) (Supplementary File 8). The clinical 
management of the participants with a serious final diagnosis is 
summarised in Supplementary File 9.
Impact on participants
Feedback about a potentially serious IF also had an impact 
(presumed to be adverse) on participants’ emotional wellbe-
ing (21/124, 16.9%), insurance or finances (11/124, 8.9%), and 
work or activities of daily living (7/124, 5.6%). The proportion 
of participants reporting an impact on emotional wellbeing was 
higher among those with a serious final diagnosis, but the absolute 
numbers were higher among those with a non-serious final 
diagnosis, for whom these impacts could be considered to 
constitute net harm (Table 3). In addition to the 21 reporting 
an impact on emotional wellbeing in response to the relevant 
survey question, participants and/or their GPs spontaneously men-
tioned worry within questionnaire free-text responses for a further 
62 participants (examples shown in Box 1).
Box 1. QUOTATIONS FROM PARTICIPANTS AND THEIR 
GENERAL PRACTITIONERS (GP)
Participant with a non-serious final diagnosis, six-week 
questionnaire: “Better to know, but I did feel anxious for a few 
weeks.”
Participant with a serious final diagnosis, six-month 
questionnaire: “Life has been a physical & emotional roller-
coaster since then, both for myself, family & friends. A serious 
risk of death on the operating table, and considering the 
consequences for my wife. All-in-all, I feel as if I was mugged by 
medical technology.”
GP of a participant with a non-serious final diagnosis: “[The 
patient] was asymptomatic. In normal practice no investigation 
would be performed - this has led to unnecessary anxiety and 
tests.”
GP of a participant with a non-serious final diagnosis: “Concerns 
over use of health resources regarding this. Using GP and 
secondary care time with potential [upper gastrointestinal 
endoscopy] +/- associated risks of this procedure. This for 
symptoms that the patient is not too concerned with at present.”
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Most participants receiving feedback reported no change in their 
health since the imaging visit (104/124, 83.9%). Similar abso-
lute numbers among those with serious versus non-serious final 
diagnoses had worse health (6/15, 40.0% versus 5/109, 4.6%), 
while a few of those with a non-serious final diagnosis (but 
none with a serious final diagnosis) reported better health (9/109, 
8.3%, Table 3).
Opinions on receiving feedback
Almost all participants reported being glad to be told about their 
potentially serious IF (142/145 (97.7%) (Table 3). Nonethe-
less, GPs who responded reported that a higher proportion of 
participants had experienced negative versus positive impact 
on emotional wellbeing (38/99, 38.4% versus 16/99, 16.2%), 
with most of the negative impact occurring among those with 
non-serious final diagnoses (Table 3). GPs also spontane-
ously highlighted concerns about use of health resources to 
manage asymptomatic people within their free-text questionnaire 
responses (Box 1). However, the responding GPs believed that a 
slightly higher proportion of participants had experienced net 
benefit compared to net harm (51/86, 59.3% versus 35/86, 40.7%).
A higher proportion of responding GPs (61/94, 64.9%) than par-
ticipants (55/149, 36.9%) thought participants should be always 
told about a potentially serious IF (Table 3). Since participants 
were asked both at six weeks and at six months about this, we 
were able to assess whether the answers of 105 participants who 
responded on both occasions changed over time. While 69 had 
consistent responses, 36 changed their views (n=21, Table 3: 
footnote 10).
Results of the qualitative study
Deliberative group discussions about consent involved a group of 
10 ‘more affluent’ participants (Townsend score <-2, four female, 
mean age 61, SD 9.1 years), and a group of 11 ‘less affluent’ par-
ticipants (Townsend score >0, six female, mean age 66 years). 
One-to-one interviews involved an additional 21 participants 
who received feedback about a potentially serious IF (13 ‘more 
affluent’, 13 female, mean age 66 years). Analysis of the inter-
view data revealed that participants were motivated to attend the 
imaging study by altruism, to experience MRI scanning first- 
hand (in case they needed to attend for investigations for a 
medical concern later in life), and to receive feedback about poten-
tially serious IFs. Participants could not always recall precise 
details of the consent process with respect to feedback of IFs,  but 
they were generally unconcerned about this as they trusted UK 
Biobank to act appropriately. One-to-one interviews further dem-
onstrated that the implications of receiving feedback were not fully 
understood until after the event, that feedback resulted in short-
term anxiety, and that participants tended to assume the worst on 
receiving feedback; indeed, some were surprised that the final 
diagnosis might be non-serious, having anticipated a diagnosis 
of cancer, an aneurysm or a serious heart condition. Further 
details of the qualitative study results are available at http://www.
ukbiobank.ac.uk/resources/.
Discussion
Compared to systematic review of images by radiologists, the 
UK Biobank IFs protocol (radiographer flagging) resulted in 
approximately 10-fold fewer participants with non-serious 
diagnoses (i.e., false positives), but missed 16/21 potentially serious 
IFs that were diagnosed ultimately as a serious disease (i.e. false 
negatives).
Extrapolation of our results to the 100,000 participants who 
will be imaged by UK Biobank over the next few years suggests 
that systematic radiologist review would generate 15,800 false 
positives, compared with 1,300 under the UK Biobank IF proto-
col (radiographer flagging), and would detect serious diagnoses 
in 2,100 participants compared with 500 under radiographer 
flagging (Figure 2).
Systematic radiologist review in our study generated a preva-
lence of potentially serious IFs of 17.9%. The prevalence in other 
whole-body MRI studies of healthy populations ranged from 
12.8% to 57.6%17–20. Since those studies used similar MRI 
sequences applied to similar tissue volumes, variations in preva-
lence are most likely to have arisen from differences in the 
definition of IFs, or in the age and other characteristics of the 
imaged populations.
Almost all participants with potentially serious IFs had subsequent 
clinical assessment, resulting in large numbers of investigations, 
referrals and procedures. Many of these were, with hindsight, 
unnecessary, with risk of direct harm as well as cost implica-
tions. Impact on emotional wellbeing, insurance or finances, and 
on work or daily activities were reported by a higher proportion 
of participants with serious final diagnoses, but affected a higher 
absolute number of participants without serious final diagnoses. In 
keeping with these results, over half of participants in the Study of 
Health in Pomerania who received feedback of an IF detected on 
whole-body MRI reported psychological distress8.
Only around one-third of our participants believed that partici-
pants should always be told about potentially serious IFs. Similar 
proportions of participants with serious and participants with 
non-serious final diagnoses expressed this opinion. However, 
almost a quarter of participants changed their opinion over the few 
months between the six-week and six-month questionnaires on 
whether participants should or should not be able to choose to 
receive feedback of an IF (Table 3: footnote 10), illustrating the 
complexities in interpreting opinions on this issue.
The findings of this study are of practical legal and ethical impor-
tance, and can be considered with regards to the duties of care, and 
the ethical principles of respect for autonomy, and beneficience and 
non-maleficence toward participants and towards the public. The 
legal and ethical background to UK Biobank’s approach was devel-
oped with input from its Imaging Working Group, its independ-
ent Ethics and Governance Council, representatives of its major 
funders (Wellcome Trust and the Medical Research Council), 
UK Biobank’s legal counsel and external legal counsel and ethics 
advice. In brief, it was considered likely that the duty of care owed 
to participants by radiographers would not be of a clinical standard, 
but rather what a reasonably competent radiographer conducting 
research imaging without clinical information could reasonable 
observe and report. This legal duty of care informs the ethical 
duties of radiographers, i.e., that they must be capable of meeting 
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the standards of care which are detailed in the consent process. 
Therefore, in order to respect potential participants’ autonomy, it 
is paramount that UK Biobank have an IFs protocol in place, and 
that this protocol and its limitations are explained to and under-
stood by participants. Our results reinforce the need for clarity in 
the information provided to participants about the feedback policy 
before they consent to imaging research studies. While partici-
pants’ understanding of what they had consented to was generally 
good, a substantial minority (around a quarter) incorrectly thought 
that they could choose whether or not to receive feedback. The 
information materials for the UK Biobank imaging study now 
further emphasize the difference between research and clinical 
diagnostic imaging, that the imaging is not a ‘health check,’ that 
not all serious disease will be detected, and that some potentially 
serious IFs will prove to be non-serious with further investiga-
tions (http://imaging.ukbiobank.ac.uk/). Considering the ethical 
principles of beneficence and non-maleficence toward both 
participants and the public, our data suggest that feeding back 
potentially serious IFs which turn out not to be serious (false 
positives) can make some participants worse off, through expo-
sure to the inconvenience, worry and potential harms of clinical 
assessments, including invasive procedures. Feedback of false 
positives also results in wider harm through the unnecessary use 
of publicly-funded health services. Missing a serious disease 
(false negative) does not make participants worse off compared 
to their status before receiving feedback of a potentially serious 
IF; rather, it fails to make participants better off. While the 
literature about IFs sometimes argues that feedback is inevitably 
beneficial21, the balance of potential benefits and harms of ear-
lier diagnosis (of IFs which are actually serious) is uncertain. It 
is important to reiterate that UK Biobank is a research resource 
which aims to facilitate research which will benefit public health, 
rather than provide any form of health services to individual 
participants. We therefore conclude that the responsibilities of 
researchers to avoid unnecessary harm to significant numbers of 
participants and disruption to publicly-funded health services 
mean that radiographer flagging (resulting in far fewer false 
positives while missing a small number of true positives with 
unclear benefit of earlier diagnosis) constitutes an ethically 
more justified approach in the UK Biobank imaging study than 
systematic radiologist review. 
Some might argue that concerns about generating false posi-
tives suggest the case for a policy of no feedback of any IFs. 
However, in the light of legal advice regarding the duty of care 
it owed to participants as described above, UK Biobank decided 
not to withhold all feedback on potentially serious IFs, but to 
minimize the generation of false positives by only feeding back 
potentially serious IFs which are also confirmed by a radiologist. 
This approach to potentially serious IFs should be seen within 
the context of large-scale, population based imaging of healthy 
volunteers; a different approach may well be appropriate for 
other types of imaging studies, which may be smaller, based in 
clinical centres, have a different duty of care between research 
participants and researchers, or include participants with different 
characteristics (e.g., age) to those in the UK Biobank study.
While our underlying objective was to test the IFs protocol for 
the UK Biobank imaging study, our findings are of potential 
relevance in other contexts in which individuals are imaged prior 
to clinical presentation of disease, including public health and 
commercial screening. In both situations, it is important to consider 
the potential benefits of making a true positive diagnosis versus 
the potential harms to the individual and to publicly-funded health 
services, of a false positive diagnosis. The significant number of 
false positives generated by systematic radiologist reporting in 
Figure 2. Extrapolation of  this study’s findings to the 100,000 UK Biobank  imaging study participants. MR = magnetic resonance, 
IF = incidental finding.
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our study implies that imaging of asymptomatic people should 
not be undertaken without appropriate concern for ensuring 
that the individuals being imaged do not end up worse off 
than they started.
Strengths
Our study is the first to systematically follow up all participants 
receiving feedback about IFs and their GPs, giving the most 
comprehensive data on the impact of feedback of potentially 
serious IFs in any research imaging study to date and providing 
the first quantitative comparison of two different protocols for 
handling IFs. We have demonstrated for the first time the much 
lower rates of potentially serious IFs and, most importantly, false 
positives detected with a protocol in which radiologists report 
only those images which radiographers flag as having poten-
tially serious IFs. Although the public support the principle of 
providing feedback of IFs14, regardless of clinical severity12, most 
previous studies did not survey people who had actually received 
feedback. Our findings are crucial to informing future policy 
surrounding feedback of IFs in research studies.
Our study was strengthened by good questionnaire response 
rates and near complete data on final diagnoses due to extensive 
efforts to gather these directly from participants and their GPs, 
and data collection at both early and later time periods following 
feedback. Results related to understanding of consent and impact 
of feedback on participants were confirmed and contextualised 
in a parallel, qualitative study.
Limitations
Radiographer flagging rates could, in principle, have been influ-
enced by a relative lack of experience with the first 1000 imaged 
participants, or by knowledge that radiologists were also review-
ing all images. However, ongoing collection of data on potentially 
serious IFs in the 7000 participants imaged subsequently showed 
the prevalence of IFs detected by radiographers to be broadly 
consistent over time with a stable prevalence of potentially seri-
ous IFs confirmed by radiologists (mean proportion of 1.7%) 
(Supplementary File 10).
Although questionnaire response rates by participants were 
generally high, only around two thirds of participants’ GPs 
responded about participants’ emotional well-being and over-
all net benefit/harm. The design of the questionnaires did not 
allow for quantification of the use of particular health services or 
evaluation of the associated costs. However, UK Biobank 
continues to collect data from participants with potentially serious 
IFs and their GPs through questionnaires, supplemented by 
linkages to national health datasets. This will enable further 
clinical, health economic and policy issues to be addressed using 
data from larger numbers of imaged participants.
Classification of final diagnoses as serious or not was based 
on clinical judgement of data available up to around six months 
following feedback of a potentially serious IF. Final diagnoses 
classified as serious may not actually shorten life span, or 
substantially impact on major body functions or quality of life 
in the 21 participants concerned, who were apparently healthy at 
the time of their imaging visits. Some potentially serious IFs may 
take longer than six months to diagnose, or for their full impact to 
become clear, potentially leading to an incomplete picture of the 
adverse impacts of feedback.
Conclusions
The handling of potentially serious IFs merits serious consid-
eration by researchers undertaking imaging research studies. Our 
data provide evidence to inform policy for large-scale research 
imaging in healthy populations, and are relevant to asymptomatic 
populations undergoing public health screening and commercial 
imaging. They demonstrate that systematic radiologist review 
of all images leads to the diagnosis of previously unknown seri-
ous disease in some participants. However, the great majority of 
these findings turn out not to be serious, resulting in unnecessary 
anxiety for the participant and unnecessary clinical assessment, 
which may include invasive procedures, provided by publicly-
funded health services. Further, for those participants whose 
IFs do turn out to be serious, it is often difficult to ascertain whether 
this knowledge results in clear clinical benefit.
There is no ‘one-size-fits-all’ approach to handling IFs, as much 
depends on the purpose of the imaging, be that research, screening, 
or clinical care. In research studies of healthy volunteers, for 
whom there is no direct benefit for taking part, it is particularly 
critical to minimise harm. Based on these results, we suggest that 
this is achieved in an imaging study of UK Biobank’s scale and 
complexity with a protocol in which radiographers flag suspi-
cious images for reporting by radiologists, rather than systematic 
review of all images by radiologists.
Data availability
Due to the confidential nature of questionnaire responses and 
clinical information on participants with potentially serious 
incidental findings, it is not possible to publicly share all of the 
data on which our analyses were based, but extensive sum-
maries of all relevant data are included in the supplementary 
material and within the linked online material.
Importantly, any bona fide researcher can apply to use the UK 
Biobank resource, with no preferential or exclusive access, for 
health related research that is in the public interest. Applica-
tion for access to UK Biobank data involves registration and 
application via the UK Biobank website, with applications con-
sidered by the UK Biobank Access Sub-Committee. Following 
approval, researchers and their institutions sign a Material Trans-
fer Agreement and pay modest access charges. Further infor-
mation on applying to access UK Biobank data is available 
at: http://www.ukbiobank.ac.uk/register-apply/.
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Supplementary File 1: Participant information leaflet 
This is the version of the UK Biobank imaging study Participant Information Leaflet sent to the first 
1000 imaged participants, and  is no longer in use. It is available here for reference only. 
The current version of the UK Biobank imaging study Participant information leaflet is available at 





Imaging Assessment Visit 
UK Biobank is inviting you to take part in an important new study to help research. It involves 
taking pictures (scans) of your brain, heart, tissue and bones, so that scientists can study your 
internal organs in detail. This will help research into a wide range of diseases, including 
cancer, heart disease, dementia, diabetes, stroke and arthritis.  
We aim to scan up to 100,000 people over the next few years. The scans, especially when 
combined with other health information you have provided to us, will create a health resource 
of global significance for many years to come. All of the information provided by you is stored 
in a confidential and secure manner. None of the data, samples and images provided to 
researchers will include personal identifying details. 
You have been invited because you live within a reasonable travelling distance from the 
imaging assessment centre in Stockport. This invitation is not based on any other information 
that we have collected about you, either at your initial assessment or afterwards.  
Taking part is entirely voluntary. Please take the time to read this leaflet carefully. It explains 
why we are asking you to help and what it would involve.  
If anything is not clear, or if you would like more information, please telephone 0800-0-276-
276 (free from most land lines) or 0292-0-765-597, Monday-Saturday 8am-7pm, or email 
us at ukbiobank@ukbiobank.ac.uk  
More information about UK Biobank is available at www.ukbiobank.ac.uk. There will also be 
further opportunities to ask questions when you arrive at the imaging assessment centre. 
 











What is UK Biobank? 
UK Biobank is a large, publicly-funded resource to help scientists from around the world to 
improve the prevention, diagnosis and treatment of a wide range of illnesses (such as cancer, 
heart disease, diabetes, dementia, and joint problems). Its goal is to improve the health of 
future generations.  
UK Biobank allows scientists to study how health is affected by lifestyle, environment and 
genes. By studying the answers, measurements and samples collected from the 500,000 
participants, researchers will be able to work out why some people develop particular 
diseases while others do not. 
This research will help to find new ways to prevent premature death and disability. While 
taking part in UK Biobank is not intended to help participants directly, it should give future 
generations a much better chance of living their lives free of diseases that disable and kill. 
Why does UK Biobank want to scan me? 
Taking pictures of organs inside the body (such as the brain and heart) as well as the 
surrounding tissues and bones will allow scientists to study how the structure and function of 
the body’s organs are related to the development of disease. The combination of these 
pictures with other information already collected about you will provide a substantial amount 
of new and important data for health research on a wide range of diseases.  
Why have I been invited? 
Participants who live within a reasonable distance from the imaging assessment centre are 
being invited to take part. The centre is at the UK Biobank’s Co-ordinating Centre in Stockport. 
The cost of setting up such a centre means it is not possible to open one in every place in 
which UK Biobank undertook its original assessments. This means that some people may 
have to travel further to participate, although we will cover your travel expenses. 









What scans will be performed and why? 
Magnetic resonance imaging (MRI): This type of scan uses painless magnetic waves to 
take detailed pictures of the inside of the body (such as organs, tissues and bones). We would 
like to take two scans: one of the brain and the other of the heart and of the body (mainly 
covering the abdomen). The scanners are similar to those used in the NHS, except for being 
a little wider so that people are as comfortable as possible.  
 Brain MRI scan. This will provide information about the structure and function of the brain. 
It will enable us to obtain information on, for example, which parts of the brain are 
important for carrying out certain tasks and how different parts of the brain are connected.  
 
 Heart and body MRI scan. This will provide information on the size of the heart chambers 
and blood vessels, and changes in heart size as it beats. It will also provide detailed 
information on the amount and distribution of fat in the body.  
 
Neck artery ultrasound scan. This scan uses ultrasound (high-frequency sound waves) to 
produce pictures of the blood vessels on either side of the neck. They will help scientists study 
the build-up of fatty substances (like cholesterol) in these major blood vessels.  
Dual-Energy X-ray Absorptiometry (DXA) scan. This scan uses low-energy x-rays to 
provide a precise measure of bone density throughout the body. Detailed pictures of the spine, 
hips and knees will help scientists studying diseases like arthritis.  
 
Am I eligible to take part? 
All of these scans are safe and painless, and are similar to those used routinely in the NHS. 
However, since MRI scans involve the use of a magnet, you will not be able to take part if you 
have any metal or electrical implant, or if you have had an accident where metal may have 
entered your body.  
If you have had recent surgery, you will be able to take part but your visit will not be able to 
occur until at least six weeks after your operation. You will also not be able to take part if you 
have medical problems that make it difficult to conduct the scans (e.g., severe hearing or 
breathing problems, tremors, etc.).  
Do I have to take part in this imaging assessment? 
No; attendance is entirely voluntary. We do understand that you may not have time or be able 




What should I do if I am interested in attending? 
Please let us know as soon as possible if you are willing to attend by telephoning us on: 
0800-0-276-276 (free from most land lines) or 0292-0-765-597,  
Monday to Saturday, 8am - 7pm  
During this call, you will be asked a series of questions to find out whether you are eligible to 
help. Please visit our website (www.ukbiobank.ac.uk) to see the questions that will be asked, 
but please do not worry if there are technical terms used that you do not understand as these 
will be explained to you during the call. If you are willing to participate, you will also be able to 
ask questions about the assessment visit.  
If you are eligible, you will be able to arrange an appointment during this call. Appointments 
are generally available from 8am to 6pm seven days a week to help find a convenient time 
for you.  
We will then send you a letter confirming your appointment, along with detailed directions to 
the assessment centre. We will also send you an email or text reminder a couple of days 
before your planned visit. 
Can I claim travel expenses for attending? 
Yes, please do claim back any reasonable travel expenses (including standard train and bus 
fares, and mileage for car, motor cycle or bicycle journeys). A claim form will be handed to 
you at the end of your visit. It would help us if you attached your travel receipts. 
There is ample free parking space at the centre. It is also within easy access of Stockport 
train station, where taxis (paid for by UK Biobank) are available. If you are registered as 
disabled, you can also claim travel expenses for a companion.  
How do I prepare for the imaging assessment visit? 
When you come for your appointment, please: 
 Bring with you the confirmation letter and travel directions, so you have no difficulty in 
finding us.  
 Bring any reading glasses that you use since you have to be able to read clearly from a 
computer screen (as at your original assessment visit). 
 Bring along your glasses prescription (if you have it), since we will need to provide you with 
specially adapted glasses that match your usual prescription for the brain MRI scan. 
 Bring details of the name and address of your doctor (GP). 
 Remove any jewellery that can be easily removed (although we will secure with removable 
tape any jewellery, such as wedding rings, that cannot be removed). Please ensure that 
your underpants do not contain metal fastenings. 
 
 
 Remove any hair grips and makeup as these may contain metallic fragments which could 
cause a heating sensation during the MRI scans. 
 Remove any skin patches (often used for hormone-replacement therapy [HRT], nicotine 
replacement, pain relief, contraception, glyceryl trinitrate [GTN], etc.) as these may also 
contain metallic components. We recommend that you bring a spare patch with you to put 
on after the scans.  
 Be prepared to spend about 4 hours at the assessment centre. Refreshments (such as 
salads, sandwiches, tea, coffee and soft drinks) will be provided during the visit. (There is 
no need to avoid eating before your visit.) 
What happens DURING the imaging assessment visit? 
The assessment will take about 4 hours. It will involve the following (in this order):  
Initial steps 
 A trained member of staff will ask the same questions you answered when you made the 
appointment. This is to double check that you are able to undergo all of the different types 
of scan. (If you cannot have some particular scans, then you would still be able to take part 
in the rest of the visit). 
 You can ask any questions that you might have, and will then be asked to sign a consent 
form. This tells us that you agree to be scanned, and that you understand the process and 
the implications. 
 You will be shown to a private cubicle where you will be given special, loose-fitting clothes 
to change in to. You will not need to remove underpants, but women will be asked to 
remove their bras, since they may contain metal.  
 You will be asked to leave any loose metal objects (such as money, credit cards, keys, 
pens, mobile phone, jewellery, watches, hair pins, metal dentures, hearing aids and 
spectacles), as well as any skin patches (e.g., nicotine or other replacement therapy), in 
one of the secure lockers. 
 Men may be asked if a staff member can shave a small section of their chest hair. This is 
so that electrical leads attached to sticky pads can be placed on the skin for the 
electrocardiogram (ECG; an electrical recording of the heart) and the heart MRI scan.  
MRI scans 
 The brain and heart/body MRI scans each take about 30 minutes.  
 You will be shown into a room that houses one of the two MRI scanners. The scanner is a 
large cylinder with a tube running through the middle which is open at both ends (see 
picture below). You will be asked to lie down on a comfortably padded table that gently 
glides you into the scanning tube. Depending on the part of your body being scanned, you 
 
 
will be moved into the scanner either head first or feet first.  
 
A magnetic resonance imaging (MRI) scanner 
 The MRI scanner is controlled by a computer which is in a different room. A specially 
trained technician will operate the computer. They will be able to see you through a window 
throughout the scan, and you will be able to talk to them through an intercom.  
 MRI scanners can be noisy. We will provide you with headphones to protect your ears, but 
you will still be able to talk to the operator throughout the scan. You will be given a hand-
held buzzer so that you can stop the process at any time if you wish.  
 During the MRI scans, you will be asked to do things. For example, you will be shown 
something on a screen during the brain scan, and you will be asked to hold your breath for 
a short period of time during the heart scan. 
Neck ultrasound scan 
 The neck scan takes about 10 minutes. 
 You will be asked to lie face-up on a firm table. A clear water-based gel will be applied to 
your neck. A hand-held probe will then be placed against your skin and moved up and 
down your neck (see picture below).  
 
 
 You will be asked to tilt or turn your head as the probe is swept over the entire length of 
both sides of your neck.  
 The probe only covers your neck and does not touch your face or other parts of your body. 
 
Neck ultrasound  
 
DXA scan 
 The DXA scan takes about 20 minutes. 
 You will be asked to lie on a firm table while an arm passes over you (see picture below) 
to take X-ray pictures of your bones. You will be asked to lie in various positions so that 
the scanner can take pictures of different parts of your body.  
 
DXA scanner  
 
 
Other assessments  
While you are with us, we would also like to take some more samples and repeat a number 
of measurements that we did at your first visit to UK Biobank several years ago. This 
information will allow scientists to take account of any changes in health and lifestyle over that 
time.  
 
We will ask you to: 
 
 Give another small sample of blood (about 3 tablespoons), saliva and urine for long-term 
storage and analysis. 
 Answer again questions on your health, lifestyle and diet, memory, work and family history. 
 Have repeat measurements of your blood pressure, pulse rate, height, weight, body fat, 
grip strength, heel bone density and lung function. You will also have an electrocardiogram 
(ECG) to measure the electrical activity of your heart.  
What are the possible BENEFITS of taking part? 
There are no direct benefits to you in taking part. However, the information about you from 
the imaging and other assessments will be valuable for helping scientists to better understand 
how a wide variety of diseases develop and to find new ways to prevent them.  
What are the possible RISKS of taking part? 
Undertaking the imaging assessment visit should not cause you any harm. We have chosen 
to perform scans and other physical measures that are safe, painless, relatively quick and 
comfortable. 
The MRI scans use powerful magnets and great care is taken to prevent magnetic objects 
from entering the MRI room.  Before you enter, we will ask you questions so that special 
precautions can be taken, if needed.  
MRI scans involve lying flat in a slightly confined space and a small number of people may 
find this uncomfortable. However, the space in the scanners used in this assessment is wider 
(at least 70 cm, or 27 inches, in diameter) than in those typically used in hospitals, to ensure 
that participants are as comfortable as possible. 
The low energy DXA scan involves a small dose of radiation (approximately 20 µSv units). 
This is the same amount as a standard chest X-ray or about one week’s worth of natural 
background X-rays. By comparison, one trans-Atlantic flight exposes you to about four times 
as much radiation as that from a DXA scan.  
You may feel some discomfort when you have blood taken, although our staff are specially 




Do I need to have all the measurements? 
When you call to make your appointment, we will check whether you are eligible to be 
scanned. This is because we do need your agreement to take part in all of the imaging scans 
before you make an appointment.  
If it turns out when you arrive at the imaging assessment centre that you are no longer eligible 
for some of the scans, then you will still be able to take part in the rest of the assessment.  
You do not have to have all the physical measures or to give a blood, urine or saliva sample 
if you don’t want to. Similarly, if you feel uncomfortable about answering certain questions 
then you do not need to answer them. 
Do I get any routine results from the visit?  
As was the case at your initial assessment, you will receive information at the end of the visit 
about some of the physical measurements made during the assessment (blood pressure, 
weight, body mass index, waist circumference, percent body fat, heel bone ultrasound and 
lung function). 
However, you will not receive any other routine results or pictures from the scans. It is 
important for you to be aware that this visit is not a clinical appointment or a ‘health check’. 
You should, therefore, not rely on the absence of feedback from us as any form of 
reassurance regarding your health.  
What will I be told if something suspicious is seen during my scans? 
Imaging scans often show abnormalities, but most of these are no cause for concern.  
The scans being performed in UK Biobank are not intended to diagnose an illness. They are 
not designed to identify any particular abnormalities and will not be routinely analysed by 
doctors or other specialists. Instead, they are being taken and stored for future research.  
The technicians conducting the scans will be looking at the images to ensure their quality. It 
is important to understand that they will not be looking at them to identify particular health 
problems.  
However, if a technician does notice something unusual that they think might be serious they 
will refer that scan to a specialist doctor for review. Something would be considered potentially 
serious if it indicated the possibility of a condition which, if confirmed, would carry a real 
prospect of seriously threatening life span, or of having a substantial impact on major body 
functions or quality of life.  
If the specialist doctor agrees that the abnormality may be serious (regardless of whether or 
not it can be treated), then we will write to you and your GP (usually within two weeks of your 
visit).  
For example, you and your GP would be informed if we saw an abnormality on one of your 
scans that looked like a tumour. However, we would not inform you if we saw an abnormality 
that looked like gallstones or a simple cyst, as such findings are common in healthy people 
 
 
and not considered serious. Please see our website (www.ukbiobank.ac.uk) for further 
information about the types of potentially serious findings that we would inform you and your 
GP about if they are noticed during the scans and confirmed by a specialist doctor. 
We estimate that about 10 to 15% of participants may have an abnormality considered to be 
potentially serious, but we will not know this number for sure until the project gets fully 
underway.  
The reporting processes set in place will be carefully monitored, with ongoing training 
provided for the technicians doing the scanning.  
What may happen if I am told about something suspicious on my scans? 
The identification of an abnormality may mean that your GP refers you to specialists for further 
investigation and treatments. While some abnormalities may result in the diagnosis of a 
serious untreatable condition, others may turn out to be of little or no concern.  
For some conditions, having an earlier diagnosis can be beneficial. But for other abnormalities 
detected on scans, knowing about them many years in advance can lead to unnecessary 
anxiety, investigations and treatments. The identification of some abnormalities could affect 
your ability to drive or work and could also make it difficult for you to obtain future travel, health 
or life insurance. It is important for you to understand that if we do not contact you and your 
GP it does not necessarily mean that you do not have any abnormalities. It simply means that 
no such abnormality was noticed by the technicians taking the scans. 
 
It is also important to note that you can only take part in the imaging study if you feel able to 
consent to both you and your GP being informed if a potentially serious abnormality is noticed 
on one of your scans. If you feel that, in your case, the potential anxiety and uncertainty of 
being told about a possible serious abnormality, or the inconvenience and disruption to your 
life caused by further investigations, is likely to outweigh any benefit to you, we would quite 
understand if you decide not to take part in the imaging study. 
How are we going to assess the impact of telling participants about potentially 
serious abnormalities?  
For participants who are told of a potentially serious abnormality, we wish to find out how this 
has affected them, their family and friends, and the people involved in their care in the NHS.  
Very little is known about the impact of receiving information like this and this research would 
allow us to improve what we do and help others doing similar research.  
We will, therefore, contact those participants 6 weeks and 6 months after providing such 
feedback to find out what, if anything, happened as a result of receiving it. We will also contact 
their GP about 6 months after writing to them to find out about any investigations and 
treatments. 
Who will be able to use my information and samples? 
Data and samples from your visit (scans, blood results and other data) will be stored for many 
years to come. The information will be used by approved researchers for medical and other 
 
 
health-related research. This includes researchers who are working in other countries and in 
commercial companies looking for new treatments. Scientists will have to obtain scientific 
and, if necessary, ethics approval.  
Results from all of these studies will be put back into the UK Biobank database for other 
researchers to use. Scientists must also publish the results of all research based on the UK 
Biobank resource so that everyone can benefit from it. Details of research that is being done 
using the resource is available on the website (www.ukbiobank.ac.uk). 
We will never forward any individual’s information, samples or test results to insurance 
companies or employers. Neither will we allow access to the police, security services, 
relatives or lawyers, unless forced to do so by the courts. 
Published research that uses the UK Biobank resource will be made available to participants, 
and anyone else who might be interested, at www.ukbiobank.ac.uk. 
How will information about me be kept confidential? 
UK Biobank has put a number of rigorous measures in place to protect the confidentiality of 
participants. These include: 
 No personal identifying details are included with data or samples provided to researchers. 
 Information that might identify individuals (such as their names and addresses) is kept 
separately from other information about them in UK Biobank’s databases. 
 High level computer security is used to block unauthorised access (for example, by 
“hackers”) to the computers that hold personal information. 
 Access to personal information is restricted as much as possible, and all staff working on 




Who do I contact if I have any questions? 
If this leaflet does not answer your questions, please telephone us on 0800-0-276-276 (free 
from most land lines) or 0292-0-765-597, Monday-Saturday 8am-7pm for more information, 
or visit our website at www.ukbiobank.ac.uk.  
If you would like to contact the person in charge, please send a letter or email to: 
Professor Sir Rory Collins 
UK Biobank 






We shall reply to your letter promptly in writing, unless you enclose your telephone number 












UK Biobank Limited (company no. 4978912) is a registered charity in England & Wales (1101332) and in Scotland (SCO39230) 
Version January 2014 
 
 
Supplementary File 2: UK Biobank magnetic resonance imaging parameters 
 
Region and sequence Voxel dimensions (mm) TR (ms) TE (ms) 
N 
slices Other parameters 
      
Brain MRI1      
T1 1 x  1x 1 2000 - 208 TI 880 ms 
FLAIR 1.05 x 1 x 1 5000 395 192 TI 1800 ms 
SWI+T2* 0.8 x 0.8 x 3 27 9.4, 272 48 - 
Functional MRI: Rest 2.4 x 2.4 x 2.4 735 39 64 MB 8, 490 volumes 
Functional MRI: Task3 2.4 x 2.4 x 2.4 735 39 64 MB 8, 332 volumes 
Diffusion4 2.0 x 2.0 x 2.0 3600 92 72 MB 3 
       
Cardiac MRI      
Long axis cine 1.8 x 1.8 x 6 32.64 1.16 - 373 ms resolution 
Short axis truFISP cine 1.8 x 1.8 x 8 31.56 1.10 - 373 ms resolution 
ShMOLLI 0.9 x 0.95 x 8 368.28 1.07 1 TI 0.1-5 s 
Cine, single breath hold tagging 1.4 x 1.4 x 8 41.05 3.90 - Grid tag, 3 short axis views 
SSFP cine LV outflow tract and aorta 1.8 x 1.8 x 6 32.64 1.16 - 373 ms resolution 
Flow sensitive cine aorta 1.8 x 1.8 x 6 37.12 2.47 - TI 1.0 ms, 373 ms resolution 
       
Body MRI      
T1 abdomen 1.9 x 1.3 x 10 450 11 12 - 
3D-Dixon water fat separation neck to knees 2.2 x 1.2 x 10 3.23 1.44 - Coronal and axial planes 
T1 pancreas 1.2 x 1.2 x 1.12 2.95 1.12 80 - 
Single breath hold liver and pancreas multi-echo 2.2 x 2.2 x 10 150 1.23-14.766 - - 
      
mm = millimetres, TR = repetition time, ms = milliseconds, TE = echo time, MRI = magnetic resonance imaging, TI = inversion 
time, FLAIR = fluid attenuation inversion recovery, SWI = susceptibility weighted imaging, MB = multiband pulses, FISP = fast 
imaging with steady-state free precession, ShMOLLI = shortened modified Look-Locker inversion recovery, SSFP = steady state 
free precession, LV = left ventricle 
- = Not applicable  
1 Participants imaged before August 18th 2014 (615/1000) also had a T2-weighted brain MRI sequence, however this was removed 
from the imaging protocol after this date and is no longer included in the UK Biobank imaging study. Additional modifications 
were made to the imaging protocol over the period during which the first 1000 participants were scanned, but these modifications 
were unlikely to affect the detectability or characterisation of potentially serious incidental findings and are not detailed here. 
2 Two echoes required 
3 Harari emotional faces task 
4 b=1000 and b=2000 s/mm2, 50 directions per shell 
5 Interpolated 





Supplementary File 3: UK Biobank lists of incidental findings 
UK Biobank developed lists of findings which would be considered potentially serious, and findings not 
considered serious for use by radiographers and reporting radiologists. These lists were based on lists generated 
by the German National Cohort, and are subject to ongoing review. 
Table i: Incidental findings on brain MRI 
Potentially serious for feedback Not for feedback 
Acute brain infarction Asymmetrical ventricles 
Acute hydrocephalus Chiari malformation4  
Acute intracranial haemorrhage1  Chronic hydrocephalus 
Arachnoid cyst3 Developmental anomalies (including venous anomalies) 
Colloid cyst of third ventricle Lipoma of corpus callosum 
Intracranial mass lesion2 Non-acute brain infarction 
Mastoiditis Non-specific white matter hyperintensities 
Suspected intracranial aneurysm or vascular malformation Regional or global atrophy 
 Suspected demyelination 
1 Not old bleeds, or microbleeds only detected on gradient recalled echo sequences 
2 Except meningiomata in locations considered highly unlikely to cause problems 
3 Only if large and considered likely to increase the risk of developing a subdural haematoma 



















Table ii: Incidental findings on cardiac MRI 
Potentially serious for feedback Not for feedback 
Aortic dissection Atelectasis 
Cardiac mass (including thrombus) Calcified pleural plaque 
Central pulmonary embolus  Calcified pulmonary nodule 
Haemodynamically relevant pericardial effusion >2 cm Emphysema 
Heart valve defects1 Right sided descending aorta 
Hilar, mediastinal, axillary or cervical lymphadenopathy2  
Lobar pneumonia or lung consolidation  
Lung mass > 2 cm  
Mediastinal mass > 2 cm  
Pleural effusion  
Pleural mass > 2 cm  
Pneumothorax  
Severe left or right ventricular dilation or dysfunction  
Severe left ventricular hypertrophy > 2 cm thick wall  
Thoracic aortic aneurysm > 5 cm  
1 Severe regurgitation jet of any valve or severe turbulence (suggesting valve stenosis) 



















Table iii: Incidental findings on the abdominal portion of the body MRI 
Potentially serious for feedback Not for feedback 
Abdominal aortic aneurysm > 5 cm Abdominal wall hernia 
Acute exudative pancreatitis Bladder diverticulum 
Adrenal lesion > 2 cm Chronic cholecystitis 
Ascites Chronic pancreatitis 
Cholestasis (intra- or extra-hepatic)1 Fatty liver 
Deep vein thrombosis Fibroids 
Hepatomegaly Gallstones 
Ileus Hiatus hernia 
Intra-abdominal mass > 3 cm Left sided inferior vena cava 
Irregular/nodular liver margin Liver cyst 
Lymphadenopathy2 Renal calculus 
Multiple small non-cystic, liver lesions (non haemangioma-like) Simple renal cyst 
Pneumoperitoneum Single kidney 
Portal vein occlusion  
Pyelonephritis  
Renal artery stenosis > 80% or bilateral  
Solid / cystic pancreatic tumour  
Solid gallbladder lesion  
Solid liver lesion   
Solid/semi-solid renal tumour > 2 cm  
Spleen infarction  
Splenomegaly > 15 cm  
Urinary obstruction  
Urinary tract mass > 2 cm  
1 Common bile duct >15 mm (or >20 mm post-cholecystectomy) 











Table iv: Incidental findings on dual energy X-ray absorptiometry 
Potentially serious for feedback Not for feedback 
Major vertebral fracture Non-skeletal findings 
Primary skeletal malignancy  
Skeletal metastases  
 
 
Carotid Doppler ultrasound 
Although asymptomatic carotid stenosis may be picked up by carotid ultrasound, its relevance in predicting 
prognosis over and above conventional vascular risk factors is not established, and so it was not considered to be 
a potentially serious incidental finding. Extra-carotid findings were not considered relevant for UK Biobank’s 
imaging study as the radiographers conducting the imaging are specifically trained in the vascular component of 
this imaging modality only. Hence, carotid Doppler data do not form part of this manuscript.
 







Invitation to make an appointment with your GP following your visit to the UK Biobank imaging 
assessment visit 
Thank you for your recent attendance at the UK Biobank imaging assessment visit.  
We are writing to inform you that, during the scanning process, something was noticed on your 
[name_of] scan that your GP may want to follow up.  We have informed «practice_name» of this 
possible abnormality, and recommend that you make an appointment to see your GP at your earliest 
convenience.  
If these GP details are incorrect, please let us know as soon as possible by telephoning the Participant 
Resource Centre on 0800-0-276-276 (free from most land lines) or 0292-0-765-597, Monday-Saturday 
8am to 7pm, or by emailing imaging.queries@ukbiobank.ac.uk. 
Please do not be unduly alarmed by this letter. Whilst we aim to inform you only of abnormalities that 
might be potentially serious, it is still likely that many of these findings will turn out not to be of concern, 
or be something of which you are already aware. As indicated to you at the time of your assessment 
visit, the scans taken by UK Biobank are not specifically designed to detect clinical abnormalities, and 
so cannot generally be used to determine exactly what a possible abnormality is.  
 






Professor Sir Rory Collins 
UK Biobank Principal Investigator, and 
Professor of Medicine & Epidemiology, 












Cc «partipant_name»; «nhs_number» 
Report of a potentially serious abnormality on an imaging scan from UK Biobank  
«partipant_name»; «nhs_number» recently attended an imaging assessment visit as part of their 
participation in UK Biobank. UK Biobank is a population-based cohort study, established by the Medical 
Research Council and Wellcome Trust with the support of the Department of Health, which recruited 
over 500,000 middle-aged people during 2006 to 2010, some of whom are now participating in our 
imaging sub-study. This involved undergoing brain, heart and abdominal MRI scans, a carotid 
ultrasound scan and a DXA low energy X-ray scan, as well as answering questions, having non-imaging 
measurements and providing biological samples. 
The imaging scans taken by UK Biobank are intended for research use only; they are not optimised for 
identifying any particular clinical abnormalities and may not provide sufficient information for diagnostic 
purposes. However, the radiologist/specialist who reviewed «participant_name»’s [name of] scan 
reported an incidental finding that may be potentially serious (i.e. indicating the possibility of a condition 
which, if confirmed, carries a real prospect of threatening life span, or of having a substantial impact on 
major body functions or quality of life). 
A copy of the specialist’s report is provided with this letter in case you feel further referral or clinical 
investigation is warranted. If required, you can request a digital copy of the relevant scans by emailing 
imaging.queries@ukbiobank.ac.uk or by telephoning Mr. Steve Garratt on 0161 475 5378. Alternatively 
you can write to us at the address shown below.  
We have informed «participant_name» that a possible abnormality was found (see attached letter) on 
one of their scans and advised them to make an appointment to see you at their earliest convenience. 
There is little consensus in the UK (or elsewhere) on the balance of benefit versus harm in telling 
research participants about incidental findings from imaging studies. In order to improve our procedures 
and those of other research projects in the future, we will contact you again in a few months with a short 
questionnaire asking you about the impact on the health service of providing this information. 
We would be grateful if you could let us know as soon as possible if «participant_name» is not registered 




Professor Sir Rory Collins, 




Supplementary File 6: Understanding of consent related to the feedback of potentially serious incidental findings: data from 607 respondents from the first 1000 




 Correct Incorrect Don’t know 
As far as you are concerned, when you consented to participate, which of the following did you agree to? n/N % n/N % n/N % 
           
My imaging scans and results would be given to me at the end of the visit2 526/607 86.7 49/607 8.1 32/607 5.3 
 
In the event a potentially serious finding was identified on a scan: 
      
       
I could choose whether my GP and I would be informed2 381/607 62.8 158/607 26.0 68/607 11.2 
Both my GP and I would automatically be contacted3 454/607 74.8 119/607 19.6 34/607 5.6 
I would be told about this finding during the assessment visit2 540/607 89.0 19/607 3.1 48/607 7.9 
I would be told about this finding after the assessment visit3 251/607 41.4 300/607 49.4 56/607 9.2 
1 Proportions of participants answering each question correctly, incorrectly or answering that they did not know were similar irrespective of whether or not participants had a 
potentially serious incidental finding (IF), and irrespective of whether any potentially serious IF was finally diagnosed as clinically serious or non-serious. 
2 The correct response was ‘no’. 
3 The correct response was ‘yes’. However, in retrospect these questions were deemed ambiguous. The participant information leaflet described the UK Biobank IF policy, 
including that a finding identified on a scan by a radiographer would only be fed if confirmed by a radiologist. Taking this in to account, if participants considered the case 
where a finding identified by a radiographer was not then confirmed by a radiologist, some participants may reasonably have concluded that they would not automatically be 




Supplementary File 7: Final diagnoses of 217 potentially serious incidental findings 
Image modality Final diagnosis Number of scans identified by radiographer flagging 
Number of scans identified 




Serious final diagnoses 
 
  
Brain MRI Pituitary tumour 0 2 
 Arachnoid cyst with hydrocephalus 1 1 
 Meningioma compressing brainstem 1 1 
    
Cardiac MRI Thoracic aortic aneurysm1 3 5 
 Lung tumour 0 3 
 Cardiomyopathy 0 2 
 Atrial fibrillation 0 1 
 Coronary heart disease 0 1 
 Heart block and LV impairment 0 1 
    
Body MRI: Abdomen Abdominal aortic aneurysm > 5 cm 0 1 
 Gastrointestinal stromal tumour 0 1 
 Pancreatic neuroendocrine tumour 0 1 
    
DXA Osteoporotic crush fracture 0 1 
    
All modalities: serious final diagnoses 5 21  
   
Non-serious final diagnoses 
Brain MRI Benign cyst/lesion 2 15 
 Already known diagnosis 0 1 
 Suspected lesion not confirmed 0 3 
    
Cardiac MRI Lung diagnosis – not serious 2 28 
 Suspected lesion not confirmed 0 18 
 Other non-serious diagnosis 0 10 
 Cardiac diagnosis – not serious 0 8 
2 
1 One participant with a thoracic aortic aneurysm was also found to have an atrial myxoma, which was resected 
at the time of aneurysm repair. 
2 Four findings could not be classed as serious or not serious by April 2016: one participant with a lung nodule 
was still under follow-up; another participant with a lung nodule underwent follow-up and was found to have 
lymphoma, but it was unclear whether the nodule was related to the lymphoma or not; one participant with lung 
consolidation reported that the final diagnosis may be scarring or bronchoalveolar cell carcinoma (this 
participant was also noted to have a meningioma compressing their brainstem on brain MRI, so that their overall 
final diagnosis clinical severity was classified as serious); we were unable to contact one participant with a crush 
fracture to determine the grade of the fracture, or whether they had been diagnosed with or treated for 
osteoporosis.
Already known cardiac diagnosis 0 7 
Already known lung diagnosis 0 2 





Body MRI: Leg 0 5 
0 2 
0 1 
DXA 1 5 
0 5 
Suspected lesion not confirmed 
Already known diagnosis 
Other non-serious diagnosis 
Abdominal aortic aneurysm < 5 cm 
Bone/soft tissue diagnosis – not serious 
Suspected lesion not confirmed 
Already known finding 
Already known diagnosis 
Non-serious diagnosis 
Suspected lesion not confirmed 0 2 
All modalities: non-serious final diagnoses 13 192 
Uncertain final diagnoses 
Cardiac MRI Lung nodule, unclear nature 0 2 
Lung consolidation, unclear nature 0 1 
DXA Crush fracture T11, unclear relevance 0 1 
All modalities: uncertain final diagnoses 0 4 
Supplementary File 8: Invasive procedures performed to diagnose or treat potentially serious incidental findings 
 
MRI = magnetic resonance imaging, LV = left ventricular, EUS FNA = endoscopic ultrasound fine needle aspiration, FNA = fine needle aspiration, GI = gastrointestinal 
1Relevant questionnaire data or additional correspondence on invasive procedures were available from 18 participants with serious final diagnoses, and 144 participants with non-serious or 
uncertain final diagnoses
 
Final diagnosis n participants in diagnostic category 
n/N with data available 
who underwent an 
invasive procedure1 
Modality Invasive procedure (one participant per procedure unless otherwise indicated) 
     
Serious 21 11/18 (61.1%) Brain MRI Third-ventriculostomy and fenestration of arachnoid cyst 
    Resection of meningioma compressing brainstem 
    Transphenoidal resection of large pituitary macroadenoma 
     
   Cardiac MRI Biopsy and resection of pulmonary nodule 
    Coronary angiogram to investigate poor LV function (n=2) 
    Resection of lung cancer 
    Repair of thoracic aneurysm (n=2) 
     
   Body MRI: Abdomen EUS FNA and Whipple procedure for pancreatic neuroendocrine tumour 
   Resection of gastrointestinal stromal tumour 
     
Non-serious or 
uncertain 
158 12/144 (8.3%) Cardiac MRI Aspiration of breast cyst 
    Bronchoscopy to investigate lung findings 
    FNA of thyroid 
    Resection of pulmonary nodule 
     
   Body MRI: Abdomen Colonoscopy to investigate thickened sigmoid (n=2) 
   Hysterectomy for ovarian cysts 
    Oopherectomy for ovarian cyst 
    Polyps resected and uterus biopsy 
    Transvaginal ultrasound for ovarian cyst (n=2) 




Supplementary File 9: Clinical management (medication and procedures) of the 21 participants with 
potentially serious incidental findings which were finally diagnosed as serious 
 
–  = Not reported, MRI = magnetic resonance imaging,  LV = left ventricular, EUS FNA = endoscopic 
ultrasound fine needle aspiration, DXA = dual energy X-ray absorptiometry
Modality 
Final diagnosis (one participant per 
diagnosis unless otherwise indicated) 
Clinical management 
   
Brain MRI Arachnoid cyst with hydrocephalus  Neurosurgical drainage  
 
Meningioma compressing brainstem Excision 
 
Pituitary tumour (n=2) Transsphenoidal resection (n=1) 
Referred to specialist, no data on interventions (n=1) 
   
Cardiac MRI Atrial fibrillation Warfarin 
 
Hypertrophic obstructive cardiomyopathy Referred to specialist, no data on interventions 
 
Cardiomyopathy  Coronary angiogram, ramipril 
 
Coronary heart disease Stress echocardiogram, coronary angiogram, aspirin, beta-blockers 
 
Heart block and LV impairment Beta-blockers  
 
Lung tumours (n=3) Excision and chemotherapy (n=1) 
Biopsy (n=1) 
Excision (n=1) 
   
 
Thoracic aortic aneurysm (n=5) Repair (n=2) 
Referred to specialist, no data on interventions (n=1) 
No data (n=2) 
   
Body MRI: Abdomen Abdominal aortic aneurysm No data 
 
Gastrointestinal stromal tumour Excision 
 
Pancreatic neuroendocrine tumour Excision and enzyme supplements 
   
DXA Osteoporotic crush fracture Prophylactic medication  
Supplementary File 10: Rates of radiographer flagging and rates of radiologist confirmation of 
potentially serious incidental findings in the first 7000 imaged UK Biobank participants 
 
Participant blocks of 1000  
(in order of attendance) 
Flagged by radiographers1  Confirmed by radiologists2 
N participants 
% of total 
imaged 
 N participants 
% of total 
imaged 
1-1000 66 6.6  18 1.8 
1001-2000 35 3.5  19 1.9 
2001-3000 61 6.1  27 2.7 
3001-4000 30 3.0  16 1.6 
4001-5000 22 2.2  14 1.4 
5001-6000 11 1.1  7 0.7 
6001-7000 27 2.7  19 1.9 
Mean per 1000 participants 36 3.6  17 1.7 
1 Chi-square 72.5, 6 degrees of freedom, p<0.0001 











This chapter described the evaluation of the UK Biobank IFs protocol (radiographer flagging 
of concerning images for a radiologist to review) against another protocol commonly used by 
research imaging studies (systematic radiologist review of all imaging). This design, and the 
systematic long-term follow-up of participants with PSIFs and their GPs, enabled several 
aims of this thesis to be addressed by describing: how prevalence of PSIFs and serious final 
diagnoses varies by IFs protocol; clinical assessments generated by PSIFs; the impacts on 
participants’ emotional wellbeing, insurance and finances, and work and activities; 
participants’ understanding of consent regarding the UK Biobank IFs handling policy; 
participants’ and GPs’ opinions about receiving feedback of a PSIF; factors associated with 
PSIFs. 
Compared to systematic radiologist review, radiographer flagging resulted in a substantially 
lower prevalence of participants with PSIFs (179/1,000 [17.9%] versus 18/1,000 [1.8%]) and 
a higher proportion of serious final diagnoses (21/179 [11.7%] versus 5/18 [27.8%]) (Gibson 
et al., 2018). While radiographer flagging resulted in false negatives (i.e. missed serious final 
diagnoses in 16/21 participants), systematic radiologist review resulted in large numbers of 
false positives (i.e. non-serious final diagnoses in 158 participants) (Gibson et al., 2018). 
While radiographer flagging was deemed to be a more appropriate approach to handling 
PSIFs than systematic radiologist review in a study of the scale of UK Biobank, there is no 
single ‘best’ protocol for handling IFs across all possible imaging contexts (Gibson et al., 
2018). 
All participants who received feedback of a PSIF had contact with their GP, and almost all 
(90%, 153/170 respondents) underwent some form of clinical assessment (most commonly 
imaging or referral to a specialist). Importantly, similar numbers of participants with serious 
and with non-serious final diagnoses underwent invasive procedures (n=11 and n=12 
respectively) (Gibson et al., 2018). While a higher proportion of participants with serious 
final diagnoses reported undergoing clinical assessments compared to those with non-serious 
diagnoses, absolute numbers were higher in the latter group due to the higher prevalence of 
participants with non-serious final diagnoses (Gibson et al., 2018). 
Variable proportions of participants reported that feedback of a PSIF had impacted on their 
emotional wellbeing (16.9%), insurance or finances (8.9%), or work or activities (5.6%). 
These non-medical impacts affected a higher proportion of participants with serious final 




diagnoses; in the latter group, such impacts could be regarded as unnecessary (Gibson et al., 
2018). 
The majority of participants correctly understood that they had consented to a protocol which 
would not provide feedback of a PSIF or access to their images at the end of their imaging 
visit (both >85%), but around a quarter of participants incorrectly thought that they could 
choose whether or not to receive feedback (158/607 [26.0%]); UK Biobank revised its 
consent materials accordingly, and evaluation of participants’ understanding of consent 
continues (Gibson et al., 2018).  
While the vast majority of participants reported being glad to have been told about a PSIF 
(98%, 142/145 respondents), and glad to have participated in the UK Biobank imaging study 
(99%, 147/148 respondents), only around one-third believed that participants should always 
be told about PSIFs (36.9%, 55/149 respondents [in contrast to 64.9% (61/94) of responding 
GPs]). Almost a quarter of participants changed their opinion on whether they should or 
should not be able to choose to receive feedback of a PSIF. The reasons for this are not clear, 
and further qualitative research is needed to understand these responses (Gibson et al., 2018). 
GPs also more frequently reported that participants had experienced negative impacts on 
emotional wellbeing rather than positive (38/99 [38.4%] versus 16/99 [16.2%] of GP 
respondents respectively), but that more frequently participants had experienced net benefit 
rather than net harm (51/86 [59.3%] versus 35/86 [40.7%] of GP respondents respectively) 
(Gibson et al., 2018). These data were limited by the lower response rate of GPs, and it 
would be useful to repeat this aspect of the evaluation study using a larger dataset which will 
be available in future. 
This chapter also provided some preliminary data on the associations of age and sex with 
PSIFs; participants with PSIFs were slightly older than those without (mean age 63 versus 61 
years, p=0.03), but there was no significant difference in the distribution of PSIFs between 
women and men (p=0.4) (Gibson et al., 2018). These results support those found during our 
systematic review and meta-analysis (Chapter 2). The factors associated with PSIFs, and 
with serious final diagnoses, are explored further in Chapter 5 using UK Biobank assessment 
data from a larger cohort of imaged participants. 
The design of the study questionnaires did not enable quantification of use or costs of health 
services generated by participants with PSIFs (Gibson et al., 2018). The economic impact of 
feedback of PSIFs is explored further in Chapter 6 using a case-control study and linked 
routinely collected healthcare data. 
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Chapter 5 Factors associated with potentially 
serious incidental findings and 
serious final diagnoses  
5.1 Introduction 
Chapter 4 demonstrated that while the participants with potentially serious incidental 
findings (PSIFs) undergo some form of clinical assessment, the majority of PSIFs do not turn 
out to represent serious disease (Gibson et al., 2018). Understanding the factors associated 
with PSIFs and with serious final diagnoses will inform on the risks of needing some form of 
clinical assessment and discovering a finding which will likely impact on health respectively. 
Such knowledge would inform individuals’ decisions to undergo imaging and researchers’ 
estimates of the probability of generating PSIFs during imaging of a particular population, 
which may influence incidental findings (IFs) policy design. 
Chapter 2 summarised our knowledge of the factors associated with PSIFs. There were only 
a small number of studies which systematically followed up unselected participants with 
PSIFs, and the available evidence suggested that PSIFs were associated with age (Brugulat-
Serrat et al., 2017; Hartwigsen et al., 2010; Illes et al., 2004b; Tsushima et al., 2005), but not 
clearly associated with sex (Bos et al., 2016; Brugulat-Serrat et al., 2017; Haberg et al., 
2016; Illes et al., 2004b; Kumar et al., 2008; Morin et al., 2009; Sandeman et al., 2013; 
Tsushima et al., 2005; Yue et al., 1997). These findings were confirmed by our study of UK 
Biobank participants in Chapter 4 (Gibson et al., 2018). There were not enough data to 
reliably comment on associations with other factors such as lifestyle or medical history, and 
there were no data available at all on the factors associated with serious final diagnoses 
(Chapter 2).  
This chapter uses data from long-term, systematic follow-up of a larger cohort (N=7,334) of 
unselected imaged UK Biobank participants. We aim to investigate the associations of a 
wider range of factors with PSIFs, including sociodemographic and lifestyle factors, body 
mass index (BMI), morbidity and PSIFs protocol, and for the first time, the association of 
these factors with serious final diagnoses. This study also enables a further evaluation of the 
variation in prevalence of PSIFs and serious final diagnoses generated by the UK Biobank 
IFs protocol compared to systematic radiologist review.  
This study manuscript has been edited by co-authors in preparation for submission to a 
journal; the current version of the draft manuscript is included in full in Section 5.2.  
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5.2 Factors associated with potentially serious 
incidental findings and with serious final 
diagnoses on multi-modal imaging in the UK 
Biobank Imaging Study: a prospective cohort 
study  
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Feedback of potentially serious incidental findings (PSIFs) to imaging research participants 
generates clinical assessment in most cases. Understanding the factors associated with 
increased risks of PSIFs and of serious final diagnoses may influence individuals’ decisions 
to participate in imaging research and will inform the design of PSIFs protocols for future 
research studies.  
Methods 
We included all UK Biobank participants who underwent imaging up to December 2015 
(N=7,334, median age 63, 51.9% women). Brain, cardiac and body magnetic resonance, and 
dual-energy X-ray absorptiometry images from the first 1,000 participants were reviewed 
systematically by radiologists for PSIFs. Thereafter, radiographers flagged concerning 
images for radiologists’ review. We classified final diagnoses as serious or not using data 
from participant surveys and clinical correspondence from general practitioners up to six 
months following imaging. We used binomial logistic regression models to investigate 
associations between age, sex, ethnicity, socio-economic deprivation, private healthcare use, 
alcohol intake, diet, physical activity, smoking, body mass index and morbidity, with both 
PSIFs and serious final diagnoses. 
Results 
Systematic radiologist review generated 13 times more PSIFs than radiographer flagging 
(179/1,000 [17.9%] versus 104/6,334 [1.6%]; age- and sex-adjusted odds ratio (OR) 13.3 
[95% confidence interval (CI) 10.3–17.1] p<0.001) and proportionally fewer serious final 
diagnoses (21/179 [11.7%] versus 33/104 [31.7%]). Risks of both PSIFs and of serious final 
diagnoses increased with age (sex-adjusted ORs [95% CI] for oldest [67–79 years] versus 
youngest [44–58 years] participants for PSIFs and serious final diagnoses respectively: 1.59 
[1.07–2.38] and 2.79 [0.86–9.0] for systematic radiologist review; 1.88 [1.14–3.09] and 2.99 
[1.09–8.19] for radiographer flagging). No other factor was significantly associated with 
either PSIFs or serious final diagnoses. 
Conclusion 
Risks of PSIFs and serious final diagnosis are substantially influenced by PSIFs protocol and 
to a lesser extent by age. As most PSIFs do not represent serious disease, evidence-based 
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PSIFs protocols are paramount to minimise over-investigation of apparently asymptomatic 
research volunteers.  
  




Brain and body imaging is increasingly used for research, diagnostic and screening purposes 
and is accompanied by the risk of identifying abnormalities which are unrelated to the 
purposes of the imaging, so-called incidental findings (IFs) (Wolf et al., 2008). Since very 
few IFs turn out to represent serious disease (Gibson et al., 2018) it is of limited value to 
feedback clearly non-serious IFs. Therefore, we focus on potentially serious IFs (PSIFs), 
defined as those which indicate the possibility of a condition which, if confirmed, would 
carry a real prospect of seriously threatening life span, or of having a substantial impact on 
major body functions or quality of life (Gibson et al., 2018). Feedback of PSIFs detected 
during research imaging generates some form of clinical assessment (e.g. general practitioner 
[GP] appointments and specialist referrals, or further investigations including imaging and 
invasive procedures) in almost all cases (Gibson et al., 2018). Information on the factors 
associated with increased risk of detection and feedback of a PSIF (and therefore of 
subsequent clinical assessment), and with increased risk of eventually receiving a serious 
final diagnosis may influence individuals’ decisions to consent to participate in imaging 
research and inform researchers’ designs of appropriate PSIFs policies, which are required 
by major research funders (Farrar and Savill, 2014; Medical Research Council and 
Wellcome Trust, 2014).  
A small number of studies (N=151 to 5,800) which followed up unselected participants with 
PSIFs suggest that PSIFs are associated with age, but not with sex, but none investigated the 
associations of PSIFs with PSIFs protocols, or any factors associated with serious final 
diagnoses (Bos et al., 2016; Brugulat-Serrat et al., 2017; Haberg et al., 2016; Hartwigsen et 
al., 2010; Illes et al., 2004b; Kumar et al., 2008; Morin et al., 2009; Sandeman et al., 2013; 
Tsushima et al., 2005; Yue et al., 1997).   
The UK Biobank Imaging Study provides an opportunity to investigate potential risk factors 
for PSIFs and serious final diagnoses. In the UK Biobank Imaging Study, 100,000 of the 
original 500,000 participants are undergoing brain, cardiac and body magnetic resonance 
imaging (MRI), dual-energy X-ray absorptiometry (DXA) and carotid Doppler ultrasound 
(Matthews and Sudlow, 2015); over 27,000 participants have been imaged as of September 
2018 (UK Biobank, 2018c). These imaging data are linked to detailed sociodemographic, 
lifestyle, physical measurement, genetic and routine healthcare data generating an extensive 
research resource (Matthews and Sudlow, 2015). 
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The UK Biobank Imaging Study will inevitably generate PSIFs. To inform the development 
of a pragmatic PSIFs protocol that aims to minimise harm to (the largely asymptomatic) 
100,000 imaged participants, UK Biobank reviewed current practice, published literature and 
guidance, and sought advice from professional bodies and from ethical and legal experts 
(Gibson et al., 2018). The protocol is based on radiographers flagging images of potential 
concern to a radiologist for their review (Gibson et al., 2018; Gibson et al., 2016b). This 
approach was evaluated against a protocol involving systematic radiologist review of all 
images (which is more commonly used in research studies), and found to generate less harm 
(i.e., less unnecessary anxiety to participants) and a lower burden on the publicly-funded UK 
National Health Service (NHS) (Gibson et al., 2018). UK Biobank is continuing to evaluate 
this PSIFs protocol by systematically following up all participants identified with a PSIF. 
Using data from the first 7,334 participants imaged during the first 20 months of the UK 
Biobank Imaging Study (including systematic follow-up data on 283 participants with 
PSIFs), we aimed to determine whether, and to what extent, sociodemographic, lifestyle, 
other health-related factors and PSIFs protocol are associated with detection of a PSIF and 
with a final diagnosis of serious disease. 
5.2.3 Methods 
We prepared this manuscript according to STROBE guidelines (von Elm et al., 2008). The 
statistical analysis code is available online (Gibson and Nolan, 2018). UK Biobank obtained 
ethics approval for the imaging study, and evaluation of the PSIFs protocol (REC Reference 
numbers: 11/NW/0382; 16/NW/0274). We provided all participants with written information 
about the imaging study and the UK Biobank imaging IFs protocol (UK Biobank, 2016). All 
participants provided consent to take part in the imaging study, and for UK Biobank to feed 
back any identified PSIFs to them and their GP. 
5.2.3.1 UK Biobank Imaging Study  
Of 9.2 million adults aged 40–69 invited to participate in UK Biobank, 0.5 million (5.5%) 
participated, providing initial baseline data between 2006 and 2010 (Fry et al., 2017). From 
April 2014 to December 2015, participants living within approximately 120 km of the 
imaging centre in Stockport were invited to take part in the UK Biobank Imaging Study (UK 
Biobank, 2015e). Participants were excluded if they had metal implants, penetrating metal 
injury, non-removable metallic items, or if they would find it difficult to complete the 
imaging, e.g. due to claustrophobia (Figure 5-1) (UK Biobank, 2015e). 




Figure 5-1. Participant flowchart 
 
At the imaging visit, participants underwent brain, heart and body MRI, whole-body, spine 
and hip DXA and carotid Doppler ultrasound (UK Biobank, 2015a; b; c; d; e; 2017b). 
Participants also repeated the UK Biobank baseline assessment, which involved: a 
touchscreen questionnaire to collect data on potentially relevant risk factors for diseases, 
including sociodemographic, lifestyle and medical history; an interview; and physical 
measurements (Sudlow et al., 2015). 
5.2.3.2 UK Biobank PSIFs protocol  
During imaging, UK Biobank radiographers may notice PSIFs and ‘flag’ concerning images 
for radiologist review; radiologist-confirmed PSIFs are then fed back to participants and 
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their GP (Gibson et al., 2018). To evaluate this PSIFs protocol, all images from the first 
1,000 participants were also systematically reviewed by radiologists for PSIFs (Gibson et al., 
2018). Radiographers did not flag any PSIFs in addition to those detected by the radiologists 
within the first 1,000 imaged participants (Gibson et al., 2018). Therefore, for the purposes 
of this present study, we classified the first 1,000 imaged participants as undergoing the 
‘systematic radiologist review’ PSIFs protocol, and subsequently imaged participants as 
undergoing the ‘radiographer flagging’ PSIFs protocol. For both protocols, to aid 
interpretation of images, radiologists received information on participants’ age, sex, 
ethnicity, alcohol intake, smoking status, blood pressure, body mass index (BMI), 
employment status, and self-reported medical history. 
Participants with PSIFs are surveyed six weeks and six months after receiving feedback, 
while their GPs are surveyed six months after feedback and asked for copies of relevant 
clinical correspondence; these responses include data on final diagnoses (Gibson et al., 
2018). 
Carotid Doppler ultrasound was deemed extremely unlikely to generate PSIFs under UK 
Biobank’s protocol (UK Biobank, 2015e), and as such was not included in this study. 
5.2.3.3 Data sources and variables  
5.2.3.3.1 PSIFs and serious final diagnoses 
We extracted data on the number, types and body region of each participant’s PSIF(s) from 
radiologists’ reports. A consultant physician and an experienced clinical radiology specialty 
trainee independently classified final diagnoses using all available survey data and clinical 
correspondence; we contacted participants and GPs by telephone where these data were 
insufficient to classify final diagnoses (Gibson et al., 2018). We classified final diagnoses as 
either: serious (if they were likely to threaten life span, or have a substantial impact on 
quality of life or major body function); not serious (if this was not the case or if available 
data suggested that the diagnosis was already known); or indeterminate (if there remained 
insufficient data to classify a final diagnosis as serious or not) (Gibson et al., 2018). We 
classified participants with more than one PSIF according to their most serious final 
diagnosis (Gibson et al., 2018).  
5.2.3.3.2 Participant factors 
We selected variables available from UK Biobank (UK Biobank, 2017a) which might be 
associated with PSIFs or would be possible confounders. These were age, sex, ethnicity, 
Townsend socio-economic deprivation score (which may reduce access to healthcare, 
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increase the risk of disease and reduce opportunities for disease detection prior to research 
imaging), use of private healthcare (which may be associated with reduced risk of serious 
final diagnoses if it increases prior knowledge of disease), alcohol intake (British Medical 
Association, 1995), fruit and vegetable intake (Cassidy et al., 2016), physical activity (UK 
Biobank, 2017c), smoking status, BMI (World Health Organisation, 2000) and morbidity. 
We measured the latter using the Elixhauser Index calculated using Hospital Episode 
Statistics data from two years before the date of imaging, and defined morbidity as ≥ 1 
Elixhauser Index health conditions (Elixhauser et al., 1998; Quan et al., 2005; The National 
Casemix Office and Health and Social Care Information Centre, 2014).  
5.2.3.4 Statistical analyses 
Since our previous study showed that the ‘systematic radiologist review’ protocol produced 
approximately ten times more PSIFs compared with the ‘radiographer flagging’ protocol 
(Gibson et al., 2018) all analyses were stratified by PSIFs protocol to control for potential 
confounding. We compared characteristics between participants with and without PSIFs, and 
with and without serious final diagnoses, and calculated age- and sex-adjusted odds ratios 
(ORs) with 95% confidence intervals (CIs) using binomial logistic regression models. 
We tested for normal distributions of continuous variables by visual inspection of graphed 
data and Kolmogorov-Smirnov goodness-of-fit tests. We attempted to normalise non-
normally distributed data using log transformations, and if this failed, recoded variables into 
categories, aiming for similar numbers of participants in each category to optimise statistical 
efficiency. We used non-parametric tests to compare distributions of non-normally 
distributed variables between two groups. We considered data to be missing if participants 
did not respond, or if they responded ‘do not know’ or ‘prefer not to answer’; such 
participants were excluded only from the relevant analyses. We present summary statistics of 
the characteristics of the whole UK Biobank cohort only; these cannot be compared directly 
to the imaged sub-cohort included in this study due to lack of independence of these two 
samples. The majority of variables had no, or only small proportions (< 4%) of missing data. 
In total, 460/7,334 (6.3%) participants had missing data for at least one variable. We 
performed all analyses using SPSS version 22.  




5.2.4.1 Participants  
By 23rd December 2015, 7,334 of 33,367 invited participants (22.0%) had been imaged and 
were included in this study (Figure 5-1). Median age of the imaged participants was 63 
(interquartile range 56–68) years and 3,804 (51.9%) were women (Table 5-1).  
Compared to the entire UK Biobank cohort, this imaged sub-cohort included lower 
proportions of women, people of minority ethnicity groups, and people with less healthy 
lifestyles, including those with harmful alcohol intake, current smokers, low physical activity 
levels, or those who were overweight or obese. Conversely, a higher proportion of the 
imaged sub-cohort had one or more health conditions as measured using the Elixhauser 
Index compared to the whole cohort (Table 5-1).  
5.2.4.2 PSIFs and final diagnoses  
PSIFs were detected in 283/7,334 (3.9%) people: 179 of the first 1,000 (17.9%) by 
systematic radiologist review; 104 of the subsequent 6,334 (1.6%) by radiographer flagging 
(OR for systematic radiologist review versus radiographer flagging: 13.3, 95% CI 10.3–17.1, 
p<0.001, Table 5-2). The majority of PSIFs were finally diagnosed as clinically non-serious 
(229/283, 80.9%). Serious final diagnoses occurred in 54/7,334 (0.7%) participants: 21 of the 
first 1,000 (2.1%) undergoing the systematic radiologist review protocol and 33 of the 6,334 
(0.5%) undergoing the radiographer flagging protocol (OR 4.2, 95% CI 2.4–7.4, p<0.001, 
Table 5-2). Radiographer flagging thus resulted in a higher proportion of PSIFs with serious 
final diagnoses than radiologist review (33/104 [31.7%] versus 21/179 [11.7%] respectively). 
The most common serious final diagnoses were tumours and vascular diseases (Table 5-3).   
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Table 5-1: Characteristics of the UK Biobank cohort and the imaged sub-cohort 
included in this study 
 Entire UK Biobank cohort 




Imaged UK Biobank 




Sociodemographics   
Agec   
  Median (IQR) 63 (55 – 68) 63 (56 – 68) 
Sexd   
  Female 273,224 (54.4) 3,804 (51.9) 
  Male 228,981 (45.6) 3,530 (48.1) 
Ethnicitye   
  White 472,493 (94.1) 7,023 (95.8) 
  Minority ethnicity groups 27,012 (5.4) 225 (3.1) 
TDIe    
  Median (IQR) -2.1 (-3.6 – 0.6) -2.5 (-3.9 – -0.5) 
Private healthcaree   
  Never used 120,934 (70.1) 5,377 (73.3) 
  Ever used 49,980 (29.0) 1,850 (25.2) 
Lifestyle   
Alcohole,f   
  None 19,942 (14.1) 848 (11.6) 
  Moderate 73,886 (52.3) 4,124 (56.2) 
  Hazardous 34,980 (24.8) 1,854 (25.3) 
  Harmful 9,084 (6.4) 376 (5.1) 
Smokinge   
  Never 273,400 (54.4) 4,350 (59.3) 
  Previous 172,980 (34.4) 2,575 (35.1) 
  Current 52,947 (10.5) 319 (4.3) 
Fruit and vegetable portions/daye,g  
  < 5 342,833 (68.3) 5,028 (68.6) 
  ≥ 5 144,064 (28.7) 2,141 (29.2) 
Days/week of moderate physical activitye,h  
  0-2 169,162 (33.7) 2,149 (29.3) 
  3-4 118,615 (23.6) 1,967 (26.8) 
  5-7 187,251 (37.3) 2,983 (40.7) 
Other factors   
Morbidityi   
  None 457,301 (91.1) 6,422 (87.6) 
  ≥1 condition 44,904 (8.9) 912 (12.4) 
BMIe,j   
  Underweight 2625 (0.5) 47 (0.6) 
  Normal 162,348 (32.3) 2,733 (37.3) 
  Overweight 212,064 (42.2) 3,061 (41.7) 
  Obese 122,228 (24.3) 1,454 (19.8) 




IQR = interquartile range, TDI = Townsend Deprivation Index (higher score indicates 
greater deprivation), BMI = body mass index 
a. Data collected at recruitment visit, unless otherwise indicated. 
b. Data collected at the imaging visit, unless otherwise indicated.  
c. Age on 30th April 2014, i.e. the start of the imaging study, for the entire cohort, 
and the imaged cohort.  
d. Sex data were only available from the recruitment visit. 
e. Data were missing for ethnicity (2,700/502,205 [0.5%], 86/7,334 [1.2%]), TDI 
(627/502,205 [0.1%], 0/7,334 [0.0%]), private healthcare use (1,694/172,608 
[1.0%, questions on private healthcare were introduced partway through the 
recruitment period on 29th April 2009, thus giving a smaller denominator], 
107/7,334 [1.5%]), alcohol (3,357/141,149 [2.3%, questions on subtypes of 
alcoholic drinks were introduced partway through the recruitment period on 
29th August 2009, thus giving a  smaller denominator], 132/7,334 [1.8%]), 
smoking (2,878/502,205 [0.6%], 90/7,334 [1.2%]), fruit and vegetable intake 
(15,308/502,205 [3.0%], 165/7,334 [2.2%]), physical activity (27,177/502,205 
[5.4%], 235/7,334 [3.2%]), BMI (2,940/502,205 [0.6%], 39/7,334 [0.5%]), from the 
whole UK Biobank cohort versus the imaged sub-cohort respectively. 
f. We calculated alcohol intake in units per week and categorised these using 
British Medical Association guidelines (women: moderate > 0 < 14, hazardous 
14–35, harmful > 35; men: moderate >0 < 21, hazardous 21–50, harmful > 50) 
(British Medical Association, 1995). 
g. We calculated portions of fruit and vegetable intake per day, and categorised 
these into five or more portions per day, or not (Cassidy et al., 2016). 
h. Participants were asked ‘in a typical week, on how many days did you do 10 
minutes or more of moderate physical activities like carrying light loads, 
cycling at normal pace (do not include walking)?’ (UK Biobank, 2017c).  
i. We calculate morbidity using an Elixhauser Index score (Elixhauser et al., 
1998; Quan et al., 2005) based on two-years of routinely collected Hospital 
Episode Statistics data, looking back from date of recruitment for the entire 
UK Biobank cohort, and the date of imaging for the imaged sub-cohort. 
Routinely collected health data are used to calculate payments for providers 
for services delivered for different conditions. The system for applying costs 
to healthcare services changed in 2012 (The National Casemix Office and 
Health and Social Care Information Centre, 2014), therefore the numbers of 
conditions coded in health records may not be directly comparable between 
the entire cohort, and the imaged cohort. 
j. We defined BMI categories as underweight, normal, overweight and obese as 
BMIs of <18.5, ≥18.5 < 25.0 , ≥ 25.0 < 30.0, ≥ 30.0  respectively (World Health 
Organisation, 2000). 
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Table 5-2: Odds ratios for potentially serious incidental findings (PSIFs) and serious 
final diagnoses comparing two protocols 
OR = odds ratio, CI = confidence interval, PSIFs = potentially serious incidental 
findings, MRI = magnetic resonance imaging, DXA = dual-energy X-ray absorptiometry 
a. Numerators are the number of participants with at least one PSIF per region. 
Multiple PSIFs occurred in four participants (who had two PSIFs each) under 
radiographer flagging, and in 33 (28 had two and five participants had three 
PSIFs each) under systematic radiologist review, giving a total of 325 PSIFs; 
therefore the sums of the body region PSIFs are greater than the 104 and 179 
participants with at least one PSIF respectively. No participant had more than 
one serious final diagnosis. 
b. Age- and sex-adjusted ORs for PSIFs and serious final diagnoses. 























PSIFs 179 (17.9) 104 (1.6) 13.3 (10.3-17.1) <0.001 
  Brain MRI 23 (2.3) 35 (0.6) 4.3 (2.5-7.3) <0.001 
  Cardiac MRI 81 (8.1) 29 (0.5) 19.7 (12.8-30.2) <0.001 
  Body MRI 83 (8.3) 27 (0.4) 21.3 (13.7-33.0) <0.001 
  DXA 14 (1.4) 16 (0.3) 5.8 (2.8-11.9) <0.001 
Serious final 
diagnoses 
21 (2.1) 33 (0.5) 4.2 (2.4-7.4) <0.001 
  Brain MRI 4 (0.4) 13 (0.2) 2.0 (0.7-6.2) 0.221 
  Cardiac MRI 13 (1.3) 10 (0.2) 8.5 (3.7-19.5) <0.001 
  Body MRI 3 (0.3) 5 (0.1) 4.1 (1.0-17.1) 0.056 
  DXA 1 (0.1) 5 (0.1) 1.3 (0.2-11.0) 0.818 
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Table 5-3: Final diagnoses of 325 potentially serious incidental findings detected in 
283 participants 
  









Serious final diagnoses   
Brain MRI Arachnoid cyst with 
hydrocephalus 
1 - 
 Arteriovenous malformation - 1 
 Cavernoma - 1 
 Meningioma requiring 
surgery 
1 3 
 Normal pressure 
hydrocephalus 
- 1 
 Pituitary tumour 2 4 
 Pleomorphic adenoma 
requiring surgery 
- 1 
 Vestibular schwannoma - 2 
    
Cardiac MRI Atrial fibrillation 1 1 
 Cardiomyopathy 2 3 
 Coronary heart disease 1 - 
 Heart block and LV 
impairment 
1 - 
 Lung tumour 3 - 
 Mesothelioma - 1 
 Myxoma - 1 
 Severe valve disease - 2 
 Thoracic aortic aneurysm 5 2 
    
Body MRI: 
Abdomen 
Abdominal aortic aneurysm > 
5 cm 
1 1 
Colonic tumour - 1 
 Gastrointestinal stromal 
tumour 
1 - 
 Pancreatic tumour 1 1 
 Renal tumour - 2 
    
DXA Osteoporotic crush fracture 1 5 
All modalities: serious final diagnoses 21 33 

















Non-serious final diagnoses 
  
Brain MRI Already known diagnosis 1 3 
 Benign cyst/lesion 15 10 
 Hydrocephalus (not serious) - 2 
 Suspected lesion not 
confirmed 
3 3 
    
Cardiac MRI Already known cardiac 
diagnosis 
7 5 
 Already known lung 
diagnosis 
2 1 
 Already under investigation - 1 
 Cardiac diagnosis – not 
serious 
8 8 
 Lung diagnosis – not serious 28 2 
 Other non-serious diagnosis 10 1 





Abdominal aortic aneurysm < 
5 cm 
2 1 
Already known diagnosis 4 3 
 Benign lesion (e.g. cyst) 57 14 
 Other non-serious diagnosis 4 - 
 Suspected lesion not 
confirmed 
13 2 
    
Body MRI: Leg Already known diagnosis 1 - 
 Bone/soft tissue diagnosis – 
not serious 
5 - 
 Suspected lesion not 
confirmed 
2 - 
    
DXA Already known diagnosis 5 5 
 Non-serious diagnosis 5 3 
 Suspected lesion not 
confirmed 
2 2 
All modalities: non-serious final diagnoses 192 67 
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MRI = magnetic resonance imaging, LV = left ventricular, DXA = dual-energy X-ray 
absorptiometry 
- = zero 
 
The two doctors agreed on the initial classification of final diagnoses in 270/283 (95.4%) of 
cases, and readily resolved the 13 cases of disagreement through discussion. 
Systematic radiologist review generated higher proportions of PSIFs on all imaged body 
regions (OR range 4.3–21.3, all p<0.001, Table 5-2) compared to radiographer flagging. 
Radiologists more commonly detected PSIFs on cardiac (8.1%) and body MRI (8.3%) 
compared to brain MRI (2.3%) or DXA (1.4%), whereas radiographer flagging generated 
similar proportions of PSIFs across body regions (range 0.3–0.6%, Table 5-2). Serious final 
diagnoses occurred most commonly on cardiac MRI assessed by systematic radiologist 
review (13/1,000, 1.3%, Table 5-2). 
5.2.4.3 Factors associated with PSIFs and serious final diagnoses 
Across the relatively narrow age range of the included participants, older age was associated 
with increased odds of PSIFs and of serious final diagnoses under both protocols, albeit not 
statistically significant for serious final diagnoses under systematic radiologist review (sex-
adjusted ORs [95% CI] for oldest [67–79 years] versus youngest [44–58 years] participants 
for PSIFs and serious final diagnoses respectively: 1.59 [1.07–2.38] and 2.79 [0.86–9.0] for 














Uncertain final diagnoses 
  
Brain MRI Lesion, unclear nature - 4 
   
Cardiac MRI Lung consolidation, unclear 
nature 
1 1 





Cysts, unclear nature - 2 
    
DXA Crush fracture T11, unclear 
relevance 
1 - 
 Fractures, unclear cause - 1 
All modalities: uncertain final diagnoses 4 8 
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radiographer flagging) (Figures 5-2 and 5-3). Of the participants with PSIFs, those with 
serious final diagnoses were older than those with non-serious final diagnoses (median ages 
[range minimum-maximum] in years: 66 [50–76] versus 64 [44–76] respectively, p=0.021). 
Of participants assessed by radiographer flagging, overweight participants had reduced odds 
of serious final diagnoses compared to those of normal or underweight BMI (age- and sex-
adjusted OR 0.21, 95% CI 0.08–0.58, p=0.003, Figure 5-3), but the number of overweight 
participants was very small (n=5). 
No significant associations were found between PSIFs or serious final diagnoses and any 
other investigated factor for participants assessed by either PSIFs protocol (Figures 5-2 and 
5-3). 
  




Figure 5-2. Age- and sex-adjusted odds ratios for potentially serious incidental 
findings (PSIFs) by PSIFs protocol.  
PSIFs = potentially serious incidental findings, OR = odds ratio, CI = confidence 
interval, TDI = Townsend Deprivation Index, BMI = body mass index.  
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Circles are weighted by the proportion of participants within a category. 
a. Age- and sex-adjusted ORs, except age tertiles which are adjusted for sex 
only, and sex which is adjusted for age only. 
b. P-value from Wald test. 
c. Data were missing for ethnicity (13/1,000 [1.3%], 73/6,334 [1.2%]), TDI (1/1,000 
[0.1%], 3/6,334 [<0.0%]), private healthcare use (15/1,000 [1.5%], 92/6,334 
[1.5%]), alcohol (20/1,000 [2.0%], 112/6,334 [1.8%]), smoking (12/1,000 [1.2%], 
78/6,334 [1.2%]), fruit and vegetable intake (27/1,000 [2.7%], 138/6,334 [2.2%]), 
physical activity (35/1,000 [3.5%], 200/6,334 [3.2%]) and BMI (5/1,000 [0.5%], 
34/6,334 [0.5%]), for participants assessed by systematic radiologist review 
and by radiographer flagging respectively. 
d. We calculated alcohol intake, fruit and vegetable intake, physical activity, 
morbidity and BMI as described in the footnotes to Table 5-1. 
  




Figure 5-3. Age- and sex-adjusted odds ratios for serious final diagnoses stratified by 
potentially serious incidental findings (PSIFs) protocol 
OR = odds ratio, CI = confidence interval, TDI = Townsend Deprivation Index, BMI = 
body mass index.  
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Circles are weighted by the proportion of participants within a category. 
a. Age- and sex-adjusted ORs, except age tertiles which are adjusted for sex 
only, and sex which is adjusted for age only. 
b. P-value from Wald test. 
c. Data were missing as described in Figure 5-2, footnote c.   
d. We calculated alcohol intake, fruit and vegetable intake, physical activity, 
morbidity and BMI as described in the footnotes to Table 5-1. 
 
5.2.5 Discussion 
Systematic radiologist review of images resulted in approximately 13 times more PSIFs, and 
four times more serious final diagnoses than the radiographer flagging protocol; these effect 
sizes are larger than those of any other risk factor assessed for association with either PSIFs 
or serious final diagnoses. Most (up to 80%) PSIFs did not turn out to represent serious 
disease. The odds of PSIFs and of serious final diagnoses increased with age, regardless of 
PSIFs protocol. There were no clear associations between either PSIFs or serious final 
diagnoses and sex, ethnicity, socio-economic deprivation, use of private healthcare, alcohol 
intake, diet, physical activity, smoking status, BMI or morbidity among participants assessed 
using either PSIFs protocol. 
Our study confirms and updates our previous findings from the first 1,000 imaged UK 
Biobank participants (Gibson et al., 2018): compared to systematic radiologist review, 
radiographer flagging resulted in substantially fewer participants with PSIFs and a higher 
proportion of these had serious final diagnoses. We also confirm the findings of the above-
mentioned smaller cohort (Gibson et al., 2018), that most PSIFs do not turn out to represent 
serious disease. Previous studies, mostly of brain MRI, found that PSIFs were associated 
with increased age (Brugulat-Serrat et al., 2017; Hartwigsen et al., 2010; Illes et al., 2004b; 
Tsushima et al., 2005), but not clearly associated with sex (Bos et al., 2016; Brugulat-Serrat 
et al., 2017; Haberg et al., 2016; Illes et al., 2004b; Kumar et al., 2008; Morin et al., 2009; 
Sandeman et al., 2013; Tsushima et al., 2005; Yue et al., 1997). We have further confirmed 
these findings in participants undergoing multi-modal imaging of multiple body regions, and 
shown this to be independent of the IFs protocol. Previous studies did not demonstrate any 
associations with PSIFs and medical history of cardiac disease (Tsushima et al., 2005), 
psychotic episodes (Sommer et al., 2013) or human-immunodeficiency virus (Loy et al., 
2015). Given the varying nature of PSIFs (tumours, aneurysms etc.), a common biological 
risk factor seems unlikely. Instead, we captured morbidity using the Elixhauser Index, which 
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comprises 30 conditions (Elixhauser et al., 1998; Quan et al., 2005). There was no 
convincing association between morbidity and either PSIFs or serious final diagnoses, but 
sparse data on both of these outcomes and exposure data on morbidity (which may be 
secondary to healthy volunteer bias and a relatively short period of retrospective capture 
within linked hospital admissions data, chosen to limit any bias that may arise from changes 
in healthcare record coding practices in 2012 (The National Casemix Office and Health and 
Social Care Information Centre, 2014)) may have attenuated any true association. 
Furthermore, different definitions of morbidity may well produce different results. 
Large studies are needed to investigate the factors associated with PSIFs and with serious 
final diagnoses, as these outcomes are relatively rare, particularly under a protocol of 
radiographer flagging. Our study is the largest so far to investigate the factors associated 
with PSIFs, and the first to investigate factors associated with serious final diagnoses, in 
unselected, healthy participants undergoing MRI of any body region. Our sample is 
approximately 25% larger than the largest previous study of factors associated with PSIFs 
detected on brain MRI (N=5,800) (Bos et al., 2016), and 50 times larger than the largest 
previous such study of multi-region MRI (N=148) (Morin et al., 2009). We systematically 
followed up 50% more participants for data on final diagnoses compared to the largest 
previous study (N=188) (Bos et al., 2016). Despite the size of our study, we still may have 
missed associations with PSIFs or final diagnoses due to sparsity of these outcomes within 
our cohort and small numbers within some exposure categories (e.g. minority ethnicity 
groups). Healthy volunteer selection bias likely affects the UK Biobank cohort, as 
participants are less deprived than non-participants and less likely to be obese, smoke, drink 
alcohol daily or have self-reported medical conditions compared to the general population 
(Fry et al., 2017). The imaged cohort are then further selected, with lower proportions of 
people having more ‘unhealthy’ lifestyles. As with all epidemiological studies which use 
self-reported data, our data on exposures may be further limited by reporting bias; 
participants may have inaccurately reported alcohol intake, smoking habits, physical activity 
and diet. The apparently reduced odds of serious final diagnoses in overweight participants 
may be spurious, secondary to data sparsity of both the outcome and the exposure. The 
direction of an association (if any) between increased BMI and PSIFs is unclear. The 
associations between increased BMI and certain cancers (Bhaskaran et al., 2014) may lead to 
increased risk of PSIFs and serious final diagnoses; alternatively, risks may be reduced if 
people with increased BMI tend not to complete all MRI sequences, or imaging of all body 
regions.  
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Our classifications of ‘serious’ final diagnoses are based on clinical judgement using data 
collected up to six months after feedback of a PSIF. Reaching final diagnoses of some PSIFs 
may take longer (Gibson et al., 2018). Feedback of PSIFs may impact on non-medical 
domains such as emotional wellbeing, insurance and finances and work and activities, 
regardless of the health-related severity of the final diagnosis (Gibson et al., 2018). 
‘Severity’ of a final diagnosis is therefore inherently difficult to judge, though we did show 
good agreement between two independent physicians’ classifications using a medical-based 
definition. 
By deliberately focusing our study on participants with PSIFs and serious final diagnoses our 
results inform on factors associated with findings which are likely to generate clinical 
assessment, and those with serious health consequences, respectively. While our cohort is 
not representative of the general population, exposure-outcome associations can be 
generalised to other populations (Collins, 2012; Fry et al., 2017; Manolio and Collins, 2010), 
to inform the design of appropriate IFs handling policies, which are required by major 
funders (Farrar and Savill, 2014), and of materials to facilitate the informed consent of 
potential research participants.  
Compared to sociodemographic, lifestyle and health-related factors, the protocol for 
identifying PSIFs protocol has by far the largest influence on the generation of PSIFs and 
serious final diagnoses. As the majority of PSIFs do not turn out to be serious, but feedback 
generates clinical assessments and negative impacts on emotional wellbeing, insurance and 
finances and work and activities (Gibson et al., 2018), our study suggests that researchers 
have the opportunity to greatly influence (for better or worse) the potential harms done to 
apparently asymptomatic research volunteers. There remain many unanswered questions on 
the impacts of different methodologies to feedback research results to participants (Wong et 
al., 2018); to inform future policy design, evaluations of the impacts of different protocols 
are paramount. 
PSIFs are rare, and few are finally diagnosed as serious disease; hence large studies are 
needed to investigate the associated factors. This study represents the largest such cohort so 
far. Furthermore, since 100,000 participants will complete the UK Biobank imaging 
assessment over the next few years, it will in due course be possible to update these analyses 
with a substantially larger sample size, providing more comprehensive and statistically better 
powered estimates of the factors associated with PSIFs and with serious final diagnoses. 
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5.2.6.1 Acknowledgements 
Ms Regina Prigge (Usher Institute of Population Health Sciences and Informatics, University 
of Edinburgh,) and Dr Sophie Cassidy (Clinical Exercise Research Group, Institute of 
Cellular Medicine, Newcastle University) kindly provided advice on using UK Biobank data 
to calculate alcohol intake and portions of fruit and vegetables respectively. This work was 
conducted on behalf of the UK Biobank Imaging Working Group.* 
*Members of the UK Biobank Imaging Working Group 
Imperial College London 
Prof Paul Matthews (Edmond and Lily Safra Chair and Head of Brain Sciences) 
Dr Tony Goldstone (Senior Clinical Research Fellow) 
Newcastle University 
Prof Andrew Blamire (Professor of Magnetic Resonance Physics) 
Queen Mary University of London 
Prof Steffen Petersen (Professor of Cardiovascular Medicine) 
University of Edinburgh 
Prof Cathie Sudlow (Chair of Neurology and Clinical Epidemiology) 
Dr Lorna Gibson (Clinical Research Fellow and Specialty Trainee in Clinical Radiology) 
University of Manchester 
Prof Alan Jackson (Professor of Radiology) 
University of Oxford 
Prof Naomi Allen (Associate Professor in Epidemiology) 
Prof Sir Rory Collins (BHF Professor of Medicine and Epidemiology) 
Prof Paul Leeson (Professor of Cardiovascular Medicine) 
  Chapter 5 
202 
 
Prof Karla Miller (Professor of Biomedical Engineering) 
Prof Stefan Neubauer (Professor of Cardiovascular Medicine) 
Prof Stephen Smith (Professor of Biomedical Engineering) 
University of Southampton 
Prof Nicholas Harvey (Professor of Rheumatology and Clinical Epidemiology) 
University of Westminster 
Prof Jimmy Bell (Professor) 
5.2.6.2 Data availability 
Due to the confidential nature of questionnaire responses and clinical information on 
participants with potentially serious incidental findings, it is not possible to publicly share all 
of the data on which our analyses were based, but summaries of all relevant data are included 
in the manuscript, and our statistical analyses code is provided online for researchers to 
understand our analytical approach. 
Importantly, any bona fide researcher can apply to use the UK Biobank resource, with no 
preferential or exclusive access, for health related research that is in the public interest. 
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This chapter confirmed the findings of Chapter 4 (Gibson et al., 2018), showing that 
systematic radiologist review resulted in 13 times more PSIFs (179/1,000 [17.9%] versus 
104/6,334 [1.6%]; age- and sex-adjusted odds ratio [OR] 13.3 [95% CI 10.3–17.1]) and four 
times more serious final diagnoses (OR 4.2 [95% CI 2.4–7.4]) than radiographer flagging. 
Furthermore, a lower proportion of PSIFs detected by radiologists resulted in serious final 
diagnoses compared to radiographer flagging (21/179 [11.7%] versus 33/104 [31.7%]). This 
chapter also confirms the findings of the systematic review presented in Chapter 2 and the 
results from a smaller cohort presented in Chapter 4 (Gibson et al., 2018): most PSIFs turn 
out not to represent serious disease. 
The influence of PSIFs protocol was the largest by far of any factor investigated for an 
association with either PSIFs or serious final diagnoses. We confirmed our findings from our 
systematic review (Chapter 2), that age is (and sex is not) associated with PSIFs. We further 
demonstrated that age is (and sex is not) associated with serious final diagnoses. In addition, 
we found no clear evidence of associations between either PSIFs or serious final diagnoses 
with ethnicity, deprivation, use of private healthcare, alcohol intake, diet, physical activity, 
smoking status, BMI or morbidity. 
While this study was the largest so far to investigate the factors associated with PSIFs and 
the first to investigate the factors associated with serious final diagnoses, we still may have 
missed significant associations due to lack of power, healthy volunteer bias and 
misclassification of exposure variables. The outcomes of PSIFs and serious final diagnoses 
are rare, and even more so under a PSIFs protocol of radiographer flagging, and as such, 
even larger studies are needed in order to have the statistical power to detect significant 
associations. UK Biobank participants are largely healthier than the general population (Fry 
et al., 2017), and the imaged sub-cohort are further selected and healthier than the broader 
UK Biobank cohort. In addition, participants may inaccurately report their alcohol intake, 
smoking habits, physical activity and diet. Limited data on exposures, due to the 
combination of healthy volunteer and reporting bias, therefore may have attenuated 
associations toward the null. 
Ongoing long-term systematic follow up of imaged UK Biobank participants will enable 
further investigation of the factors associated with PSIFs and serious final diagnoses in 
future. As PSIFs protocol had by far the largest effect on the prevalence of PSIFs and serious 




IFs policies which minimise the unnecessary impacts resulting from feedback of PSIFs 
which turn out not to be serious. We explored the impact of feedback of PSIFs in Chapter 4 
in terms of the clinical assessments generated and impacts on participants’ emotional 
wellbeing, insurance and finances and work and activities. The following chapter will build 
further on this work by evaluating the economic impact of feedback of PSIFs on hospital 
services.
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Chapter 6 Economic impact of potentially 
serious incidental findings on 
hospital services  
6.1 Introduction 
Chapter 1 outlined the challenges of studying the economic impact of feedback of incidental 
findings (IFs). Due to the range of different types of IFs that can occur across body regions, 
care will be required from many different health services, and a comprehensive assessment 
of costs will therefore be complex. While a number of studies have been conducted (Bendix 
et al., 2011; Flicker et al., 2008; Gluecker et al., 2003; Goehler et al., 2014; Lee et al., 2010; 
Machaalany et al., 2009; Maizlin et al., 2007; Mutneja et al., 2017; Pickhardt et al., 2008; 
Schramm et al., 2016; Veerappan et al., 2010; Wagner et al., 2002), the majority have 
focused on patient populations undergoing single-region clinical computed tomography 
(CT), and most were conducted in non-UK health systems, which limits their generalisability 
to apparently asymptomatic people undergoing multi-region research magnetic resonance 
imaging (MRI) within the UK. 
Our systematic review (Chapter 2) demonstrated that there are limited published data on the 
long-term systematic follow-up of unselected apparently asymptomatic participants with IFs, 
and that which is available does not enable the use and costs of health services during 
follow-up to be quantified. Similarly, while UK Biobank perform long-term systematic 
follow-up of their participants with potentially serious IFs (PSIFs), the follow-up surveys do 
not enable quantification of clinical assessments (i.e., binary data are collected on whether or 
not a participant saw a specialist doctor, but not on the number of outpatient appointments 
(Chapter 4) (Gibson et al., 2018)). Without quantification of the types of follow-up, costs 
cannot be attached. The impact of feedback of PSIFs detected on research MRI of apparently 
asymptomatic volunteers on use or costs of publicly-funded UK health services is still not 
clearly understood. 
However, simply quantifying the health service uses and costs associated with the clinical 
assessment of PSIFs, or with serious final diagnoses, will be of limited value. UK Biobank 
participants are older adults, and as such will already use health services for any current 
health concerns, symptoms or diagnoses. It is not known if PSIFs, or serious final diagnoses, 
result in any significant increase in use or cost of health services (or indeed which services 
bear the majority of these burdens), either compared to such participants’ uses and costs 
before they received feedback of a PSIF, or to control participants without PSIFs.  
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The UK Biobank cohort offers a unique opportunity to study the economic impact of PSIFs 
given the availability of linked healthcare data for participants with and without PSIFs, 
which covers the time periods both before and after feedback of PSIFs. In addition, the UK 
Biobank participants with PSIFs are systematically followed-up through participant and GP 
surveys to collect data on final diagnoses. The majority of PSIFs turn out not to be serious, 
and as such any follow-up may be deemed unnecessary (Chapter 2, Chapter 4) (Gibson et al., 
2018). Understanding the relative impacts on health services of subgroups of participants 
with serious and with non-serious final diagnoses will inform judgements on the benefits and 
harms of feedback, and in turn influence the design of policies to handle IFs.  
This chapter describes a study which used data from the UK Biobank Imaging Study to 
assess the NHS hospital costs generated by feedback of PSIFs. We used data from cases with 
PSIFs and controls without, both before and after feedback of PSIFs, to conduct four-way 
comparisons of the hospital contacts and costs generated by: cases after versus controls after 
feedback; cases after versus cases before feedback; cases before versus controls before 
feedback; controls after versus controls before feedback. We explored potential explanations 
for any observed differences in costs. As hospital data linkages were complete, and primary 
care data linkages were incomplete for UK Biobank participants at the time of this study, the 
comparisons are of hospital use and costs. 
This study manuscript has been edited by co-authors in preparation for submission to a 
journal; the current version of the draft manuscript is included in full in Section 6.2, and 
supplementary materials are included in full in Section 6.3.  
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6.2 Use and cost of hospital services by UK Biobank 
participants with potentially serious incidental 
findings: a case-control and before-after study 
utilising linked English Hospital Episode 
Statistics data from 2013-2016 
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Potentially serious incidental findings (PSIFs) on research imaging lead to clinical 
assessment in almost all cases. Previous studies have been small, or focused on patient 
populations, or non-UK health services. We assessed the economic impact on UK hospital 
services of feeding back PSIFs to population-based apparently asymptomatic participants of 
the UK Biobank Imaging Study. 
Methods 
We matched (by age, sex, imaging date and morbidity score) 179 cases with PSIFs on either 
magnetic resonance imaging or dual-energy X-ray absorptiometry to controls without. We 
attached National Reference Costs to linked Hospital Episode Statistics inpatient, outpatient, 
accident and emergency and critical care datasets from 2013-2016. Using data from cases 
and controls during the year before and after feedback of a PSIF, we conducted four-way 
comparisons of hospital contacts and costs using Wilcoxon signed rank tests, and proportions 
with ≥ 1 hospital contact using McNemar’s tests, and plotted cumulative costs. 
Results 
There were no differences in hospital contacts or costs between cases and controls before 
feedback, or between controls before and after feedback of a PSIF. Following feedback, 144 
(80.5%) cases, and 94 (52.5%) controls used hospital services; cases’ median numbers of 
hospital contacts and median costs were significantly higher compared to controls, and to the 
year before (hospital contacts: three versus one and versus one; costs: £522 versus £114 and 
versus £128 [all p<0.001]). Rates of cases’ cumulative costs began to increase approximately 
30-60 days following feedback of a PSIF. A year after feedback of a PSIF, total cases’ 
hospital costs (£431,114) were higher than controls’ (£147,817, 2.9-fold) and cases’ costs the 
year before (£167,434, 2.6-fold); these increases were greater in serious than non-serious 
cases (10.5-fold, 1.9-fold respectively). Most PSIFs were non-serious (158/179 [88%]) and 
non-serious cases generated greater total absolute costs than serious cases (£239,021 versus 
£192,093). These patterns of costs persisted over longer follow-up. After feedback of a PSIF, 
the majority of cases’ cost and service use impacts were borne by inpatient (68.3%) and 
outpatient services (82.3%) respectively. 
 




After feedback of a PSIF, research volunteers use substantially more hospital services than 
controls, and compared to the year before; the majority of cost and service impacts are borne 
by inpatient and outpatient services respectively. Absolute cost and service impacts are 
higher in cases with non-serious, rather than serious final diagnoses, as most PSIFs represent 
non-serious disease; avoidance of unnecessary feedback through the design of appropriate 
PSIFs policies would enable researchers and policymakers to minimise unwarranted impacts 
on publicly-funded healthcare services. 
  




While imaging is increasingly used to collect data for research, it may generate incidental 
findings (IFs) unrelated to the aim of the study (Wolf et al., 2008). IFs vary widely in the 
clinical severity of their associated final diagnosis, and it is of limited value to feed back 
clearly non-serious IFs to individuals and their healthcare team. We therefore focus on 
potentially serious IFs (PSIFs), i.e. findings which indicate the possibility of a condition 
which, if confirmed, would carry a real prospect of seriously threatening life span, or of 
having a substantial impact on major body functions or quality of life (Gibson et al., 2018).  
Unlike clinical imaging, research imaging is usually not optimised to accurately diagnose an 
abnormality. Hence, feedback of PSIFs generates some form of clinical assessment in almost 
all cases in order to resolve diagnostic uncertainty and determine the appropriate clinical 
management (Gibson et al., 2018; Gibson et al., 2017b). Any structural disease affecting any 
body region (such as a tumour or an aneurysm) may be detected as a PSIF. As such, people 
with PSIFs may require care from a broad range of health services, including primary care, 
outpatient specialty appointments, imaging and other diagnostic services, invasive 
procedures and/or hospital admission (Gibson et al., 2018; Gibson et al., 2017b). This makes 
assessment of the economic impact of feedback of PSIFs on health services challenging.  
Our knowledge of the economic impact of IFs is mostly informed by studies performed in 
the USA, the results of which may not be generalisable to the UK or other socialised health 
systems (Bendix et al., 2011; Flicker et al., 2008; Gluecker et al., 2003; Goehler et al., 2014; 
Lee et al., 2010; Machaalany et al., 2009; Maizlin et al., 2007; Morgan et al., 2015; 
Pickhardt et al., 2008; Veerappan et al., 2010; Wagner et al., 2002). Furthermore, isolated 
data on the costs of clinical assessment of people with PSIFs may be of limited usefulness to 
policymakers without information on the usual costs of healthcare for comparison; such 
context is paramount to enable judgments of the significance of any financial impact on 
health services. Most PSIFs turn out not to represent serious disease (Gibson et al., 2018), so 
the resulting costs generated during investigation to determine their non-serious nature may 
be deemed in retrospect to have been unnecessary. Empirical data on the economic impact of 
feedback of PSIFs on publicly-funded healthcare services (and the relative impacts generated 
by cases with serious or with non-serious final diagnoses) will inform judgments of the 
benefits and harms of feedback of PSIFs, and pragmatic approaches to the design of policies 
for handling imaging IFs. 
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The UK Biobank Imaging Study presents a key opportunity to investigate the economic 
impact of feedback of PSIFs in research volunteers. Brain, cardiac and body MRI, carotid 
Doppler ultrasound and dual-energy X-ray absorptiometry imaging of 100,000 largely 
asymptomatic adults already participating in UK Biobank is ongoing (over 27,000 have been 
imaged by September 2018 (UK Biobank, 2018c)). Linked routinely collected UK National 
Health Service (NHS) hospital data are available for all UK Biobank participants (Matthews 
and Sudlow, 2015) as well as systematic follow-up data from participant and general 
practitioner (GP) surveys to determine the final diagnoses of participants with PSIFs (Gibson 
et al., 2018). 
Using data from participants in the UK Biobank Imaging Study, we aimed to assess the 
impact on NHS hospital services in terms of hospital contacts (which we define as inpatient 
admissions, outpatient appointments, accident and emergency care attendances and critical 
care admissions) and associated costs generated by feedback of PSIFs. To do this, we used 
data from cases with PSIFs (and subgroups with serious and non-serious final diagnoses) and 
controls without PSIFs, both before and after feedback of PSIFs, to conduct four-way 
comparisons of the hospital contacts and costs generated by: cases after versus controls after 
feedback; cases after versus cases before feedback; cases before versus controls before 
feedback; and controls after versus controls before feedback. We aimed to explore potential 
explanations for any observed differences in costs between groups. As hospital data linkages 
were complete, and primary care data linkages were incomplete for UK Biobank participants 
at the time of this study, this study focuses on hospital use and costs. 
6.2.3 Methods 
We prepared this manuscript according to RECORD guidelines (Benchimol et al., 2015). UK 
Biobank provided all imaged participants with written information about the imaging study 
and the UK Biobank imaging IFs protocol (UK Biobank, 2016). All participants provided 
written consent to take part in the imaging study and for UK Biobank to feed back any PSIFs 
to them and their GP. UK Biobank obtained specific ethics approval for the imaging study, 
and for evaluation of the PSIFs protocol (Research Ethics Committee reference numbers: 
11/NW/0382; 16/NW/0274).  
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6.2.3.1 UK Biobank Imaging Study  
UK Biobank is a population-based prospective cohort study that recruited half a million 
participants between 2006 and 2010 from England, Scotland and Wales. Between April and 
October 2014, UK Biobank invited participants living within approximately 120 km of the 
imaging centre in Stockport to the first phase of the UK Biobank Imaging Study (Gibson et 
al., 2018; UK Biobank, 2015e). Participants with metal implants, penetrating metal injury 
and non-removable metallic items were excluded, as were those likely to have difficulties 
completing the imaging, e.g. people with claustrophobia (Figure 6-1) (Gibson et al., 2018; 
UK Biobank, 2015e).  
 
  





Imaged by 2nd October 2014 and 
images reviewed systematically by 
radiologists for PSIFsa 
n=1,000 
Invited to imaging 
n=4,890 
 
Did not respond n=2,712 
Declined invitation n=453 
Ineligible after pre-screen 
n=428 
Plan to undergo imaging at a 
future appointment n=297 
179 participants with PSIFs (cases) 







































Cases matched to controls on:b 
 Age within five years 
 Sex 




Included in this study: 
179 cases with ≥ 1 PSIF  
179 matched controls without a PSIF 
Figure 6-1: Participant flowchart 
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PSIFs = potentially serious incidental findings 
a. Radiologists systematically reviewed 942 brain, 948 cardiac and 944 body 
magnetic resonance imaging (MRI) scans and 997 dual-energy X-ray 
absorptiometry (DXA) scans from the first 1,000 imaged UK Biobank 
participants for PSIFs. PSIFs were defined as those ‘indicating the possibility 
of a condition which, if confirmed, would carry a real prospect of seriously 
threatening life span, or of having a substantial impact on major body 
functions or quality of life (Gibson et al., 2018).’  
b. Cases were matched to controls on: age and sex (which may influence health 
and access to health services); date of imaging within two weeks (to reduce 
differences in lengths of follow-up within Hospital Episode Statistics (HES) 
data which may bias calculations of hospital service use and cost); and 
morbidity (calculated using a binary Elixhauser Index score (Elixhauser et al., 
1998; Quan et al., 2005) of 0 or ≥ 1 using HES data from the two years before 
the date of imaging, to reduce the risk of bias which may occur following 
changes in health resource group coding structures in 2012 (The National 
Casemix Office and Health and Social Care Information Centre, 2014). 
 
At the imaging visit, participants underwent brain, heart and body MRI, whole-body dual-
energy X-ray absorptiometry (DXA) and carotid Doppler ultrasound (UK Biobank, 2015a; b; 
c; d; 2017b). Carotid Doppler ultrasound was deemed unlikely to generate PSIFs as the 
clinical relevance of asymptomatic carotid stenosis is not well established, and extra-carotid 
abnormalities were not likely to be relevant as UK Biobank sonographers are trained in 
vascular Doppler US only (Gibson et al., 2018); therefore carotid Doppler ultrasound was 
not included in this study. 
6.2.3.2 UK Biobank PSIFs protocol and classifications of final diagnoses  
Images from the first 1,000 participants were reviewed systematically by radiologists, who 
detected PSIFs (most commonly tumours and aneurysms) in 179 participants (Gibson et al., 
2018). UK Biobank sent two surveys to participants with PSIFs, six weeks and six months 
after giving feedback, and sent surveys and requests for copies of relevant clinical 
correspondence to their GPs six months after feedback. The surveys collect data on follow-
up and final diagnoses of PSIFs (UK Biobank, 2018b); the classification of these and 
summary diagnoses for these 179 participants have been published previously (Gibson et al., 
2018). In brief, a consultant physician and an experienced specialty trainee in clinical 
radiology independently classified final diagnoses as either: serious (if they were likely to 
threaten life span, or have a substantial impact on quality of life or major body function); not 
serious (if this was not the case or if available data suggested that the diagnosis was already 
known); or uncertain (if there remained insufficient data to classify them as serious or not). 
We used the most serious final diagnosis to classify participants with more than one PSIF 
(Gibson et al., 2018). 
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6.2.3.3 Matching of cases and controls 
We matched each of the 179 cases with PSIFs to one of the available 821 controls without a 
PSIF on age (within five years), sex, date of imaging (within two weeks, to reduce bias 
generated by differing lengths of follow-up period) and morbidity score (Figure 6-1). We 
defined the latter by calculating Elixhauser Index scores (Elixhauser et al., 1998; Quan et al., 
2005) using linked Hospital Episode Statistics (HES) inpatient data covering the two years 
prior to the date of imaging (The National Casemix Office and Health and Social Care 
Information Centre, 2014). We matched participants on a binary score (0 or ≥ 1), as the 
majority of participants did not have a health condition listed in the Elixhauser Index.  
6.2.3.4 Obtaining linked HES data and attaching costs 
HES data were linked at individual-level to UK Biobank participants’ data by NHS Digital 
matching algorithms; the quality of matching was assessed using matched rank scores (UK 
Biobank, 2014b). NHS Digital de-duplicated records, and both NHS Digital and UK 
Biobank checked and cleaned HES data to optimise the availability of valid, correctly 
formatted codes (HES Data Quality Team, 2016a; b; UK Biobank, 2013b). However, some 
invalid codes and duplicate records could still exist. We obtained linked HES admitted 
patient care (i.e. inpatient), outpatient, accident and emergency and critical care (together 
termed ‘hospital’) data from financial years 2013-2016 from the UK Biobank linked 
healthcare datasets for all cases and controls. We double-checked for duplicate records using 
NHS Digital methods (HES Data Quality Team, 2016b), and based on the assumption that 
no patient had multiple outpatient appointments on the same date with the same consultant 
within the same specialty after being referred on the same date by the same GP; we 
amalgamated such duplicate records and retained the maximum number of available 
treatment and diagnosis codes.  
To attach costs to each record, we first generated currency codes (known as healthcare 
resource groups [HRGs]), using HRG4+ 2016-2017 Reference Costs Grouper software 
(NHS Digital, 2017b) (NHS Digital, UK) and NHS Digital methodology (NHS Digital, 
2017a). Errors generated by the HRG4+ 2016-2017 Reference Costs Grouper software due 
to ICD-10 codes which were subsequently deleted following the introduction of the 5th 
edition of ICD-10 (n=34 inpatient records, 21 cases, 13 controls) were checked by a doctor 
(6-years qualified), who chose an appropriate updated 5th edition ICD-10 code from lists 
provided by NHS Digital blind to cost and PSIF final diagnosis (The National Casemix 
Office and NHS Digital, 2017). There was insufficient diagnostic information available for 
one control inpatient record, which was excluded from analyses as a HRG could not be 
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generated. Second, we attached national average unit costs to HRGs using the National 
Schedule of Reference Costs 2016-2017 (NHS Improvement, 2017) to enable comparisons 
across the different years of data (i.e. 2013-2016).  
None of the included cases or controls had died, moved outside of England or withdrawn 
from UK Biobank prior to March 31st 2016, so we censored HES data follow up for all cases 
and controls at this date. 
6.2.3.5 Statistical analyses 
We calculated the frequency distributions of baseline characteristics between cases with 
PSIFs and controls without. We defined the date of feedback of PSIFs as one day after UK 
Biobank sent feedback letters to cases via first class postal mail. For these analyses, we 
defined each control’s ‘date of feedback’ as the same as their matched case. We tested for 
normal distributions of continuous cost variables by visual inspection of graphed data and 
Kolmogorov-Smirnov goodness-of-fit tests; substantial proportions of both cases and 
controls had no costs, and given this skewed data we conducted comparisons using non-
parametric statistical analyses (Min and Agresti, 2002).  
Using data from cases and controls from the year before and the year after feedback of a 
PSIF, we performed four-way comparisons of: 1) cases after versus controls after feedback; 
2) cases after versus cases before feedback; 3) controls after versus controls before feedback; 
and 4) cases before versus controls before feedback. In addition, we compared hospital costs 
between cases and controls from the entire available follow-up period after feedback of a 
PSIF. We used McNemar’s tests to compare proportions of discordant case-control and 
before-and-after feedback pairs with 0 versus ≥ 1 hospital contacts. We used related-samples 
Wilcoxon signed rank tests to compare the numbers of hospital contacts, and hospital costs, 
between groups. We repeated all analyses for subgroups of cases with serious and non-
serious final diagnoses. We considered p-values of <0.05 to be significant.  
We used SPSS version 22 for analyses.  
6.2.4 Results 
6.2.4.1 Cases and controls 
Of the 179 included cases, 21 (11.7%) had serious final diagnoses (mostly suspected tumours 
and aneurysms) and 158 (88.3%) had non-serious final diagnoses (Gibson et al., 2018). 
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Cases and controls were sufficiently matched on age (median age of 64, interquartile range 
[IQR] 57–69 years), sex (99/179 [55.3%] women), duration of available follow-up (median 
number of days 575 [IQR 551–623]) and on a binary measure of morbidity (32/179 [17.9%] 
had at least one Elixhauser Index health condition) (Supplementary Tables 6-1 and 6-2). 
Both groups were predominantly white, had not used private healthcare, drank alcohol in 
moderation, were non-smokers, and were either of normal body mass index (BMI) or 
overweight. A higher proportion of controls ate five or more portions of fruit and vegetables 
per day compared to cases (40.8% versus 30.2%) and undertook moderate exercise on at 
least three days per week (72.1% versus 64.3%). Cases had a higher median Townsend 
Deprivation Score (i.e. more deprived) (-1.87 [IQR -3.70–0.31]) compared to controls (-2.47 
[IQR -3.95–0.13]) (Supplementary Table 6-1). 
6.2.4.2 Background hospital contacts and costs 
6.2.4.2.1 Cases versus controls before feedback of a PSIF 
Before feedback, there were no significant differences between cases and controls with 
respect to: the proportions with ≥ 1 hospital contact (Table 6-1); their median numbers of 
total hospital (or inpatient, outpatient, emergency or critical care) contacts (Figure 6-2, Table 
6-2) or costs (Figure 6-3, Table 6-3).  
6.2.4.2.2 Controls’ hospital contacts and costs following feedback of a PSIF to their 
matched case 
Comparing the year before and the year after feedback of a PSIF (to their matched cases), 
there were no significant differences between: the proportions of controls with ≥ 1 hospital 
contact (Table 6-1); controls’ median numbers of hospital contacts (Figure 6-2, Table 6-2) or 
costs (Figure 6-3, Table 6-3). 
  

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6-1: Numbers (%) of 179 cases (21 with serious and 158 with non-serious 
final diagnoses) and their 1:1 matched controls with ≥ 1 hospital contact 
during the year before and the year after feedback of a potentially serious 
incidental finding 
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a. Only pairs with differences in binary (0 or ≥ 1) numbers of contacts (i.e. 
discordant pairs) are included in the McNemar test. 
b. Exact two-tailed p-value from McNemar test. 
c. Binomial distribution used. 
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Figure 6-2: Total numbers (% of total) of hospital contacts generated by 179 cases (21 
with serious and 158 with non-serious final diagnoses) and their 1:1 matched 
controls during the year before and after feedback of a potentially serious incidental 
finding 
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PSIF = potentially serious incidental finding. 
* Statistically significantly higher median numbers of contacts generated by cases 
compared to controls during the year after feedback of a PSIF. See Table 6-2 for 
details. 
† Statistically significantly higher median numbers of contacts generated by cases 
during the year after feedback of a PSIF, compared to the year before. See Table 6-2 
for details. 
There were no statistically significant differences in median numbers of contacts 
generated: by controls during the year after feedback of a PSIF, compared to the year 
before; or by cases compared to controls during the year before feedback of a PSIF. 
See Table 6-2 for details. 
  






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6-2: Median numbers (interquartile and full range) of hospital contacts 
generated by 179 cases (21 with serious and 158 with non-serious final diagnoses) 
and their 1:1 matched controls during the year before and after feedback of a 
potentially serious incidental finding 
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IQR = interquartile range, PSIF = potentially serious incidental finding 
a. 25th and 75th percentile values calculated using Tukey’s Hinges. 
b. Only pairs with differences in numbers of contacts (i.e. discordant pairs) are 
included in the related-samples Wilcoxon signed rank test. 
c. Exact two-tailed p-value from related-samples Wilcoxon signed rank test for 
differences in numbers of contacts between groups. 
  




Figure 6-3: Total hospital costs in £ (% of total) generated by 179 cases (21 with 
serious and 158 with non-serious final diagnoses) and their 1:1 matched controls 
during the year before and the year after feedback of a potentially serious incidental 
finding 
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PSIF = potentially serious incidental finding. 
* Statistically significantly higher median costs in cases compared to controls during 
the year after feedback of a PSIF. See Table 6-3 for details. 
† Statistically significantly higher median costs in cases during the year after 
feedback of a PSIF, compared to the year before. See Table 6-3 for details. 
There were no statistically significant differences in median costs generated: by 
controls during the year after feedback of a PSIF, compared to the year before; or by 
cases compared to controls during the year before feedback of a PSIF. See Table 6-3 
for details.  






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6-3: Median (interquartile and full range) hospital costs (£) generated by 179 
cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls during the year before and after feedback of a potentially serious 
incidental finding 
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IQR = interquartile range, PSIF = potentially serious incidental finding 
a. 25th and 75th percentile values calculated using Tukey’s Hinges. 
b. Only pairs with differences in costs (i.e. discordant pairs) are included in the 
related-samples Wilcoxon signed rank test. 
c. Exact two-tailed p-value from related-samples Wilcoxon signed rank test for 
differences in costs between groups. 
 
6.2.4.3 Cases’ hospital contacts and costs following feedback of a PSIF 
After feedback, 144 (80.5%) cases, and 94 (52.5%) controls had contact with hospital 
services and generated some hospital costs (i.e. substantial portions had no such costs) 
(Table 6-1). By one year after feedback of a PSIF, a significantly higher proportion of cases 
had had ≥ 1 hospital contact compared to controls, and compared to the year before (Table 6-
1). After feedback of a PSIF, cases’ median numbers of hospital contacts were significantly 
higher than controls, and compared to cases the year before (three versus one and versus one, 
both comparisons p<0.001 [Figure 6-2, Table 6-2]). 
Rates of cases’ hospital (and inpatient and outpatient) costs began to increase around 30–60 
days following feedback of a PSIF, regardless of the severity of the final diagnosis, and 
continued at an increased rate for the remainder of the year (Figure 6-4). After feedback of a 
PSIF, cases generated higher median hospital costs compared to controls, and to the year 
before (£522 versus £114 and versus £128, both p<0.001); the same pattern of significantly 
higher median hospital costs was seen in subgroups of serious and non-serious cases [Figure 
6-3, Table 6-3]). The total costs generated by the group of serious cases by one year after 
feedback was 10.5-fold higher than their total costs the year before, compared to a 1.9-fold 
increase for non-serious cases (Figure 6-3). However, the group of non-serious cases 
generated higher absolute total hospital costs than serious cases by one year after feedback 
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Figure 6-4: Cumulative hospital costs (£) generated by cases and controls over the 
year before and after feedback of a potentially serious incidental finding (time zero) 
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6.2.4.3.1 Inpatient care 
Following feedback of a PSIF, higher proportions of cases (and serious and non-serious 
subgroups) had ≥ 1 hospital admission compared to the year before, and compared to 
controls (although this was not statistically significant for serious cases compared to their 
controls) (Table 6-1). This same pattern was evident for cases’ median numbers of inpatient 
admissions (Table 6-2).  
Inpatient costs accounted for the majority of the total hospital costs generated by cases 
during the year after feedback (68.3%), and for a higher proportion of serious cases’ total 
hospital costs than non-serious cases’ (80.7% versus 58.3% respectively) (Figure 6-3). 
During the year after feedback of a PSIF, cases generated higher total inpatient costs 
compared to controls, and compared to the year before (3.1 and 2.9-fold higher respectively, 
Figure 6-3). The magnitude of total inpatient cost increase following feedback of a PSIF was 
higher for the group of serious cases compared to the non-serious cases (25.9-fold, 1.4-fold 
respectively) (Figure 6-3). After feedback of a PSIF, cases (and serious and non-serious 
subgroups) had significantly higher median inpatient costs compared to controls, and 
compared to the year before (Figure 6-3, Table 6-3).  
Elective admissions contributed to the majority of cases’ inpatient costs after feedback 
(80.1%), with smaller proportions contributed by non-elective admissions (17.6%), and other 
types of costs (1.3% [including chemotherapy, excess bed days, high cost drugs or 
rehabilitation]) (Supplementary Figure 6-1). After feedback of a PSIF, cases’ median 
elective inpatient costs were significantly higher compared to controls’, and to cases’ costs 
the year before (both p=0.001) (Supplementary Figure 6-1, Supplementary Table 6-3).  
6.2.4.3.2 Outpatient care 
While inpatient care accounted for the majority of cases’ hospital costs after feedback of a 
PSIF, outpatient care accounted for the majority of cases’ hospital contacts (82.3%, Figure 6-
2). Following feedback of a PSIF, a significantly higher proportion of cases had ≥ 1 
outpatient appointment compared to controls and compared to cases the year before (Table 
6-1), and the median number of outpatient appointments was significantly higher amongst 
cases compared to these two groups (Figure 6-2, Table 6-2). 
One year after feedback of a PSIF, cases’ total outpatient costs were higher than controls’ 
and than cases’ costs the year before (2.8 and 2.1-fold respectively), and cases’ median 
outpatient costs were significantly higher than these two groups (both p<0.001 [Figure 6-3, 
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Table 6-3]). Compared to the year before feedback, both serious and non-serious cases’ total 
outpatient costs had increased by a similar magnitude (2.5 and 2.0-fold respectively) and 
median outpatient costs were significantly higher (Figure 6-3, Table 6-3). 
Consultant-led appointments accounted for 69.8% of cases’ total outpatient costs after 
feedback of a PSIF; non-consultant-led appointments, procedures and other costs (including 
imaging, chemotherapy, high cost drugs, nuclear medicine and radiotherapy costs [the latter 
of which were generated by nine cases and three controls]) accounted for the remainder of 
the total outpatient costs (Supplementary Figure 6-2). Only a minority (2.0%) of cases’ 
outpatient costs appeared to be attributable to imaging (n=21, Supplementary Figure 6-2). 
After feedback of a PSIF, median consultant-led appointment costs were higher for cases 
compared to controls, and to cases costs the year before (both p<0.001), but small numbers 
of case-control and before-and-after case pairs precluded any firm conclusion on any 
differences of other outpatient costs (Supplementary Table 6-4).  
6.2.4.3.3 Emergency and critical care 
After feedback of a PSIF, there were no significant differences between cases (or subgroups 
of serious and non-serious cases) and controls, or compared to the year before, regarding: 
proportions with ≥ 1 contact with emergency care services (Table 6-1); median number of 
emergency care contacts (Figure 6-2, Table 6-2); median emergency care costs (Figure 6-3, 
Table 6-3).   
While the proportions of admitted cases, median number of contacts, and median costs of 
critical care were significantly higher for serious cases compared to their controls during the 
year after feedback of a PSIF (Tables 6-1, 6-2 and 6-3, Figures 6-2 and Figure 6-3), the 
absolute numbers of cases admitted to critical care, and their associated costs, were small 
(6/21 [28.6%] serious cases generated £7,642 of costs); no controls were admitted to critical 
care (Table 6-1, Figure 6-3). 
6.2.4.4 Costs generated by cases and controls over a longer follow-up period 
As HES data were available until the end of the 2015-2016 financial year, in total 282.5 
person-years of follow-up was available for 179 cases and their controls. Magnitudes of total 
cost differences, and median cost differences during this longer period of follow-up were 
consistent with the analyses reported above, which were based on one year (i.e. 179 person-
years) of follow-up. Cases generated 2.3-fold higher total costs compared to controls, with a 
greater difference in costs for serious cases than non-serious cases compared to their 
respective controls (3.9-fold higher, 1.9-fold higher respectively) (Supplementary Figure 6-
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3). Cases (and serious and non-serious subgroups) generated significantly higher median 
costs of total hospital, inpatient and outpatient care compared to controls (Supplementary 
Table 6-5).  
There were no significant differences in median costs of emergency care between cases (or 
serious or non-serious subgroups) and controls (Supplementary Table 6-5).  
Again, serious cases had significantly higher median costs of critical care compared to 
controls (p=0.016) (Supplementary Table 6-5), but the absolute numbers of cases admitted to 
critical care, and their associated costs, remained small (7/21 [33.3%] serious cases 
generated £8,664); no controls were admitted to critical care (Supplementary Figure 6-3 and 
Supplementary Table 6-5).  
6.2.5 Discussion 
6.2.5.1 Main findings 
Before feedback of a PSIF, there were no differences between numbers of hospital contacts 
or costs between cases and controls, and controls’ numbers of hospital contacts and costs did 
not significantly differ during the year after compared to the year before feedback of a PSIF 
to their matched case. However, after feedback of a PSIF, 144 (80.5%) cases and 94 (52.5%) 
controls used hospital services, and cases’ median numbers of hospital contacts and median 
hospital costs were significantly higher compared to controls, and compared to the year 
before (hospital contacts: three versus one and versus one; hospital costs: £522 versus £114 
and versus £128 [all p<0.001]). Rates of cases’ cumulative costs began to increase 
approximately 30–60 days following feedback of a PSIF. A year after feedback of a PSIF, 
total hospital costs were higher amongst cases compared to controls’, and to cases’ costs the 
year before (2.9- and 2.6-fold respectively); serious cases’ total hospital costs had increased 
by a far greater relative magnitude than non-serious cases (10.5- and 1.9-fold respectively). 
However, the majority of PSIFs (88%) were finally diagnosed as non-serious, and non-
serious cases generated greater absolute costs than serious cases (£239,021 versus £192,093). 
These patterns of cost differences between cases and controls persisted over a longer follow-
up period. After feedback of a PSIF, the majority of the cost burden generated by cases was 
borne by inpatient services (68%), but the majority of their service burden fell to outpatient 
services (82%). 
6.2.5.2 Strengths of the study 
Images from the first 1,000 imaged participants were all reviewed systematically by 
radiologists for PSIFs under an established definition and protocol (Gibson et al., 2018). We 
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selected all the cases with PSIFs, and matched them to controls from this imaged group. Our 
selection of controls therefore satisfies two key requirements: they were selected from the 
same imaged population from which the cases are drawn and would have been selected as 
cases had they had a PSIF; all images from the controls were also reviewed by radiologists 
for PSIFs, and therefore their exposure status has been measured with the same accuracy as 
cases. These methods minimise selection and information bias respectively (Wacholder et 
al., 1992).  
Our study is approximately ten-fold larger than the largest previous study to assess the 
economic impact of IFs in healthy volunteers undergoing MRI (N=18) (Pinato et al., 2012), 
over twice as large as similar studies of patient groups (N=65) (Hayes et al., 2016) (N=83) 
(Wagner et al., 2002), and larger than other previous studies of the economic impact of IFs 
studied within a UK health service (N=18-114) (Bromage et al., 2012; Pinato et al., 2012). 
Unlike previous studies, we did not limit our assessment of healthcare costs to a single type 
of clinical assessment (such as imaging or other diagnostic tests) (Flicker et al., 2008; 
Gluecker et al., 2003; Lee et al., 2010; Maizlin et al., 2007; Priola et al., 2013; Schramm et 
al., 2016; Veerappan et al., 2010; Wagner et al., 2002) but used HES datasets and well-
established methods to calculate service use and costs generated across inpatient, outpatient, 
emergency and critical care services. To our knowledge, no previous study has attempted to 
provide a context for the costs generated by people with PSIFs by comparing these to either 
a control group without PSIFs, or cases’ costs before feedback of a PSIF. By checking for 
censored records, and matching cases to controls who were imaged within a fortnight, we 
have minimised any bias which may have been introduced by variability of length of follow-
up periods within the HES datasets. Two doctors rigorously applied a definition of PSIFs 
after going to considerable lengths to obtain data on final diagnoses from participants and 
their GPs in order to classify cases into subgroups of those with serious versus non-serious 
final diagnoses. 
6.2.5.3 Limitations 
The routinely collected data that our study is based on does not permit accurate classification 
of hospital contacts into those directly due to the clinical assessment of PSIFs and those 
which are unrelated. However, the magnitudes of differences in hospital contacts and costs 
between cases and controls after feedback of a PSIF, the lack of difference between these 
groups before feedback of a PSIF, and the increase in costs after compared to before 
feedback which occurred in cases, but not in controls, strongly implies that feeding back 
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PSIFs to apparently asymptomatic research volunteers has an impact on hospital use and 
costs.  
We matched cases and controls using a binary Elixhauser Index score, rather than on exact 
conditions, as the latter method would have reduced the number of case-control pairs 
available for analyses. It is unlikely that the difference in conditions, or differences in other 
baseline characteristics, between small numbers of case-control pairs accounts entirely for 
the observed differences in hospital contacts and costs, but this could be explored further 
using adjusted modelling techniques and/or sensitivity analyses. 
We followed up all participants within HES data for at least one year (i.e. 179 person-years), 
and for a maximum of 282.5 person-years; however, this may not be long enough for the full 
impact of diagnosis and treatment of all PSIFs to become manifest. A similar proportion of 
cases and controls reported having used private healthcare services, although the dates of 
these are not known. As stated previously, linked primary care data were not available 
during the time of this study, hence our focus on the impact on hospital services only. As a 
result of these limitations, our study likely underestimates the economic impact of feedback 
of PSIFs. 
All the cases and controls underwent research imaging and attended healthcare services in 
England, and we used English National Reference Costs, which are averages that may result 
in under- or over-estimates of costs in individual cases, but enable comparisons across 
groups. The costs of healthcare will vary between countries, healthcare systems and over 
time, and so our cost results may not be directly generalisable beyond the English NHS. 
However, the magnitude of increased costs in cases and controls is worthy of further study in 
different healthcare systems.   
Substantial proportions of participants (both cases and controls) did not generate any hospital 
cost, which is not surprising given our cohort is comprised of community-based research 
volunteers, who are healthier than the general population (Fry et al., 2017). This skewed cost 
data necessitated the use of non-parametric tests, which have lower statistical power than 
their parametric counterparts as they discard concordant pairs of data from analyses 
(Kirkwood and Stern, 2003). As such, we may have missed some significant differences. 
Conversely, due to the number of comparisons performed, some results may be statistically 
significant through chance. We considered performing a correction for multiple 
comparisons, but these may be too conservative and may potentially place too much 
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emphasis on the statistical p-value; instead, we report all of the p-values and interpret these 
in the context of the available data and the clinical plausibility (Perneger, 1998).  
6.2.5.4 Comparisons with other studies 
Compared with previously published self-reported data from the cases included in this 
current study and their GPs, data from HES records showed that fewer cases had undergone 
imaging after feedback of a PSIF (n=134 versus n=21), and more cases had attended 
outpatient appointments (n=109 versus n=140) (Gibson et al., 2018). These differences may 
be due to incomplete coding of imaging attendances within HES datasets, and reflect the 
longer follow-up period in this current study (1 year versus 6 months) respectively. The 
Diagnostic Imaging Dataset, which is compiled from hospital radiology information systems 
(NHS England, 2018), may capture cases’ and controls’ use of imaging services more 
completely than HES datasets, and should be considered for use in future studies. 
We found that cases with non-serious final diagnoses generated higher total costs than those 
with serious final diagnoses, due to the majority of PSIFs turning out not to represent serious 
disease. Similarly, a study of follow-up of IFs detected on CT of 114 patients with 
haematuria found that costs were higher for patients with IFs who did not need intervention, 
compared to those who did need intervention (£34,734, £12,622 respectively), as there was a 
higher prevalence of the former (Bromage et al., 2012). 
Follow-up of 116 patients with IFs on CT colonography over 12–24 months generated 
£34,329 in total costs (including inpatient, outpatient, diagnostic tests and surgical 
procedures (Xiong et al., 2006). This is far lower than the results of our study even 
accounting for differences in sample size and use of HRGs and National Reference Costs 
from different financial years, and is likely due to the inclusion of selected hospital records 
only: Xiong et al. reviewed patient records and attached costs only to those hospital contacts 
which were directly related to follow-up of IFs (Xiong et al., 2006), whereas we attached 
costs to all hospital contacts which occurred during specified time periods in order to enable 
four-way comparisons between cases and controls before-and-after feedback and thus 
provide a context for our cases’ costs after feedback of a PSIF. 
Using cost data from UK hospital imaging departments in 2012, imaging performed for 19 
participants with IFs on research MRI of the torso generated £7,775. This is relatively high 
compared to our estimates for outpatient imaging, which were based on average 2016-2017 
National Reference Costs, rather than costs from a single department (Pinato et al., 2012), 
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and as noted above, our use of HES records may have underestimated the volume (and 
therefore the cost) of imaging performed.  
6.2.5.5 Implications for policy, practice and research 
The findings of this study are of practical importance to current debates on the design of 
ethical policies for handling PSIFs detected in apparently asymptomatic research volunteers. 
The vast majority of PSIFs turned out not to be serious; such findings may be considered as 
‘false-positives’, and as such our results may also be informative to public health and 
commercial screening, and clinical imaging contexts. It may be assumed that feedback of a 
PSIF will inevitably benefit a participant, however our previous study demonstrated that 
feedback results in clinical assessments such as invasive procedures (with the inconvenience 
and harms associated with these) and impacts on individuals’ emotional wellbeing, insurance 
and finances and work and activities, regardless of the severity of the final diagnosis (Gibson 
et al., 2018).  Our current work focuses on the impacts of feedback of PSIFs on a societal 
level, namely, on publicly-funded hospital services. Feeding back findings which turn out 
not to be serious (i.e. the majority) impacts on already overstretched healthcare services by 
shifting publicly-funded services away from patients in need while providing little benefit 
(and certainly some harm (Gibson et al., 2018)) to research volunteers with PSIFs, ultimately 
limiting the value of health services overall. There is considerable scope for better handling 
of PSIFs in order to reduce the unnecessary impacts on research volunteers, patients and 
health services. Robust, empirical data on the natural history of IFs, head-to-head 
comparisons of different IFs handling protocols, and randomised controlled trials of active 
treatment versus no treatment or surveillance of different types of IFs are needed (Gibson et 
al., 2017b). 
Our study involves participants whose images were assessed by radiologists for PSIFs, and 
followed up within the UK health care system. Different protocols for detection of PSIFs 
may result in different proportions of serious and non-serious final diagnoses, and in turn 
different economic impacts. In future, data from UK Biobank will provide the opportunity to 
study the impact of feedback of PSIFs from a radiographer flagging protocol on both 
primary care and hospital services, using a larger cohort of participants, with a longer 
follow-up period. The economic impacts on health services, and societal costs such as lost 
working days or wages as a result of feedback of PSIFs from public health, commercial 
screening and clinical imaging contexts would further inform the debate on the value of 
feedback of such findings. 
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Our study of UK Biobank participants is the first to use a four-way comparison approach to 
enable data on hospital use and costs generated by cases with PSIFs to be set in context, and 
is the largest study of the health economic impact of feedback of PSIFs to apparently 
asymptomatic research volunteers. Over the next few years, UK Biobank will complete 
imaging of 100,000 participants and add linkages to other health-related datasets including 
primary care; this will enable us to complete a more comprehensive assessment of the 
economic impact of the feedback of PSIFs, and of those which result in serious and non-
serious final diagnoses.  
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6.2.6 Additional information 
6.2.6.1 Data availability 
Due to the confidential nature of questionnaire responses and clinical information on 
participants with potentially serious incidental findings, it is not possible to publicly share all 
of the data on which our analyses were based, but summaries of all relevant data are included 
within the manuscript and supplementary material. 
Importantly, any bona fide researcher can apply to use the UK Biobank resource, with no 
preferential or exclusive access, for health related research that is in the public interest. 
Application for access to UK Biobank data involves registration and application via the UK 
Biobank website, with applications considered by the UK Biobank Access Sub-Committee. 
Following approval, researchers and their institutions sign a Material Transfer Agreement 
and pay modest access charges. Further information on applying to access UK Biobank data 
is available at: http://www.ukbiobank.ac.uk/register-apply/. 
6.2.6.2 Competing interests 
L.M. Gibson: Member of the UK Biobank Imaging Working Group. UK Biobank Imaging 
Consultant, University of Edinburgh. 
J. Nolan: UK Biobank Data Analyst, University of Edinburgh. 
E. Mathieu: Former UK Biobank Data Analyst, University of Edinburgh. 
T.J. Littlejohns: UK Biobank Epidemiologist, University of Oxford. 
S. Garratt: Member of the UK Biobank Imaging Working Group. Senior Project Manager of 
UK Biobank Imaging Study.  
S. Sheard: UK Biobank Director of Operations. 
N. Doherty: UK Biobank Senior Clinical Study Administrator. 
C. Keerie: None. 
N.E. Allen: Member of UK Biobank Steering Committee, UK Biobank Imaging, 
Enhancements, Follow-up and Outcomes and Infectious Diseases Working Groups. UK 
Biobank Senior Epidemiologist.  
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J.M. Wardlaw: Advised on imaging protocols for the UK Biobank imaging study. Author of 
reports on IFs and guidance on their management in the UK; Currently analysing UK 
Biobank brain imaging and numeric data.  
J. Leal: None. 
A.M. Gray: None. 
C.L.M. Sudlow: Member of UK Biobank Steering Committee, and UK Biobank Imaging, 
Enhancements, and Follow-up and Outcomes Working Groups. UK Biobank Chief Scientist. 
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S. Sheard: Data curation, review and editing 
N. Doherty: Project administration 
C. Keerie: Methodology, review and editing 
N.E. Allen: Review and editing 
J.M. Wardlaw: Conceptualisation, funding acquisition, supervision, review and editing 
J. Leal: Methodology, supervision, review and editing 
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editing 
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supervision, review and editing 
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6.3 Supplementary materials 
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Supplementary Table 6-1: Baseline characteristics of cases and controls 
 Cases with potentially 
serious incidental findings 
(N=179) n (%) 
Controls without potentially 
serious incidental findingsa 
(N=179) n (%) 
Matched variables   
Age   
  Median (IQR) 64 (57-69) 64 (57-69) 
Sex   
  Female 99 (55.3) 99 (55.3) 
  Male 80 (44.7) 80 (44.7) 
Duration of available follow-upb  
  Median N days (IQR) 575 (551-623) 575 (551-623) 
Morbidityc   
  None 147 (82.1) 147 (82.1) 
  ≥1 condition 32 (17.9) 32 (17.9) 
Other variables   
Ethnicityd   
  White 170 (95.0) 175 (97.8) 
  Minority ethnic groups 5 (2.8) 3 (1.7) 
Townsend Deprivation Index  
  Median (IQR) -1.87 (-3.70-0.31) -2.47 (-3.95-0.13) 
Private healthcared   
  Never used 126 (70.4) 127 (70.9) 
  Ever used 50 (27.9) 51 (28.5) 
Alcohold,e   
  None 24 (13.4) 15 (8.4) 
  Moderate 98 (54.7) 96 (53.6) 
  Hazardous 40 (22.3) 53 (29.6) 
  Harmful 10 (5.6) 14 (7.8) 
Smokingd   
  Never 106 (59.2) 100 (55.9) 
  Previous 61 (34.1) 71 (39.7) 
  Current 8 (4.5) 7 (3.9) 
Fruit and vegetable portions/dayd,e  
  < 5 120 (67.0) 101 (56.4) 
  ≥ 5 54 (30.2) 73 (40.8) 
Days/week of moderate physical activityd,e  
  0-2 54 (30.2) 44 (24.6) 
  3-4 37 (20.7) 55 (30.7) 
  5-7 78 (43.6) 74 (41.3) 
BMId,e   
  Underweight 3 (1.7) 2 (1.1) 
  Normal 79 (44.1) 78 (43.6) 
  Overweight 68 (38.0) 65 (36.3) 
  Obese 27 (15.1) 34 (19.0) 
IQR = interquartile range, BMI = body mass index 
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a. One control was matched to each case based on age (within 5 years), sex, 
date of imaging (within two weeks), and morbidity. 
b. We calculated the duration of follow-up as the number of days between the 
date of feedback of a potentially serious incidental finding to a case and March 
31st 2016, the last date of the available Hospital Episode Statistics (HES) 
dataset. We assigned the same date of feedback to controls to match their 
cases. 
c. Morbidity was calculated using an Elixhauser Index score based on two years 
of HES data prior to the date of imaging (Elixhauser et al., 1998; Quan et al., 
2005; The National Casemix Office and Health and Social Care Information 
Centre, 2014). 
d. Data were missing for ethnicity (4 [2.2%], 1 [0.6%]), private healthcare (3 
[1.7%], 1 [0.6%]), alcohol (7 [3.9%], 1 [0.6%]), smoking (4 [2.2%], 1 (0.6%]), fruit 
and vegetable intake (5 [2.8%], 5 [2.8%]), physical activity (10 [5.6%], 6 [3,4%]) 
and BMI (2 [1.1%], 0 [0.0%]) for 179 cases and 179 controls respectively. 
e. Methodology for classifying alcohol intake, fruit and vegetable intake, physical 
activity and BMI was the same as that used in Chapter 5. 
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Supplementary Table 6-2: Details of 32 cases with at least one Elixhauser Index 
condition and their matched controls 
Case-control pair 
number 
Case’s Elixhauser Index 
condition(s)a 
Control’s Elixhauser Index 
condition(s)a 
1 Cardiac arrhythmias Alcohol abuse 
Diabetes, uncomplicated 
Hypertension, uncomplicated 
Solid tumour without 
metastases 
2 Cardiac arrhythmias Hypertension, uncomplicated 
3 Cardiac arrhythmias Hypertension, uncomplicated 
Hypothyroidism 
4 Depression Diabetes, uncomplicated 
Hypertension, uncomplicated 
Solid tumour without 
metastases 
5 Depression Hypertension, uncomplicated 
6 Hypertension, uncomplicated Chronic pulmonary disease 
Hypertension, uncomplicated 
7 Hypertension, uncomplicated Hypertension, uncomplicated 
8 Hypertension, uncomplicated Hypertension, uncomplicated 
Hypothyroidism 
9 Hypertension, uncomplicated Chronic pulmonary disease 
10 Hypertension, uncomplicated Alcohol abuse 
Cardiac arrhythmias 
11 Hypothyroidism Diabetes, uncomplicated 





Solid tumour without 
metastases 
13 Weight loss Hypothyroidism 
14 Alcohol abuse 
Depression 
Chronic pulmonary disease 




16 Congestive heart failure 
Hypertension, uncomplicated 
Alcohol abuse 









19 Fluid and electrolyte disorders 
Hypertension, uncomplicated 
Hypertension, uncomplicated 
20 Hypertension, uncomplicated 
Hypothyroidism 
Hypertension, uncomplicated 






Chronic pulmonary disease 
Fluid and electrolyte disorders 
  





Case’s Elixhauser Index 
condition(s)a 
Control’s Elixhauser Index 
condition(s)a 
23 Metastatic cancer 




Chronic pulmonary disease 
24 Metastatic cancer 
Solid tumour without 
metastasesb 
Other neurological disorders 









27 Cardiac arrhythmias 
Rheumatoid arthritis/collagen 
vascular diseases 
Solid tumour without 
metastases 
Hypothyroidism 
















Other neurological disorders 
Alcohol abuse 
32 Alcohol abuse 
Chronic pulmonary disease 
Congestive heart failure 
Fluid and electrolyte disorders 
Hypertension, uncomplicated 




a. Elixhauser Index conditions were identified using Hospital Episode Statistics 
(HES) inpatient data covering the two years prior to the date of imaging 
(Elixhauser et al., 1998; Quan et al., 2005; The National Casemix Office and 
Health and Social Care Information Centre, 2014) 
b. These two cases had multiple HES records, at least one of which contained 
codes relating to both ‘metastatic cancer’ and ‘solid tumour without 
metastases’; such coding may represent either a diagnostic coding error, or 
simultaneous primary tumours.  
  




Supplementary Figure 6-1: Total costs in £ (% of total) of inpatient care generated by 
179 cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls during the year before and the year after feedback of a potentially 
serious incidental finding 
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PSIF = potentially serious incidental finding. 
* Statistically significantly higher median inpatient costs in cases compared to 
controls during the year after feedback of a PSIF. See Supplementary Table 6-3 for 
details. 
† Statistically significantly higher median inpatient costs in cases during the year 
after feedback of a PSIF, compared to the year before. See Supplementary Table 6-3 
for details. 
There were no statistically significant differences in median inpatient costs generated: 
by controls during the year after feedback of a PSIF, compared to the year before; or 
by cases compared to controls during the year before feedback of a PSIF. See 
Supplementary Table 6-3 for details. 
a. Including chemotherapy, excess bed days, high cost drugs and rehabilitation 
costs.  
  








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 6-3: Median (interquartile and full range) inpatient costs (£) 
generated by 179 cases (21 with serious and 158 with non-serious final diagnoses) and 
their 1:1 matched controls during the year before and after feedback of a potentially 
serious incidental finding 
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IQR = interquartile range, PSIF = potentially serious incidental finding 
a. 25th and 75th percentile values calculated using Tukey’s Hinges. 
b. Only pairs with differences in costs (i.e. discordant pairs) are included in the 
related-samples Wilcoxon signed rank test. 
c. Exact two-tailed p-value from related-samples Wilcoxon signed rank test for 
differences in costs between groups. 









Supplementary Figure 6-2: Total costs in £ (% of total) of outpatient care generated 
179 cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls during the year before and the year after feedback of a potentially 
serious incidental finding 
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PSIF = potentially serious incidental finding. 
* Statistically significantly higher median outpatient costs in cases compared to 
controls during the year after feedback of a PSIF. See Supplementary Table 6-4 for 
details. 
† Statistically significantly higher median outpatient costs in cases during the year 
after feedback of a PSIF, compared to the year before. See Supplementary Table 6-4 
for details. 
There were no statistically significant differences in median outpatient costs 
generated: by controls during the year after feedback of a PSIF, compared to the year 
before; or by cases compared to controls during the year before feedback of a PSIF. 
See Supplementary Table 6-4 for details. 
a. Including chemotherapy, high cost drugs, nuclear medicine and radiotherapy 
costs. 
  





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 6-4: Median (interquartile and full range) outpatient costs (£) 
generated by 179 cases (21 with serious and 158 with non-serious final diagnoses) 
and their 1:1 matched controls during the year before and after feedback of a 
potentially serious incidental finding 
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IQR = interquartile range, PSIF = potentially serious incidental finding 
a. 25th and 75th percentile values calculated using Tukey’s Hinges. 
b. Only pairs with differences in costs (i.e. discordant pairs) are included in the 
related-samples Wilcoxon signed rank test. 
c. Exact two-tailed p-value from related-samples Wilcoxon signed rank test for 
differences in costs between groups. 
d. Including chemotherapy, high cost drugs, nuclear medicine and radiotherapy 
costs. 
  





Supplementary Figure 6-3: Total hospital costs in £ (% of total) generated by 179 
cases (21 with serious and 158 with non-serious final diagnoses) and their 1:1 
matched controls during the 282.5 person-years of follow-up available after feedback 
of a potentially serious incidental finding 
PSIF = potentially serious incidental finding. 
* Statistically significantly higher median costs in cases compared to controls during 
the 282.5 person-years of follow-up after feedback of a PSIF. See Supplementary 
Table 6-5 for details. 
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Supplementary Table 6-5: Median (interquartile and full range) hospital costs (£) 
generated by 179 cases (21 with serious and 158 with non-serious final diagnoses) 
and their 1:1 matched controls after feedback of a potentially serious incidental 
finding over 282.5 person-years of follow-up 
 Median (IQR, range) hospital costs (£) 
generated by 179 cases (21 with serious and 
158 with non-serious final diagnoses) and 
their matched controls over 282.5 person-


























































































































IQR = interquartile range, PSIF = potentially serious incidental finding 
a. 25th and 75th percentile values calculated using Tukey’s Hinges. 
b. Only pairs with differences in costs (i.e. discordant pairs) are included in the 
related-samples Wilcoxon signed rank test. 
c. Exact two-tailed p-value from related-samples Wilcoxon signed rank test for 





This chapter explored the impact on hospital services of feedback of PSIFs to apparently 
asymptomatic volunteers. There were no differences in hospital contacts or costs between 
cases and controls before feedback (or between controls before and after feedback of a PSIF 
to their matched case). However, after feedback of a PSIF, 144 (80.5%) cases with PSIFs 
had contact with hospital services (either inpatient, outpatient, emergency or critical care) at 
least once, compared to 94 (52.5%) of controls without a PSIF, and cases’ numbers of 
hospital contacts and costs were significantly higher compared to controls, and compared to 
cases’ hospital contacts and costs the year before (hospital contacts: three versus one and 
versus one; hospital costs: £522 versus £114 and versus £128 [all p<0.001]). The rates of 
cases’ cumulative costs began to increase approximately 30–60 days following feedback of a 
PSIF. A year after feedback of a PSIF, cases’ total hospital costs were higher than controls’ 
and higher than cases’ costs the year before (£431,114 versus £147,817 [2.9-fold] and versus 
£167,434 [2.6-fold] respectively). Serious cases’ total costs had increased much more than 
non-serious cases’ total costs one year after feedback of a PSIF (10.5-fold, 1.9-fold 
respectively). However, as the vast majority (158/179 [88%]) of PSIFs were finally 
diagnosed as non-serious, non-serious cases generated greater absolute costs than serious 
cases (£239,021 versus £192,093). These patterns of costs were similar over a longer follow-
up period which included an additional 103.5 person-years of follow-up. After feedback, the 
majority of cases’ cost burden impacted on inpatient services (68%), but the majority of 
cases’ service use burden impacted on outpatient services (82%). 
This chapter did not address the economic impact of feedback of PSIFs on primary 
healthcare services (as such data were not available), the length of follow-up (median 
number of days 575 [interquartile range 551-623]) may not have been long enough for the 
economic impact of some PSIFs to fully manifest, and HES datasets did not appear to 
capture all of the imaging performed in cases with PSIFs when compared to cases’ self-
reported data presented in Chapter 4 (Gibson et al., 2018); as such our results on the 
magnitudes of the economic impact of feedback of PSIFs are likely underestimates.  
This chapter includes cases with PSIFs identified using a protocol of systematic radiologist 
review; subsequent UK Biobank participants’ images are now handled using a protocol of 
radiographer flagging (Gibson et al., 2018), which may result in different proportions of 
serious and non-serious final diagnoses, and a different economic impact. The UK Biobank 
Imaging Study will generate more cases with PSIFs over the forthcoming years, a greater 




care) will become available, which will all enable further exploration of the economic impact 
of feedback of PSIFs in future. 
The next chapter summarises the key results from the studies included in Chapters 2, 4, 5 
and 6, and compares these results with other studies, describes the strengths, limitations and 




Chapter 7 Discussion 
7.1 Summaries of key findings relating to potentially 
serious incidental findings 
7.1.1 Prevalence and nature 
7.1.1.1 Key findings 
Chapter 2 reported that the pooled prevalences of potentially serious incidental findings 
(PSIFs) on brain, thorax, abdomen and brain and body magnetic resonance imaging (MRI) 
were 1.4%, 1.3%, 1.9% and 3.9% respectively. These prevalence estimates rose when IFs of 
uncertain potential seriousness were included, to 1.7%, 3.0%, 4.5% and 12.8% respectively. 
Suspected malignancies accounted for around half of PSIFs on each imaged body region 
(brain 0.6%; thorax 0.6%; abdomen 1.3%; brain and body 2.3%). There was substantial 
between-study and within-study heterogeneity, but few data to reliably inform on sources of 
this.  
7.1.1.2 Comparison with other studies 
Pooled point prevalence estimates of PSIFs appeared to increase from brain and thorax, to 
abdomen, to brain and body MRI. Although this observation was not statistically robust, this 
finding is biologically plausible, given the range of pathologies possible across regions, and 
is supported by similar patterns found in primary studies of brain and body MRI (Gibson et 
al., 2018; Hegenscheid et al., 2013) and recent summary reports (The Royal College of 
Radiologists, 2011).  
Individual studies of whole-body MRI of apparently asymptomatic people found prevalences 
of incidental findings (IFs) ranging from 12.8–57.6% (Baumgart and Egelhof, 2007; 
Cieszanowski et al., 2014; Goehde et al., 2005; Hegenscheid et al., 2013; Lo et al., 2008; 
Morin et al., 2009; Saya et al., 2017; Tarnoki et al., 2015). These differences in prevalence 
are likely due to different definitions of IFs and PSIFs across these, and our, studies, and 
may be influenced by other characteristics, such as participants’ ages (see Section 7.1.3).  
An umbrella review which repeated meta-analyses of studies of patient populations 
undergoing cardiac MRI, and of mixed patient and apparently asymptomatic populations 
undergoing brain MRI, in existing systematic reviews found prevalences of IFs that were 
much higher than our estimates (around 34% and 22% respectively (Dunet et al., 2016; 
Morris et al., 2009; O'Sullivan et al., 2018; Takashima et al., 2017)). However these 




as well as populations (patients versus apparently asymptomatic people) (Dunet et al., 2016; 
Morris et al., 2009; O'Sullivan et al., 2018; Takashima et al., 2017).  
7.1.2 Follow-up and final diagnoses 
7.1.2.1 Key findings 
Our systematic review did not identify any study which enabled the types of follow-up of 
PSIFs to be quantified (Chapter 2). We provided new evidence on the follow-up of PSIFs in 
Chapter 4, and found that every participant with survey data reported that they had contacted 
their general practitioner (GP) (Gibson et al., 2018). The vast majority (90%) of participants 
with PSIFs had some form of clinical assessment, most commonly imaging or referral to a 
specialist (Gibson et al., 2018). Similar numbers of participants had invasive procedures, 
regardless of the seriousness of their final diagnoses (Gibson et al., 2018). 
Regarding final diagnoses, three of our studies consistently found that the majority (around 
80%) of PSIFs do not turn out to represent serious disease (Chapters 2, 4 and 5) (Gibson et 
al., 2018).  
7.1.2.2 Comparison with other studies 
Authors of a recent umbrella review aimed to summarise the final diagnoses of IFs across a 
range of modalities, but inadvertently presented suspected final diagnoses as firm final 
diagnoses in some cases, notably for studies of brain MRI (O'Sullivan et al., 2018). This 
highlights an issue with reporting and interpreting studies of IFs: descriptions of IFs detected 
on research imaging should not be taken as firm diagnoses unless the report specifically 
states that participants have had systematic clinical follow-up. As we show in the UK 
Biobank cohort, the majority of PSIFs turn out not to be serious (Gibson et al., 2018), that is 
to say, final diagnoses may differ from the IF description in a large number of cases. 
7.1.3 Factors associated with PSIFs and with serious final 
diagnoses 
7.1.3.1 Key findings 
Of all the factors we investigated in Chapter 5, PSIFs protocol had by far the greatest effect 
on prevalence of PSIFs and serious final diagnoses. Systematic radiologist review of images 
resulted in 13 times more PSIFs (179/1,000 [17.9%]; 104/6,334 [1.6%]; age- and sex-
adjusted odds ratio [OR] 13.3 [95% confidence interval (CI) 10.3–17.1]) and four times 
more serious final diagnoses (OR 4.2 [95% CI 2.4–7.4]) compared to radiographer flagging. 
A lower proportion of PSIFs detected by radiologists resulted in serious final diagnoses 




(Gibson et al., 2018). Chapters 2, 4 and 5 also found that PSIFs were more common with 
increasing age, and Chapter 5 found that increasing age was also associated with serious 
final diagnoses.  
With regards to other participant factors, the studies presented in Chapters 2, 4 and 5 found 
no significant associations of PSIFs or serious final diagnoses with sex (Gibson et al., 2018). 
Neither were there any significant associations between PSIFs or serious final diagnoses and 
participants’ ethnicity, Townsend Deprivation Index score, use of private healthcare services, 
alcohol intake, fruit and vegetable intake, physical activity, smoking status, body mass index 
(BMI) or morbidity (Chapter 5).  
Of several imaging factors investigated in our systematic review (including imaging setting 
[research versus non-research], blinding versus non-blinding of image readers to information 
on participants, and numbers of image readers [one versus more than one]) there was no 
evidence of any clinically meaningful differences in the prevalence of PSIFs between these 
subgroups (Chapter 2). There was not sufficient data on any other investigated factor to 
reliably inform on any other associations with PSIFs. 
7.1.3.2 Comparison with other studies 
No other studies of the effect of different PSIFs protocols on the prevalence of either PSIFs 
or serious final diagnoses were identified by the time of writing. The results in this thesis 
support previously published data that demonstrate trends toward increased IFs (of all 
clinical severity) with age, and not with sex (Bos et al., 2016; Brugulat-Serrat et al., 2017; 
Haberg et al., 2016; Hartwigsen et al., 2010; Illes et al., 2004a; Kumar et al., 2008; Morin et 
al., 2009; Sandeman et al., 2013; Tsushima et al., 2005; Yue et al., 1997). This thesis extends 
upon this knowledge by demonstrating that these associations hold when selecting only IFs 
of potential seriousness, and with serious final diagnoses, on multiple body regions, and in 
the case of age, independent of the great effect of PSIFs protocol (Chapter 5). There was no 
association of PSIFs on brain and body imaging with morbidity, extending on the findings of 
a systematic review of IFs on brain MRI only, which found no evidence of a difference in 
prevalence among participants either with comorbidities, without, or where their medical 




7.1.4 Participants’ understanding of consent to feedback 
7.1.4.1 Key findings 
Chapter 4 reported the results of a survey of UK Biobank participants to assess their 
understanding of consent to feedback of PSIFs. Around one quarter of respondents (158/607, 
26%) incorrectly thought that they could choose whether or not to be informed about a PSIF. 
7.1.4.2 Comparison with other studies 
Participants of the Netherlands Epidemiology of Obesity (NEO) study also misunderstood 
consent materials with regards to feedback of IFs. Despite consent materials stating that only 
IFs with ‘serious health consequences’ would be fed back, focus groups found that 
participants incorrectly thought that all IFs would be fed back (de Boer et al., 2018). 
 
7.1.5 Non-medical impacts of feedback on participants 
7.1.5.1 Key findings 
Participants who received feedback of PSIFs reported impacts on their emotional wellbeing, 
insurance and finances and work and activities (17%, 9%, and 6% respectively). These non-
medical impacts affected a higher proportion of participants with serious final diagnoses, but 
affected a higher absolute number of participants with non-serious final diagnoses (Gibson et 
al., 2018). 
7.1.5.2 Comparison with other studies 
These findings are in keeping with data from the Study of Health in Pomerania (SHIP) and 
NEO studies which found that around half the participants who received feedback of an IF 
reported that they experienced some psychological distress or worry (de Boer et al., 2018; 
Schmidt et al., 2013). Furthermore, a similar magnitude of participants with IFs in the SHIP 
reported impairments to work life (4%) and leisure (5%) compared to the UK Biobank 
participants (6%) (Schmidt et al., 2013). No informative published data on the impacts of 
feedback of PSIFs on insurance and finances had been identified by the time of writing to 
allow comparison.  
7.1.6 Opinions of receiving feedback 
7.1.6.1 Key findings 
Despite participants reporting that feedback of PSIFs results in non-medical impacts, and 
GPs reporting that a higher proportion of participants experienced negative, compared to 
positive, impacts on emotional wellbeing, the vast majority of participants were glad to have 




When asked if participants should always receive feedback of a PSIF, a higher proportion of 
GPs agreed with this statement than participants (61/94 [65%] vs 55/149 [37%]), and around 
a quarter of participants changed their mind on this between the six-week and six-month 
questionnaires (Gibson et al., 2018).  
7.1.6.2 Comparison with other studies 
Similarly, participants of the NEO study experienced impacts on their wellbeing following 
feedback of an IF, but were glad to have been informed; this apparent contradiction may be 
due to participants’ misunderstandings of research imaging as a screening service (de Boer et 
al., 2018). Regarding the results of screening, finding disease is seen as an opportunity to 
benefit from early treatment, and lack of disease is seen as conferring health; both scenarios 
are seen as beneficial by patients (Ransohoff et al., 2002). This does however highlight the 
possibility that research participants do not understand the limitations of research imaging. 
UK Biobank has since updated its consent materials to emphasise more strongly that the 
research imaging does not detect all disease, that some findings will turn out not to be 
serious, and that lack of feedback does not constitute an ‘all clear’ (Gibson et al., 2018; UK 
Biobank, 2018c). As such, it is imperative to continue to monitor participants’ understanding 
of consent, and if possible, with regards to these concepts in particular. 
No other study was identified that asked GPs and research participants their opinions on 
whether or not feedback of PSIFs should always be given, but this binary question may not 
do justice to the potential answers to this question, as respondents may consider the different 
types of findings, their clinical severity (Opinion Leader, 2012), or the circumstances and 
wishes that may differ between individuals. 
7.1.7 Economic impact of feedback 
7.1.7.1 Key findings 
Before feedback of a PSIF, there were no differences in hospital contacts or costs between 
cases and controls, and controls’ hospital contacts and costs did not differ between the years 
before and after feedback of a PSIF to their matched case. However, after feedback of a 
PSIF, 144 (81%) cases generated some hospital costs, compared to 94 (53%) controls, and 
cases’ median numbers of hospital contacts and median costs were significantly higher than 
controls, and compared to cases’ hospital contacts and costs the year before feedback 
(hospital contacts: three versus one and versus one; hospital costs: £522 versus £114 and 
versus £128 [all p<0.001]). Cases’ cumulative hospital costs began to increase approximately 




costs were higher compared to controls’, and to cases’ costs the year before (£431,114 versus 
£147,817 and versus £167,434 respectively). Compared to the year before feedback, after 
feedback of a PSIF serious cases’ total hospital costs had increased by a far greater 
magnitude than non-serious cases (10.5- and 1.9-fold respectively). However, the majority of 
PSIFs (158/179 [88%]) turned out not to be serious, and these non-serious cases generated 
greater absolute costs than serious cases (£239,021 versus £192,093).  
After feedback of a PSIF, the majority of cases’ cost burden fell to inpatient services (68%) 
while the vast majority of cases’ service use burden fell to outpatient services (82%). 
7.1.7.2 Comparison with other studies 
Compared to self-reported data from the cases with PSIFs (Gibson et al., 2018), Hospital 
Episode Statistics (HES) data found that they had apparently attended fewer imaging 
appointments and more outpatient appointments; this is likely due to incomplete coding of 
imaging appointments in HES data and a longer length follow-up respectively (six months of 
participant surveys versus one year within HES datasets). Incomplete coding of imaging 
appointments also likely explains the lower imaging costs in our study of 179 cases (total 
£2,385) compared to follow-up imaging of IFs detected on research MRI in a much smaller 
cohort (n=19) of elderly volunteers (£7,775) (Pinato et al., 2012). 
Cases with non-serious final diagnoses generated higher total costs than those with serious 
final diagnoses (due to the higher number of the former). Similarly, patients who did not 
need intervention for IFs detected on computed tomography (CT) generated higher costs 
than those who did need intervention, due to their higher absolute prevalence (Bromage et 
al., 2012). 
Total costs of follow-up of 116 patients with IFs on CT colonography were far lower than 
our study (£34,329) (Xiong et al., 2006). This is likely due to attachment of costs only to 
those hospital contacts which were directly related to follow-up of IFs (as identified by 
review of patient records) (Xiong et al., 2006), rather than to all hospital contacts over a 
specified time period as in our study, which allowed us to make comparisons between 
groups. 
7.2 Strengths and limitations 
The strengths and limitations of each study are discussed in detail within each chapter. This 




The studies in this thesis have focused on PSIFs (defined as those ‘indicating the possibility 
of a condition which, if confirmed, would carry a real prospect of seriously threatening life 
span, or of having a substantial impact on major body functions or quality of life’ (Gibson et 
al., 2018)) rather than IFs more generally. By specifically excluding non-serious IFs, this 
thesis has generated data on findings which are potentially clinically significant, and have 
implications for research participants, study staff and healthcare services. Furthermore, we 
made extensive efforts to gather data on and rigorously apply a methodology to classify final 
diagnoses. There were good questionnaire response rates in Chapter 4, and minimal missing 
data in Chapters 5 and 6, which minimises any information bias which may have affected 
results. The majority of previous studies of IFs on MRI had focused only on participants 
undergoing brain MRI, which may not be generalisable to those undergoing MRI of other 
body regions. This thesis presents data on both brain and body MRI, and the results are 
therefore generalisable to participants undergoing either whole-body MRI, or a component 
body region. 
This thesis is strengthened by the originality and size of the studies presented. To my 
knowledge, it presents the first studies to: systematically review and meta-analyse the 
prevalence and types of PSIFs on both brain and body MRI and to attempt to systematically 
summarise the literature on follow-up and final diagnoses of unselected participants, and 
factors associated with PSIFs (Chapter 2); compare two protocols for PSIFs (Chapter 4); 
quantitatively assess the understanding of consent to feedback of PSIFs of an unselected 
group of imaged participants (Chapter 4); assess the impact of feedback of PSIFs on 
unselected participants’ insurance and finances (Chapter 4); and to use routinely collected 
healthcare data to investigate the economic impact of feedback of PSIFs on hospital services 
(Chapter 6). Chapter 5 also represents the largest study so far of factors associated with 
serious final diagnoses, and Chapter 6 is the largest study so far to assess the economic 
impact on any health service of feedback of IFs detected in a cohort undergoing MRI, and is 
the first study to set the economic impact of PSIFs in the context of usual healthcare costs in 
order to aid judgements of the magnitude of this impact. 
Limited data precluded analyses in some studies which may have affected our ability to 
reliably detect or exclude associations between exposures and outcomes. It was possible to 
perform only a small number of subgroup analyses to investigate the heterogeneity in 
prevalence estimates of PSIFs in the systematic review (Chapter 2) due to either incomplete 
data or imbalanced subgroups. The study of the factors associated with PSIFs and serious 




rarity (Chapter 5). In addition, healthy volunteer bias may explain the lack of data on 
particular exposures in Chapter 5 (e.g. harmful levels of alcohol intake), and also the 
substantial proportion of participants who had no hospital costs in Chapter 6, although most 
people do not generate hospital costs during any given time period. Conversely, given the 
numbers of different statistical tests performed in Chapters 5 and 6, some results may be 
significant due to chance; in line with published advice, each result was interpreted within 
the context of the available data and the clinical plausibility, rather than analysed further 
with statistical corrections which may potentially put too much emphasis on a statistical p-
value (Perneger, 1998). This thesis was not able to investigate the economic impact of 
feedback of PSIFs on primary care services, as linkages to routinely collected primary care 
datasets were not available at the time of the study. 
Classification of serious final diagnoses was subjective, although there was good reliability 
of this process between two doctors. The definition of ‘serious final diagnosis’ focuses on 
the medical impact of PSIFs rather than non-medical impacts. While the study presented in 
Chapter 4 demonstrated impacts of non-serious final diagnoses on some non-medical 
domains (Gibson et al., 2018), this thesis was not able to capture impacts on other non-
medical domains such as socio-economic impacts on participants related to costs of travel to 
appointments, or numbers of workdays lost when attending for healthcare. Final diagnoses 
classified as serious may have not in fact shortened life span, or had a substantial impact on 
major organ function or quality of life. Furthermore, some PSIFs may take longer than six 
months to diagnose, or for their impact to fully manifest, and as such, our data on impacts 
are likely underestimates. 
7.3 Impact on participants, research and policy 
In 2014, the Medical Research Council and the Wellcome Trust published a framework to 
guide researchers on the points that they should consider when designing IFs policies 
(Medical Research Council and Wellcome Trust, 2014), and the results of this thesis inform 
on a number of these. Firstly, researchers are advised to consider the probability of 
identifying health-related findings, their potential severity and the certainty of this 
knowledge, and the risks of false positives, and that ‘factors relating to the study population, 
such as age, may also be relevant’ (Medical Research Council and Wellcome Trust, 2014). 
The results in this thesis from Chapters 2, 4, and 5 inform on the prevalence of PSIFs, 
including those which were finally diagnosed as non-serious (i.e., false positives), and the 
factors associated with these, which included the PSIFs protocol and age (Gibson et al., 




(Medical Research Council and Wellcome Trust, 2014), and Chapters 2 and 4 demonstrated 
that on brain, thorax and abdominal MRI the most common types of PSIFs are suspected 
tumours and aneurysms (Gibson et al., 2018). Thirdly, researchers should follow good 
practice guidelines where available, and tailor their protocols to the context of the study 
(including the local practice and legal structures) (Medical Research Council and Wellcome 
Trust, 2014); the detailed information presented in this thesis on the UK Biobank protocol 
and its evaluation provides one such approach from which researchers could draw if 
appropriate (Medical Research Council and Wellcome Trust, 2014). Finally, the best 
interests of the participants, and the potential benefits and harms of feedback should be 
considered (Medical Research Council and Wellcome Trust, 2014). Participants within 
research studies do not generally stand to benefit directly from their involvement; rather the 
benefit of research is for the public good, and as such, the risks of harms to individual 
participants must be minimised. This thesis provides data to show the impact of feedback of 
PSIFs on participants’ emotional wellbeing, insurance and finances, and work and activities, 
as well as the economic impacts on hospital services, and that these impacts occur even in 
participants with non-serious final diagnoses. As this thesis also shows that the majority of 
PSIFs turned out not to be serious, feeding back such findings unnecessarily burdens 
overstretched healthcare services and shifts these publicly-funded services away from the 
patients who need them, while providing little benefit (but certainly some harm) to research 
volunteers, and ultimately limiting the value of health care services overall. Such harms can 
never be completely avoided, as the specificity for serious disease of non-targeted, non-
diagnostic imaging is not optimal. However, researchers and policymakers should aim to 
minimise these unnecessary impacts to research volunteers, patients and health services, and 
(as this thesis shows in Chapter 5) they would be able to substantially influence these 
impacts through the design of appropriate IFs protocols. 
UK Biobank took a pragmatic approach, and aimed to design an IFs protocol that was 
scalable and resulted in minimal harm to the 100,000 apparently asymptomatic volunteers. 
We investigated two possible options to minimise the harms associated with feedback of 
PSIFs, and in the context of a study the scale of UK Biobank, deemed a protocol of 
radiographer flagging to be more appropriate than one of radiologist review based on the 
empirical evidence presented in this thesis. While this approach may not be suitable for other 
studies, the principle of minimising harm will still be important (Gibson et al., 2018).  
The prevalence of PSIFs, and of those which are finally diagnosed as serious versus non-




for PSIFs may be assumed to be the most appropriate protocol (Bunnik et al., 2017) and 
indeed, expected by some participants (Kirschen et al., 2006), the results presented in this 
thesis challenge this assumption within the context of large-scale imaging of apparently 
asymptomatic populations. As such, the results may be informative to other research studies, 
particularly those of large-scale, or of multi-region imaging, or those including healthy 
controls or population-based participants, and also to public health screening and direct-to-
consumer commercial imaging contexts. 
Informed consent for imaging is necessary across all imaging contexts to promote the 
autonomy of individuals, and facilitating potential research participants’ informed decision 
making to take part in a study is essential to maintaining public trust in medical research 
(Farrar and Savill, 2014; Jefford and Moore, 2008). This thesis shows, however, that despite 
informing participants about the PSIFs protocol, a substantial proportion did misunderstand 
elements of it. This highlights the need for researchers and policymakers to make consent 
materials as clear as possible; the data from this thesis may inform the content included in 
such materials, and inform the assessment of these materials by research ethics committees. 
7.4 Unanswered questions and future research 
The studies presented in this thesis include cohorts of up to 7,334 imaged UK Biobank 
participants. The UK Biobank Imaging Study continues, and aims to image up to 100,000 
participants. Data from this larger cohort will enable several questions on PSIFs to be 
addressed in future. In response to the study presented in Chapter 4, UK Biobank amended 
their consent materials with a view to improving participants’ understanding of consent, the 
effect of which could be evaluated using an interrupted time series study. A larger cohort 
may also enable an exploration of the effects of factors such as age, education, and opinions 
on the participant information leaflet on participants’ understanding of consent to potentially 
identify further opportunities to optimise informed consent processes. Relatively few 
participants reported impacts of feedback of PSIFs on their emotional wellbeing, insurance 
and finances and work and activities in Chapter 4; a larger cohort would provide more robust 
data on the prevalence of these impacts, and may enable exploration of how these vary by 
other factors, such as severity of final diagnoses, or participant age, sex, or employment 
status. Chapter 4 also demonstrated that around one third of participants thought feedback of 
PSIFs should always be given, rather than that they should be able to choose whether they 
receive feedback or not, and around one quarter changed their minds on this issue between 
the six-week and six-month questionnaires, although the reasons for this remain unclear. 




such as follow-up, final diagnoses or non-medical impacts. In addition, participants’ reasons 
for changing their minds could be further explored by analysing the available free-text 
responses from the participants’ questionnaires, or using other qualitative methods such as 
interviews. Only around two-thirds of GPs provided opinions on the impacts of feedback of 
PSIFs on their patients’ emotional wellbeing and the net benefit versus net harm of feedback; 
the response rate and opinions from the larger cohort may provide more robust results. 
Furthermore, robust qualitative analyses of the vast quantity of free text data provided by 
participants and their GPs on their follow-up questionnaires may generate insights in to the 
experiences of receiving feedback of a PSIF, and inform the direction of future studies. A 
larger cohort may overcome the limitations of the study presented in Chapter 5, in which 
sparse data on exposures and limited power due to relatively rare outcomes may have led to 
associations between several factors and either PSIFs or serious final diagnoses being 
missed. 
Lack of linkages to the relevant datasets precluded investigations of the health economic 
impact of feedback of PSIFs on primary care services, and underestimated the burden on 
imaging services but these impacts could be investigated when these linkages become 
available in future. In addition, Chapter 6 investigates the economic impact of PSIFs 
detected using a protocol of systematic radiologist review. UK Biobank now use a protocol 
of radiographer flagging of concerning images for a radiologist to review, which results in 
lower overall numbers of PSIFs and different proportions of those which are finally 
diagnosed as serious versus non-serious. UK Biobank continues to collect data on 
participants with PSIFs, and to update and add linkages to routinely collected datasets; this 
will provide the opportunity in future to study the impact of feedback of PSIFs from a 
radiographer flagging protocol on both primary and secondary care services, using a larger 
cohort of participants, with a longer follow-up period. Although it would unlikely change the 
overall pattern of observed differences in hospital contacts and costs between groups, 
adjusted statistical models, such as generalised estimating equations, and/or sensitivity 
analyses would enable further exploration of the economic impact of feedback of PSIFs on 
health services. Our novel methodology of a four-way comparison using data from cases and 
controls before and after feedback of a PSIF may inform the design of future studies of the 
impacts of PSIFs in other healthcare systems. 
Further questions could be addressed using other quantitative and qualitative studies. Firstly, 
our knowledge of the effect of PSIFs protocol on the prevalence of PSIFs and serious final 




The influence on prevalence of other PSIFs protocols, which may use radiology trainee or 
non-medical image readers, multiple versus single readers, readers blind to clinical 
information or not, is well worthy of further study, as systematic radiologist review of 
images may not be feasible in some contexts, and radiographer flagging may not be deemed 
appropriate in others. Different PSIFs protocols could be investigated either in head-to-head 
comparisons within individual imaging studies, or by creating an online image set and 
inviting different groups of readers to interpret research images. To inform the design of 
such studies, quantitative and qualitative work with different stakeholders, including 
research participants, patients, research staff and primary and secondary care physicians 
could identify these groups’ preferred outcomes for PSIFs protocols, such as high specificity 
for serious final diagnoses. Qualitative studies would be useful to shed light on the reasons 
behind the participants’ gratitude for feedback of a PSIF despite experiencing negative 
impacts, and their changes in opinions on whether or not feedback of PSIFs should always 
be provided. Further work is needed to assess participants’ understanding of consent, in 
particular, how this may vary by the provision of different information materials and how 
factors such as age, education level, and cognitive function influence understanding. Such 
work would facilitate evidence-based design of consent materials and processes by 
researchers and their evaluation by research ethics committees; feasibly UK Biobank data 
would enable such investigations.  
While UK Biobank survey participants up to six months following feedback of a PSIF, 
studies with longer follow-up periods are likely needed to elucidate final diagnoses in some 
cases, and to more fully capture the medical and non-medical impacts of feedback. 
Furthermore, while the UK Biobank surveys GPs, and qualitative studies have interviewed 
small groups of physicians who manage patients with IFs (Booth and Boyd-Ellison, 2015; 
Zafar et al., 2016), the views of secondary healthcare professionals such as radiologists or 
speciality physicians and surgeons on managing apparently asymptomatic research 
volunteers with PSIFs within publicly-funded healthcare systems would also be useful to 
inform the debates on the benefits and harms of feedback. 
Finally, while this thesis did not aim to evaluate the management of particular types of 
PSIFs, such as conservative versus active treatments, our data on the prevalence of PSIFs 
would inform the power calculations for trials of treatments, which are needed in order to 
ensure that individuals receive good clinical care, and that publicly-funded healthcare 




7.5 Final summary 
PSIFs, i.e. findings with the potential to impact on health, occur in around 1.5% of 
apparently asymptomatic adults undergoing either brain or thorax MRI, and in around 2% 
undergoing abdomen MRI and 4 to 13% on brain and body MRI. Around half of PSIFs are 
suspected to be malignant on research imaging, but most (around 80%) PSIFs turn out not to 
represent serious disease. 
Feedback of PSIFs results in substantial impacts in terms of clinical assessments, non-
medical impact on participants (including on emotional wellbeing, insurance and finances 
and work and activities), and economic impacts on hospital services. Importantly, as the 
majority of PSIFs turned out not to be serious, many of these impacts may well be deemed 
unnecessary in retrospect. 
Researchers and policymakers may mitigate against these potential harms through careful 
design of their PSIFs protocols, as this has the greatest effect on the prevalence of PSIFs and 
on serious final diagnoses, far more than any participant-level characteristic. We show that 
systematic radiologist review of images generated around 13 times more PSIFs and a lower 
proportion of serious final diagnoses than a protocol of radiographer flagging of concerning 
images for radiologists to review. There is no ‘one-size-fits-all’ best PSIFs protocol, and 
neither of these protocols may be feasible or appropriate for other studies conducted in other 
contexts; data on the impacts of other PSIFs protocols would further facilitate evidence-
based policy design, and provide further empirical data to inform the ongoing debate on the 
benefits and harms of feedback. 
Researchers must take care to clearly explain to potential participants how their images and 
PSIFs will be handled in order to obtain truly informed consent. Ideally, researchers would 
evaluate participants’ understanding of consent, and factors associated with correct 
understanding, which in turn would inform on methods to design consent materials and 
processes for future studies. Furthermore, qualitative work is needed to understand 
participants’ and GPs’ opinions on whether or not PSIFs should always be provided, 
participants’ gratitude for feedback of PSIFs despite the measured negative impacts, and 
different stakeholders’ preferred outcomes of a PSIFs protocol. Finally, further work is 
needed to confirm the results in this thesis using data from a larger cohort, which will be 
available in future as the UK Biobank Imaging Study continues to work toward imaging 









ACMG  American College of Medical Genetics and Genomics 
BMI  Body mass index 
CI  Confidence interval 
CT  Computed tomography 
DXA  Dual-energy X-ray absorptiometry 
GNC  German National Cohort 
GP  General practitioner 
HES  Hospital episode statistics 
HRG  Healthcare resource group 
IFs  Incidental findings 
IQR  Interquartile range 
MRI  Magnetic resonance imaging 
NEO  Netherlands Epidemiology of Obesity 
NHS  National Health Service 
OR  Odds ratio 
PSIFs  Potentially serious incidental findings 
RECORD Reporting of studies Conducted using Observational Routinely-collected 
health Data 
SHIP  Study of Health in Pomerania 
STROBE Strengthening the Reporting of Observational Studies in Epidemiology 









Apparently asymptomatic people People who were not selected on the basis of any 
symptoms, risk factors, or disease, and who 
attended for population-based research imaging 
studies, commercial or occupational screening, or as 
research controls 
Brain and body MRI   MRI of the brain, thorax and abdomen 
IFs  Findings unrelated to the purpose of imaging 
Indeterminate final diagnoses   See uncertain final diagnoses  
Indeterminate IFs IFs which could not be classified as either PSIFs or 
non-serious IFs 
Non-malignant PSIFs PSIFs which were neither suspected malignancies 
or possible indicators of malignancy 
Non-serious final diagnoses  Final diagnoses which were not likely to 
significantly threaten lifespan or have a major 
impact on quality of life or major body functions, or 
diagnoses which were already known 
Non-serious IFs IFs which were not likely to indicate a condition 
which would seriously threaten life span, or of have 
a substantial impact on major body functions or 
quality of life 
Patients People selected for a study based on symptoms, risk 
factors or disease, or those admitted to or attending 
a health care facility for clinical assessment 
Possible indicator of malignancy PSIFs which were not masses, but could be related 
to malignancy, e.g. pleural effusions 
PSIFs  Findings indicating the possibility of a condition 




seriously threatening life span, or of having a 
substantial impact on major body functions or 
quality of life 
Serious final diagnoses Final diagnoses which were likely to significantly 
threaten lifespan or have a major impact on quality 
of life or major body functions 
Suspected malignancy PSIFs which were described as tumours, masses, 
complex cysts or lesions 
Uncertain final diagnoses Final diagnoses which could not be classified as 
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